0001739104-18-000005.txt : 20181108 0001739104-18-000005.hdr.sgml : 20181108 20181108125011 ACCESSION NUMBER: 0001739104-18-000005 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 69 CONFORMED PERIOD OF REPORT: 20180930 FILED AS OF DATE: 20181108 DATE AS OF CHANGE: 20181108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Elanco Animal Health Inc CENTRAL INDEX KEY: 0001739104 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: IN FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38661 FILM NUMBER: 181169021 BUSINESS ADDRESS: STREET 1: 2500 INNOVATION WAY CITY: GREENFIELD STATE: IN ZIP: 46140 BUSINESS PHONE: 877-352-6261 MAIL ADDRESS: STREET 1: 2500 INNOVATION WAY CITY: GREENFIELD STATE: IN ZIP: 46140 10-Q 1 elanco-20180930document10q.htm 10-Q Document


 
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
Quarterly Report Under Section 13 or 15(d) of the
Securities Exchange Act of 1934
FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2018
COMMISSION FILE NUMBER 001-38661
Elanco Animal Health Incorporated
(Exact name of Registrant as specified in its charter)
INDIANA
 
82-5497352
(State or other jurisdiction of
 
(I.R.S. Employer
incorporation or organization)
 
Identification No.)
2500 INNOVATION WAY, GREENFIELD, INDIANA 46140
(Address of principal executive offices)
Registrant’s telephone number, including area code (877) 352-6261
Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months and (2) has been subject to such filing requirements for the past 90 days.
Yes o No ý
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes ý No o
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of a “large accelerated filer,” “accelerated filer,” “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer o
 
 
 
 
 
Accelerated filer o
Non-accelerated filer ý
 
 
 
Smaller reporting company o
 
 
 
 
 
 
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes o No ý
The number of shares of common stock outstanding as of November 6, 2018 were 365,625,000
 



Elanco Animal Health Incorporated
Form 10-Q
For the Quarter Ended September 30, 2018
Table of Contents
 
 
 
 
Page
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Condensed Consolidated and Combined Statements of Operations
 
 
 
Condensed Consolidated and Combined Statements of Comprehensive Income (Loss)
 
 
 
Condensed Consolidated and Combined Balance Sheets
 
 
 
Condensed Consolidated and Combined Statements of Equity
 
 
 
Condensed Consolidated and Combined Statements of Cash Flows
 
 
 
Notes to Condensed Consolidated and Combined Financial Statements
 
 
Management's Discussion and Analysis of Financial Condition and Results of Operations
 
 
 
 
Overview
 
 
 
Results of Operations
 
 
 
Summary of Changes
 
 
 
Liquidity and Capital
 
 
 
Contractual Obligations
 
Item 3.
 
Quantitative and Qualitative Disclosures About Market Risk
 
Item 4.
 
Controls and Procedures
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Item 3.
 
Defaults Upon Senior Securities
 
Item 4.
 
Mine Safety Disclosures
 
Item 5.
 
Other Information
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

2


Forward-Looking Statements
This Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of the federal securities laws. This quarterly report contains forward-looking statements, including, without limitation, statements concerning our industry and our operations, performance and financial condition, including in particular, statements relating to our business, growth strategies, product development efforts and future expenses.
          Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, our actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national, or global political, economic, business, competitive, market, and regulatory conditions, including but not limited to the following:
•
heightened competition, including from new innovation or generics;
•
the impact of disruptive innovations and advances in veterinary medical practices, animal health technologies and alternatives to animal-derived protein;
•
changes in regulatory restrictions on the use of antibiotics in food animals, as well as changing market demand regarding the use of antibiotics and productivity products;
•
our ability to implement our business strategies or achieve targeted cost efficiencies and gross margin improvements;
•
consolidation of our customers and distributors;
•
the success of our R&D, acquisition and licensing efforts;
•
unanticipated safety, quality or efficacy concerns associated with our products;
•
the impact of weather conditions and the availability of natural resources;
•
changes in U.S. foreign trade policy, imposition of tariffs or trade disputes;
•
the impact of global macroeconomic conditions; and
•
the effect on our business of the transactions involving the separation of our business from that of Eli Lilly & Co. (Lilly) and distribution of Lilly's interest in us to its shareholders, if consummated.
See "Risk Factors" in the final prospectus relating to our initial public offering filed on September 21, 2018 with the SEC for a further description of these and other factors. Although we have attempted to identify important risk factors, there may be other risk factors not presently known to us or that we presently believe are not material that could cause actual results and developments to differ materially from those made in or suggested by the forward-looking statements contained in this quarterly report. If any of these risks materialize, or if any of the above assumptions underlying forward-looking statements prove incorrect, actual results and developments may differ materially from those made in or suggested by the forward-looking statements contained in this quarterly report. For the reasons described above, we caution you against relying on any forward-looking statements, which should also be read in conjunction with the other cautionary statements that are included elsewhere in this quarterly report. Any forward-looking statement made by us in this quarterly report speaks only as of the date hereof. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update or to revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance, unless specifically expressed as such, and should be viewed as historical data.


3


PART I. Financial Information
Item 1. Financial Statements
Elanco Animal Health Incorporated
Unaudited Condensed Consolidated and Combined Statements of Operations
(Dollars and shares in millions, except per-share data)
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Revenue
$
761.1

 
$
697.1

 
$
2,267.5

 
$
2,134.7

Costs, expenses and other:
 
 
 
 
 
 
 
Cost of sales
369.8

 
376.2

 
1,161.3

 
1,088.9

Research and development
58.9

 
61.9

 
185.5

 
189.7

Marketing, selling and administrative
179.0

 
194.7

 
550.1

 
583.0

Amortization of intangible assets
48.7

 
51.6

 
147.3

 
161.0

Asset impairments, restructuring and other special charges (Note 6)
12.4

 
23.7

 
82.8

 
189.3

Other–net, (income) expense
13.5

 
(1.9
)
 
24.2

 
—

 
682.3

 
706.2

 
2,151.2

 
2,211.9

Income (loss) before income taxes
78.8

 
(9.1
)
 
116.3

 
(77.2
)
Income tax expense
18.6

 
11.6

 
46.2

 
72.0

Net income (loss)
$
60.2

 
$
(20.7
)
 
$
70.1

 
$
(149.2
)
 
 
 
 
 
 
 
 
Earnings (loss) per share:
 
 
 
 
 
 
 
Basic and diluted
$
0.16

 
$
(0.06
)
 
$
0.19

 
$
(0.41
)
Weighted average shares outstanding:
 
 
 
 
 
 
 
Basic and diluted
365.6

 
365.6

 
365.6

 
365.6

See notes to unaudited condensed consolidated and combined financial statements.

4


Elanco Animal Health Incorporated
Unaudited Condensed Consolidated and Combined Statements of Comprehensive Income (Loss)
(Dollars in millions)
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Net income (loss)
$
60.2

 
$
(20.7
)
 
$
70.1

 
$
(149.2
)
Other comprehensive income (loss), net of tax
94.5

 
(4.0
)
 
(9.8
)
 
231.8

Comprehensive income (loss)
$
154.7

 
$
(24.7
)
 
$
60.3

 
$
82.6

See notes to unaudited condensed consolidated and combined financial statements.


5


Elanco Animal Health Incorporated
Condensed Consolidated and Combined Balance Sheets
(Dollars in millions)
 
September 30, 2018
 
December 31, 2017
Assets
(Unaudited)
 
 
Current Assets
 
 
 
Cash and cash equivalents
$
300.0

 
$
323.4

Accounts receivable, net of allowances of $8.8 (2018) and $9.8 (2017)
606.1

 
567.4

Other receivables
30.8

 
34.5

Inventories (Note 7)
1,008.7

 
1,062.3

Prepaid expenses and other
123.2

 
136.1

Restricted cash (Note 14)
634.9

 
—

Total current assets
2,703.7

 
2,123.7

Noncurrent Assets
 
 
 
Investments (Note 9)
14.9

 
12.3

Goodwill
2,968.8

 
2,969.2

Other intangibles, net
2,514.8

 
2,672.8

Other noncurrent assets
100.0

 
242.0

Property and equipment, net of accumulated depreciation $894.5 (2018) and $834.1 (2017)
909.3

 
920.3

Total assets
$
9,211.5

 
$
8,940.3

Liabilities and Equity
 
 
 
Current Liabilities
 
 
 
Accounts payable
$
202.7

 
$
203.8

Employee compensation
81.3

 
89.3

Sales rebates and discounts
147.9

 
165.5

Other current liabilities
178.6

 
184.5

Payable to Lilly (Note 14)
634.9

 
—

Total current liabilities
1,245.4

 
643.1

Noncurrent Liabilities
 
 
 
Long-term debt (Note 8)
2,478.5

 
—

Accrued retirement benefits
136.0

 
139.0

Deferred taxes
125.0

 
251.9

Other noncurrent liabilities
89.5

 
126.0

Total liabilities
4,074.4

 
1,160.0

Commitments and Contingencies (Note 11)

 

Equity
 
 
 
Net parent company investment
—

 
8,036.9

Common stock, no par value, 5,000,000,000 shares authorized 365,625,000 shares issued and outstanding as of September 30, 2018
—

 
—

Additional paid-in capital
5,347.4

 
—

Accumulated other comprehensive loss
(210.3
)
 
(256.6
)
Total equity
5,137.1

 
7,780.3

Total liabilities and equity
$
9,211.5

 
$
8,940.3

See notes to unaudited condensed consolidated and combined financial statements.

6


Elanco Animal Health Incorporated
Unaudited Condensed Consolidated and Combined Statements of Equity
(Dollars and shares in millions)
 
Common Stock
 
 
 
 
 
Accumulated Other Comprehensive Income (Loss)
 
 
 
Shares
 
Amount
 
Additional Paid-in Capital
 
Net Parent Company Investment
 
Foreign Currency Translation

Defined Benefit Pension and Retiree Health Benefit Plans
 
Total
 
Total Equity
December 31, 2016
—

 
$
—

 
$
—

 
$
7,474.3

 
$
(437.3
)
 
$
(19.6
)
 
$
(456.9
)
 
$
7,017.4

Net loss
—

 
—

 
—

 
(149.2
)
 
—

 
—

 
—

 
(149.2
)
Other comprehensive income, net of tax
—

 
—

 
—

 
—

 
228.1

 
3.7

 
231.8

 
231.8

Transfers (to)/from Lilly, net
—

 
—

 
—

 
862.7

 
—

 
—

 
—

 
862.7

September 30, 2017
—

 
$
—

 
$
—

 
$
8,187.8

 
$
(209.2
)
 
$
(15.9
)
 
$
(225.1
)
 
$
7,962.7

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
December 31, 2017
—

 
$
—

 
$
—

 
$
8,036.9

 
$
(227.2
)

$
(29.4
)
 
$
(256.6
)
 
$
7,780.3

Adoption of Accounting Standards Update 2016-16
—

 
—

 
—

 
(0.3
)
 
—

 
—

 
—

 
(0.3
)
Net income
—

 
—

 
—

 
70.1

 
—

 
—

 
—

 
70.1

Other comprehensive income (loss), net of tax
—

 
—

 
—

 
—

 
(20.6
)
 
10.8

 
(9.8
)
 
(9.8
)
Transfers (to)/from Lilly, net
—

 
—

 
—

 
(226.3
)
 
—

 
—

 
—

 
(226.3
)
Separation adjustments
—

 
—

 
—

 
2.2

 
56.1

 
—

 
56.1

 
58.3

Issuance of common stock
365.6

 
—

 
1,659.7

 
—

 
—

 
—

 
—

 
1,659.7

Consideration to Lilly in connection with the Separation
—

 
—

 
(4,194.9
)
 
—

 
—

 
—

 
—

 
(4,194.9
)
Reclassification of net parent company investment
—

 
—

 
7,882.6

 
(7,882.6
)
 
—

 
—

 
—

 
—

September 30, 2018
365.6

 
$
—

 
$
5,347.4

 
$
—

 
$
(191.7
)
 
$
(18.6
)
 
$
(210.3
)
 
$
5,137.1

See notes to unaudited condensed consolidated and combined financial statements.


7


Elanco Animal Health Incorporated
Unaudited Condensed Consolidated and Combined of Cash Flows
(Dollars in millions)
 
Nine Months Ended September 30,
 
2018
 
2017
Cash Flows from Operating Activities
 
Net income (loss)
$
70.1


$
(149.2
)
Adjustments to Reconcile Net Income (Loss) to Cash Flows from Operating Activities:



Depreciation and amortization
222.3


231.3

Change in deferred income taxes
12.6


(7.0
)
Stock-based compensation expense
20.2


18.7

Asset impairment charges
102.5


43.8

Gain on sale of assets
—


(16.0
)
Other changes in operating assets and liabilities, net of acquisitions and divestitures
(83.4
)

42.7

Other non-cash operating activities, net
3.5


2.8

Net Cash Provided by Operating Activities
347.8

 
167.1

Cash Flows from Investing Activities
 
 
 
Net purchases of property and equipment
(74.3
)
 
(31.7
)
Cash paid for acquisitions, net of cash acquired
—


(882.1
)
Other investing activities, net
(4.6
)

(15.3
)
Net Cash Used for Investing Activities
(78.9
)
 
(929.1
)
Cash Flows from Financing Activities
 
 
 
Proceeds from issuance of long-term debt (Note 8)
2,477.7

 
—

Proceeds from issuance of common stock (Note 1)
1,659.7

 
—

Consideration paid to Lilly in connection with the Separation (Note 1)
(3,559.1
)

—

Other financing activities, net
(3.7
)

(0.5
)
Other net transactions with Lilly
(247.4
)

844.0

Net Cash Provided by Financing Activities
327.2

 
843.5

Effect of exchange rate changes on cash and cash equivalents
15.4


3.3

Net increase in cash, cash equivalents and restricted cash
611.5

 
84.8

Cash, cash equivalents and restricted cash at January 1
323.4

 
258.8

Cash, cash equivalents and restricted cash at September 30
$
934.9

 
$
343.6


 
September 30,
 
2018
 
2017
Cash and cash equivalents
$
300.0


$
343.6

Restricted cash (Note 14)
634.9


—

Cash, cash equivalents and restricted cash at September 30
$
934.9


$
343.6

See notes to unaudited condensed consolidated and combined financial statements.


8


Elanco Animal Health Incorporated
Notes to Condensed Consolidated and Combined Financial Statements
(Tables present dollars in millions, except per-share data)
Note 1. Nature of Business and Organization
Nature of Business
Elanco Animal Health Incorporated (Elanco Parent) and its subsidiaries (collectively, Elanco, the Company, we, us or our) was formed as a wholly-owned subsidiary of Eli Lilly and Company (Lilly). Elanco is a global animal health company that innovates, develops, manufactures and markets products for companion and food animals. We offer a diverse portfolio of more than 125 brands to veterinarians and food animal producers in more than 90 countries.
Organization
Elanco Parent was formed in 2018, as a wholly-owned subsidiary of Lilly, to serve as the ultimate parent company of substantially all of the animal health businesses of Lilly.
On September 24, 2018, Elanco Parent completed an initial public offering resulting in the issuance of 72.3 million shares of its common stock (including shares issued pursuant to the underwriters’ option to purchase additional shares), which represents 19.8% of the outstanding shares, at $24 per share (IPO) for a total net proceeds, after underwriting discounts and commissions, of $1.7 billion.  In connection with the completion of the IPO, through a series of equity and other transactions, Lilly transferred to Elanco Parent the animal health businesses that form its business going forward. In exchange Elanco Parent has paid, or will pay, to Lilly approximately $4.2 billion, which includes the net proceeds from the IPO, the net proceeds from the debt offering completed by Elanco Parent in August 2018 and the term loan facility entered into by Elanco Parent in September 2018 (see Note 8). As of September 30, 2018, Elanco Parent has paid Lilly $3.6 billion. These transactions are collectively referred to herein as the Separation.
Note 2. Basis of Presentation
We have prepared the accompanying unaudited condensed consolidated and combined financial statements in accordance with the requirements of Form 10-Q and, therefore, they do not include all information and footnotes necessary for a fair presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States (GAAP). In our opinion, the financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for a fair presentation of the results of operations for the periods shown. In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates.
Certain reclassifications have been made to prior periods in the unaudited condensed consolidated and combined financial statements and accompanying notes to conform with current presentation. In addition, during the period ended September 30, 2018, certain combined balance sheet amounts related to the prior year have been revised to correct the sales rebates and discounts liability, which did not correctly reflect an accrual for rebates related to product held in the wholesalers' pipeline.  In accordance with Securities and Exchange Commission Staff Accounting Bulletin No. 99, Materiality, and Accounting Standards Codification (ASC) 250, Presentation of Financial Statements, we assessed the materiality of this correction and concluded that the accrual for the rebate related to product held in the wholesalers' pipeline was not material to prior periods, and therefore, amendments of previously filed reports are not required.
As such, in accordance with ASC 250, we revised the previously reported combined balance sheet and combined statements of equity. The adjustment, which originates in periods prior to those presented, resulted in a  $10.5 million increase as of December 31, 2017 in the accrual for sales rebates and discounts of $155.0 million, total current liabilities of $632.6 million and total liabilities of $1,149.5 million. In addition, previously reported amounts at December 31, 2017 and December 31, 2016 of net parent company investment of $8,047.4 million and $7,484.8 million, respectively, and total equity of $7,790.8 million and $7,027.9 million, respectively, have been reduced by $10.5 million to reflect the correction above.  
The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our combined financial statements and accompanying notes as of and for the three years ended December 31, 2017 included in our final prospectus relating to our IPO filed on September 21 2018 (IPO Prospectus) with the Securities and Exchange Commission (SEC).
For the periods after Separation, the financial statements are prepared on a consolidated basis. For periods prior to the Separation, our financial statements are combined, have been prepared on a standalone basis, and are derived from Lilly's consolidated financial statements and accounting records. The unaudited condensed combined financial

9


statements reflect the financial position, results of operations and cash flows related to the animal health businesses that were transferred to Elanco Parent and are prepared in conformity with GAAP.
The unaudited condensed combined financial statements include the attribution of certain assets and liabilities that historically have been held at the Lilly corporate level but which are specifically identifiable or attributable to the businesses that have been transferred to Elanco Parent. All intercompany transactions and accounts within Elanco have been eliminated. All transactions between us and Lilly are considered to be effectively settled in the unaudited condensed combined financial statements at the time the intercompany transaction is recorded. The total net effect of the settlement of these intercompany transactions is reflected in the unaudited condensed combined statements of cash flows as a financing activity and in the condensed combined balance sheets as net parent company investment.
These unaudited condensed combined financial statements include an allocation of expenses related to certain Lilly corporate functions, including executive oversight, treasury, legal, finance, human resources, tax, internal audit, financial reporting, information technology and investor relations. These expenses have been allocated to us based on direct usage or benefit where specifically identifiable, with the remainder allocated primarily on a pro rata basis of revenue, headcount and other measures. We consider the expenses methodology and results to be reasonable for all periods presented. However, the allocations may not be indicative of the actual expense that would have been incurred had we operated as an independent, publicly traded company for the periods presented. It is impractical to estimate what the standalone costs of Elanco would have been in the historical periods.
The income tax amounts in the unaudited condensed combined financial statements have been calculated based on a separate return methodology and presented as if our operations were separate taxpayers in the respective jurisdictions. We file income tax returns in the United States (U.S.) federal jurisdiction and various state, local and non-U.S. jurisdictions. Certain of these income tax returns are filed on a consolidated or combined basis with Eli Lilly and Company and/or its subsidiaries.
Lilly maintains various benefit and combined stock-based compensation plans at a corporate level and other benefit plans at a country level. Our employees participate in such programs and the portion of the cost of those plans related to our employees is included in our financial statements. However, the condensed combined balance sheets do not include any equity issued related to stock-based compensation plans or any net benefit plan obligations unless the benefit plan covers only our dedicated employees or where the legal obligation associated with the benefit plan will transfer to Elanco.
Prior to Separation, the equity balance in the unaudited condensed combined financial statements represents the excess of total assets over liabilities, including intercompany balances between us and Lilly (net parent company investment) and accumulated other comprehensive loss. Net parent company investment is primarily impacted by contributions from Lilly which are the result of treasury activities and net funding provided by or distributed to Lilly. See Note 14 for further information.
Note 3. Impact of Separation
In connection with the Separation, we issued $2.0 billion aggregate principal amount of senior notes in a private placement, and we also entered into a $750.0 million senior unsecured revolving credit facility and $500.0 million senior unsecured term credit facility. See Note 8 for further information.
In connection with the Separation, we entered into various agreements with Lilly, including a master separation agreement. In connection with the terms of the Separation, there were certain assets and liabilities included in the pre-Separation balance sheet that were retained by Lilly and there were certain assets not included in the pre-Separation balance sheet that were transferred to us. The cumulative adjustment to the historical balance sheet increased net assets and total equity by approximately $58.3 million. The impact on net assets primarily represent the elimination of certain income tax assets and liabilities and the contribution of additional fixed assets.
After Separation, Lilly owns approximately 80.2% of the outstanding shares of our common stock. Lilly has informed us that it may make a tax-free distribution to its shareholders of all or a portion of its remaining equity interest, which may include one or more distributions effected as a dividend to all Lilly shareholders, one or more distributions in exchange for Lilly shares or other securities, or any combination thereof. Lilly does not have any obligation to pursue or consummate any further dispositions of its ownership interest in us by any specified date or at all. In connection with the Separation, we will continue to have certain ongoing relationships with Lilly as described in Note 14.


10


Note 4. Implementation of New Financial Accounting Pronouncements
The following table provides a brief description of accounting standards that were effective January 1, 2018 and were adopted on that date:
Standard
 
Description
 
Effect on the financial statements or other significant matters
Accounting Standards Update 2014-09 and various other related updates, Revenue from Contracts with Customers
 
This standard replaced existing revenue recognition standards and requires entities to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. An entity can apply the new revenue standard retrospectively to each prior reporting period presented or with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. We applied the latter approach.
 
Application of the new standard to applicable contracts had no impact to net parent company investment as of January 1, 2018. Disclosures required by the new standard are included in Note 5.
Accounting Standards Update 2016-16, Income Taxes: Intra-Entity Transfers of Assets Other Than Inventory
 
This standard requires entities to recognize the income tax consequences of intra-entity transfers of assets other than inventory at the time of transfer. This standard requires a modified retrospective approach to adoption.
 
Upon adoption, the cumulative effect of applying the standard resulted in a decrease to net parent company investment of approximately $0.3 million. Adoption of this standard did not result in a material change in net income for the three and nine months ended September 30, 2018.
Accounting Standards Update 2017-07, Compensation-Retirement Benefits: Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost
 
This standard was issued to improve the transparency and comparability among organizations by requiring entities to separate their net periodic pension cost and net periodic postretirement benefit cost into a service cost component and other components. Previously, the costs of the other components along with the service cost component were classified based upon the function of the employee. This standard requires entities to classify the service cost component in the same financial statement line item or items as other compensation costs arising from services rendered by pertinent employees. The other components of net benefit cost are now presented separately from the line items that include the service cost component. When applicable, the service cost component is now the only component eligible for capitalization. An entity should apply the new standard retrospectively for the classification of the service cost and other components and prospectively for the capitalization of the service cost component.
 
Upon adoption of this standard, pension and postretirement benefit cost components other than service costs are presented in other–net, (income) expense. Retrospective application was not material to the combined statement of operations for the three and nine months ended September 30, 2017. We do not expect application of the new standard to have a material impact on an ongoing basis.

11


The following table provides a brief description of the accounting standard that has not yet been adopted and could have a material effect on the consolidated financial statements:
Standard
 
Description
 
Effective Date
 
Effect on the financial statements or other significant matters
Accounting Standards Update 2016-02, Leases
 
This standard was issued to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities, including leases classified as operating leases under current GAAP, on the balance sheet and requiring additional disclosures about leasing arrangements. An entity can apply the new leases standard retrospectively to each prior reporting period presented or with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. We plan to use the latter approach.
 
This standard is effective January 1, 2019, with early adoption permitted. We intend to adopt this standard on that date.
 
We are in the process of determining the impact on our consolidated financial statements. We have selected a software solution to be compatible with our enterprise software system. Development of our selected solution is ongoing, as it is not yet fully compliant with the requirements of the standard. The timely readiness of the lease software system is critical to ensure an efficient and effective adoption of the standard.
Note 5. Revenue
Effective January 1, 2018, we adopted Accounting Standards Update 2014-09, Revenue from Contracts with Customers (ASU 2014-09) and other related updates. The new standard has been applied to contracts for which performance had not been completed as of the date of adoption. Revenue presented for periods prior to 2018 were accounted for under previous standards and has not been adjusted. Revenue and net income for the three and nine months ended September 30, 2018 do not differ materially from amounts that would have resulted from application of the previous standards.
Product Sales
We recognize revenue primarily from product sales to customers. Revenue from sales of products is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation, which generally is at the time we ship the product to the customer. Payment terms differ by jurisdiction and customer, but payment terms in most of our major jurisdictions typically range from 30 to 100 days from date of shipment. Revenue for our product sales has not been adjusted for the effects of a financing component as we expect, at contract inception, that the period between when we transfer control of the product and when we receive payment will be one year or less. Any exceptions are either not material or we collect interest for payments made after the due date. Provisions for rebates and discounts, and returns are established in the same period the related sales are recognized. We generally, ship product shortly after orders are received; therefore, we generally only have a few days of orders received but not yet shipped at the end of any reporting period. Shipping and handling activities are considered to be fulfillment activities and are not considered to be a separate performance obligation. We exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are imposed on our sales of product and collected from a customer.
Significant judgments must be made in determining the transaction price for sales of products related to anticipated rebates and discounts, and returns. The following describe the most significant of these judgments:
Sales Rebates and Discounts - Background and Uncertainties
•
Most of our products are sold to wholesale distributors. We initially invoice our customers contractual list prices. Contracts with direct and indirect customers may provide for various rebates and discounts that may differ in each contract. As a consequence, to determine the appropriate transaction price for our product sales at the time we recognize a sale to a direct customer, we must estimate any rebates or discounts that ultimately will be due to the direct customer and other customers in the distribution chain under the terms of our contracts. Significant judgments are required in making these estimates.
•
The rebate and discount amounts are recorded as a deduction to arrive at our net product sales. We estimate these accruals using an expected value approach.
•
In determining the appropriate accrual amount, we consider our historical experience with similar incentives programs and current sales data to estimate the impact of such programs on revenue and continually monitor the impact of this experience and adjust as necessary. Although we accrue a liability for rebates related to these

12


programs at the time the sale is recorded, the rebate related to that sale is typically paid up to six months after rebate or incentive period expires. Because of this time lag, in any particular period rebate adjustments may incorporate revisions of accruals for several periods.
Our sales rebates and discounts are based on specific agreements and the majority relate to sales in the U.S. As of September 30, 2018 and 2017, liability for sales rebates and discounts in the U.S. represents approximately 70% and 71%, respectively, of our total liability with the next largest country representing approximately 8% and 6%, respectively, of our total liability.
The following table summarizes the activity in the sales rebates and discounts liability in the U.S.:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,

2018
 
2017
 
2018
 
2017
Beginning balance
$
99.1

 
$
118.7

 
$
114.8

 
$
116.1

Reduction of revenue
53.5

 
48.6

 
154.2

 
184.9

Payments
(49.1
)
 
(49.6
)
 
(165.5
)
 
(183.3
)
Ending balance
$
103.5

 
$
117.7

 
$
103.5

 
$
117.7

Adjustments to revenue recognized as a result of changes in estimates for the judgments described above during the three and nine months ended September 30, 2018 for product shipped in previous periods were not material.
Sales Returns - Background and Uncertainties
•
We estimate a reserve for future product returns related to product sales using an expected value approach. This estimate is based on several factors, including: local returns policies and practices; returns as a percentage of revenue; an understanding of the reasons for past returns; estimated shelf life by product; and estimate of the amount of time between shipment and return. Adjustments to the returns reserve have been and may in the future be required based on revised estimates to our assumptions, which would have an impact on our consolidated results of operations. We record the return amounts as a deduction to arrive at our net product sales.
•
Actual product returns have been approximately 1% of net revenue for the three and nine months ended September 30, 2018 and 2017 and have not fluctuated significantly as a percentage of revenue.
Disaggregation of Revenue
The following table summarizes our revenue disaggregated by product category:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Companion Animal Disease Prevention
$
188.6

 
$
140.4

 
$
603.9

 
$
519.7

Companion Animal Therapeutics
80.5

 
63.5

 
211.1

 
181.8

Companion Animal Other
27.7

 
48.3

 
69.3

 
119.9

Food Animal Future Protein & Health
162.8

 
164.5

 
502.1

 
456.0

Food Animal Ruminants & Swine
301.5

 
280.4

 
881.1

 
857.3

Revenue
$
761.1

 
$
697.1

 
$
2,267.5

 
$
2,134.7

Note 6. Asset Impairment, Restructuring and Other Special Charges
We have historically participated in Lilly's cost-reduction initiatives. Our total charges related to asset impairment, restructuring and other special charges, including integration of acquired businesses, in the unaudited condensed consolidated and combined statements of operations consisted of the following:

13


 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Cash expense:
 
 
 
 
 
 
 
Severance
$
(0.2
)
 
$
5.8

 
$
(2.8
)
 
$
62.1

Integration and other
4.9

 
6.4

 
10.5

 
75.1

Exit costs
1.5

 
11.5

 
11.2

 
24.3

Total cash expense
6.2

 
23.7

 
18.9

 
161.5

Non-cash expense
 
 
 
 
 
 
 
Asset impairment
6.2

 
—

 
63.9

 
43.8

Total non-cash expense
6.2

 
—

 
63.9

 
43.8

Gain on sale of fixed assets
—

 
—

 
—

 
(16.0
)
Total
$
12.4

 
$
23.7

 
$
82.8

 
$
189.3

Severance costs represent costs incurred as a result of actions taken to reduce our cost structure.
Integration and other costs primarily represent costs related to our integration efforts as a result of our acquired businesses.
Exit costs primarily represent contract termination costs and reserves for costs related to facilities which we have exited.
Asset impairment recognized during the nine months ended September 30, 2018 resulted from $19.9 million of intangible asset impairments and $44.0 million of fixed asset impairments. The intangible asset impairments primarily related to revised projections of fair value due to product rationalization. The fixed asset impairments were primarily due to the decision to dispose of a manufacturing facility in the U.S. and to the suspension of commercial activities for Imrestor®.
Asset impairment recognized during the nine months ended September 30, 2017 resulted primarily from intangible asset impairments related to revised projections of fair value due to product rationalization and to a lessor extent competitive pressures. The fair value measurements utilized to determine the intangible asset impairments in 2018 and 2017 represent Level 3 fair value measurements.
Gain on sale of fixed assets for the nine months ended September 30, 2017 represents a gain on the disposal of a site that was previously closed as part of the acquisition and integration of Novartis Animal Health.
The following table summarizes the activity in our reserves established in connection with these restructuring activities:
 
Exit costs
 
Severance
 
Total
Balance at December 31, 2016
$
11.5

 
$
26.6

 
$
38.1

Charges
24.3

 
62.1

 
86.4

Cash paid
(7.6
)
 
(61.8
)
 
(69.4
)
Balance at September 30, 2017
$
28.2

 
$
26.9

 
$
55.1

 
 
 
 
 
 
Balance at December 31, 2017
$
34.9

 
$
43.1

 
$
78.0

Charges
11.2

 
(2.8
)
 
8.4

Separation adjustment
(5.9
)

—


(5.9
)
Cash paid
(10.9
)
 
(22.6
)
 
(33.5
)
Balance at September 30, 2018
$
29.3

 
$
17.7

 
$
47.0

Substantially all of the reserves are expected to be paid in the next twelve months. We believe that the reserves are adequate.



14


Note 7. Inventories
We state all inventories at the lower of cost or market. We use the last-in, first-out (LIFO) method for a portion of our inventories located in the continental U.S. Other inventories are valued by the first-in, first-out (FIFO) method. FIFO cost approximates current replacement cost.
Inventories consisted of the following:
 
September 30, 2018
 
December 31, 2017
Finished products
$
408.1

 
$
452.0

Work in process
572.3

 
580.0

Raw materials and supplies
71.4

 
70.4

Total (approximates replacement cost)
1,051.8

 
1,102.4

Decrease to LIFO cost
(43.1
)
 
(40.1
)
Inventories
$
1,008.7

 
$
1,062.3

During the nine months ended September 30, 2018, we recognized $38.6 million of inventory write-offs in cost of sales primarily related to the suspension of commercial activities for Imrestor.
Note 8. Debt
Long-term debt as of September 30, 2018 consisted of the following:
 
September 30, 2018

Term credit facility
$
500.0

3.912% Senior Notes due 2021
500.0

4.272% Senior Notes due 2023
750.0

4.900% Senior Notes due 2028
750.0

Other obligations
0.2

Unamortized debt issuance costs
(21.7
)
Total long-term debt
2,478.5

Less current portion of long-term debt
—

 
$
2,478.5

Long-term debt as of December 31, 2017 was not material.
Revolving and Term Credit Facilities
On September 5, 2018, we entered into a revolving credit agreement with a syndicate of banks providing for a five-year $750.0 million senior unsecured revolving credit facility (Revolving Facility). The Revolving Facility bears interest at a variable rate plus specified margin as defined in the agreement and is payable quarterly. There were no borrowings outstanding under the Revolving Facility at September 30, 2018. The Revolving Facility is payable in full at the end of the term.
On September 5, 2018 we also entered into a $500.0 million three-year term loan under a term credit facility with a syndicate of banks (the Term Facility and collectively with the Revolving Facility, the Credit Facilities.) The Term Facility bears interest at a variable rate plus margin as defined in Term Facility (3.50% at September 30, 2018) and is payable quarterly. The Term Facility is payable in full at the end of the term.
The Credit Facilities are subject to various financial and other covenants including restrictions on the level of borrowings based on a consolidated leverage ratio and a consolidated interest coverage ratio. We were in compliance with all such covenants as of September 30, 2018.

15


Senior Notes
On August 28, 2018, we issued $2.0 billion of senior notes (Senior Notes) in a private placement. The Senior Notes comprised of $500.0 million of 3.912% Senior Notes due August 27, 2021, $750.0 million of 4.272% Senior Notes due August 28, 2023, and $750.0 million of 4.900% Senior Notes due August 28, 2028. The interest rate payable on each series of Senior Notes is subject to adjustment if Moody's Investor Services, Inc. or Standard & Poor's Financial Services LLC downgrades, or subsequently upgrades, its ratings on the respective series of Senior Notes.
The indenture that governs the Senior Notes contains covenants, including limitations on our ability, and certain of our subsidiaries, to incur liens or engage in sale-leaseback transactions. The indenture also contains restrictions on our ability to consolidate, merge or sell substantially all of our assets, in addition, to other customary terms. We were in compliance with all such covenants under the indenture governing the Senior Notes as of September 30, 2018.
We have entered into an agreement that requires us to use commercially reasonable efforts to cause a registration statement to become effective with the SEC by August 28, 2019, relating to an offer to exchange the Senior Notes for registered Senior Notes having substantially identical terms, or, in certain cases, to register the Senior Notes for resale. If we do not register or exchange the Senior Notes pursuant to the terms of the registration rights agreement, we will be required to pay additional interest to the holders of the Senior Notes under certain circumstances.
Note 9. Financial Instruments and Fair Value
Financial instruments that are potentially subject to credit risk consist principally of trade receivables. Collateral is generally not required. The risk associated with this concentration is mitigated by our ongoing credit-review procedures and insurance.
A large portion of our cash is held by a few major financial institutions. We monitor the exposure with these institutions and do not expect any of these institutions to fail to meet their obligations. All highly liquid investments with a maturity of three months or less from the date of purchase are considered to be cash equivalents. The cost of these investments approximates fair value. We also consider the carrying value of restricted cash balances to be representative of its fair value.
As of September 30, 2018 and December 31, 2017, we had $14.9 million and $12.3 million, respectively, of cost and equity method investments.
The following table summarizes the fair value information at September 30, 2018 and December 31, 2017 for contingent consideration liabilities measured at fair value on a recurring basis in the respective balance sheet line items:
 
 
 
Fair Value Measurements Using
 
 
Financial statement line item
Carrying
Amount
 
Quoted Prices in Active Markets for Identical Assets
(Level 1)
 
Significant
Other Observable Inputs
(Level 2)
 
Significant
Unobservable
Inputs
(Level 3)
 
Fair
Value
September 30, 2018
 
 
 
 
 
 
 
 
 
Other current liabilities- contingent consideration
$
17.4

 
$
—

 
$
—

 
$
17.4

 
$
17.4

Other noncurrent liabilities- contingent consideration
41.4

 
—

 
—

 
41.4

 
41.4

December 31, 2017
 
 
 
 
 
 
 
 
 
Other current liabilities- contingent consideration
1.3

 
—

 
—

 
1.3

 
1.3

Other noncurrent liabilities- contingent consideration
45.2

 
—

 
—

 
45.2

 
45.2

Contingent consideration liabilities relate to Galliprant for which the fair value was estimated using a discounted cash flow analysis and Level 3 inputs, including projections representative of a market participant view for the probability of achieving potential future payments to Aratana Therapeutics, Inc. and an estimated discount rate. The amount to be paid is dependent upon certain development, success-based regulatory, and sales-based milestones. In addition, the amount of royalties to be paid is calculated as a percentage of net sales dependent upon the timing and geography and will, therefore, vary directly with increases and decreases in net sales of Galliprant. There is no cap on the amount that may be paid pursuant to this arrangement. During the second quarter of 2018, as a result of an increase in the

16


projected cash flows related to Galliprant, we increased the fair value of the contingent consideration liabilities by $8.5 million. The additional expense was recognized in other-net (income) expense.
We have long term debt of $2.5 billion that is recorded at amortized cost in our condensed consolidated balance sheet as of September 30, 2018. We consider the carrying value of the long term debt to be representative of its fair value as of September 30, 2018. The fair value of this long term debt is estimated based on quoted market prices of similar liabilities and is classified as Level 2. As of December 31, 2017, long term debt was not material.
Note 10. Income Taxes
Prior to Separation
During the periods presented in the unaudited condensed consolidated and combined financial statements, our operations were generally included in the tax grouping of other Lilly entities within the respective entity's tax jurisdiction; however, in certain jurisdictions, we filed separate tax returns. Prior to the Separation, the income tax expense included in these financial statements has been calculated using the separate return basis as if Elanco filed separate tax returns.
For the three and nine months ended September 30, 2018, we incurred $18.6 million and $46.2 million, respectively, of income tax expense. For the three and nine months ended September 30, 2018, the effective tax rate of 23.6% and 39.7%, respectively, was primarily attributable to a net operating loss in the U.S. for which no tax benefit was recognized and a valuation allowance was recorded.
For the three and nine months ended September 30, 2017, despite reporting a loss before taxes of $9.1 million and $77.2 million, respectively, we incurred $11.6 million and $72.0 million of income tax expense. The tax expense recorded related primarily to income generated in certain foreign jurisdictions as no tax benefit was recorded for U.S. net operating losses.
In December 2017, the President of the U.S. signed into law the Tax Cuts and Jobs Act (2017 Tax Act), which includes significant changes to the U.S. corporate income tax system, including a reduction in the corporate income tax rate, transition to a territorial tax system, and modifications to the international tax provisions. At September 30, 2018, our accounting for the 2017 Tax Act is incomplete; however, we expect to complete our accounting by December 2018. As discussed in our combined financial statements and accompanying notes as of and for the year ended December 31, 2017 included in our IPO Prospectus, we recorded provisional adjustments for effects that we were able to reasonably estimate. Those effects included the one-time repatriation transition tax (also known as the Toll Tax), re-measurement of deferred tax assets and liabilities, unremitted earnings, executive compensation, and uncertain tax positions. At December 31, 2017, we were not able to make reasonable estimates for Global Intangible Low-Taxed Income (GILTI) deferred taxes or changes to the valuation allowances; therefore, we did not record provisional amounts. We are still evaluating the effects of the GILTI provisions and assessing our valuation allowances, and we have not yet concluded upon our accounting policy election with respect to GILTI deferred taxes or the application of intra entity transfers of inventory; therefore, the estimated annual effective tax rate reflects GILTI as a period expense. For the three and nine months ended September 30, 2018, we have not made any additional measurement-period adjustments related to provisional amounts as we are continuing to collect and analyze additional information as well as evaluate the interpretations and assumptions made. Updates to the calculations may result in material changes to the provisional adjustments recorded at December 31, 2017 and the estimated annual effective tax rate.
As part of Lilly, we are included in Lilly's U.S. tax examinations by the Internal Revenue Service (IRS). The IRS examination of tax years 2013-2015 began in 2016. While we believe it is reasonably possible that this audit could reach a resolution within the next twelve months, the IRS examination of tax years 2013-2015 remains ongoing. For periods prior to the Separation, Lilly will retain the liabilities related to such IRS audit resolutions.
Impact of Separation
In connection with the Separation, we entered into a tax matters agreement (TMA) with Lilly that, among other things, formalized our agreement related to the responsibility for historical tax positions for the periods prior to the Separation for jurisdictions where our business was included in the consolidated or combined tax returns of Lilly. The TMA also established a tax sharing agreement for jurisdictions where our business will continue to be included in Lilly's consolidated or combined tax returns for a period of time.

17


Based on the TMA, Lilly retained the tax benefits and liabilities associated with all periods prior to the Separation date for any jurisdiction where we were included in a consolidated or combined tax return. The financial statements for periods prior to Separation included certain deferred tax assets related to tax credit and net operating loss carryovers that resulted from our tax expense being calculated on a separate return basis that will not transfer to us either because they were used by Lilly or are retained by Lilly and reflected certain tax liabilities that will be retained by Lilly. We recorded an adjustment to our consolidated balance sheet at the date of Separation to reflect our tax positions based on the TMA. This resulted in a decrease in tax liabilities by $31.2 million as these tax liabilities will be retained by Lilly.
At September 30, 2018, we have net operating losses for international tax purposes of approximately $190 million which will expire between 2022 and 2028. These net operating losses are partially reserved. Deferred tax assets related to state net operating losses are $6.2 million. The state net operating losses will generally expire between 2035 and 2037.
Note 11. Contingencies
We are party to various legal actions in the normal course of business. We record a liability if there is a claim for which it is probable a payment will be made and the amount is estimable. At September 30, 2018 and December 31, 2017, we had no liabilities established related to litigation as there are no claims which were probable and estimable. We have not historically had any significant litigation expense and are not currently subject to any claim.
Note 12. Geographic Information
We operate as a single operating segment engaged in the development, manufacturing, marketing and sales of animal health products worldwide for both food animals and companion animals. Consistent with our operational structure, our President and Chief Executive Officer (CEO), as the chief operating decision maker, makes resource allocation and business process decisions globally across our consolidated business. Strategic decisions are managed globally with global functional leaders responsible for determining significant cost/investments and with regional leaders responsible for overseeing the execution of the global strategy. Our global research and development organization is responsible for development of new products. Our manufacturing organization is responsible for the manufacturing and supply of products and for the optimization of our supply chain. Regional leaders are responsible for the distribution and sale of our products and for local direct costs. The business is also supported by global corporate staff functions. Managing and allocating resources at the global corporate level enables our CEO to assess the overall level of resources available and how to best deploy these resources across functions, product types, regional commercial organizations and research and development projects in line with our overarching long-term corporate-wide strategic goals, rather than on a product or geographic basis. Consistent with this decision-making process, our CEO uses consolidated, single-segment financial information for purposes of evaluating performance, allocating resources, setting incentive compensation targets, as well as forecasting future period financial results.
Our products include Rumensin®, Optaflexx®, Denagard®, Tylan®, Maxiban® and other products for livestock and poultry, as well as Trifexis®, Interceptor®, Comfortis® and other products for companion animals.
We have a single customer who accounted for 11.1% and 9.4% of revenue for the three months ended September 30, 2018 and 2017, respectively, and for 11.5% and 11.9% of revenue for the nine months ended September 30, 2018 and 2017, respectively. The product sales resulted in accounts receivable with this customer of $79.5 million and $88.0 million as of September 30, 2018 and December 31, 2017, respectively.
We are exposed to the risk of changes in social, political and economic conditions inherent in foreign operations and our results of operations and the value of its foreign assets are affected by fluctuations in foreign currency exchange rates.
Selected geographic area information was as follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Revenue—to unaffiliated customers (1)
 
 
 
 
 
 
 
United States
$
382.2

 
$
321.4

 
$
1,108.6

 
$
1,054.6

International
378.9

 
375.7

 
1,158.9

 
1,080.1

Revenue
$
761.1

 
$
697.1

 
$
2,267.5

 
$
2,134.7


18


 
September 30, 2018
 
December 31, 2017
Long-lived assets (2)
 
 
 
United States
$
589.5

 
$
604.7

United Kingdom
195.9

 
204.4

Other foreign countries
190.5

 
190.2

Long-lived assets
$
975.9

 
$
999.3

 
(1)    Revenue is attributed to the countries based on the location of the customer.
(2)    Long-lived assets consist of property and equipment, net, and certain noncurrent assets.
Note 13. Earnings Per Share
We have calculated earnings per share assuming 365,625,000 shares were outstanding for all periods presented. This represents an aggregate of 293,290,000 shares of our common stock held by Lilly (which represents the 100 shares held by Lilly prior to giving effect to the 2,932,900-for-1 stock split that occurred on September 19, 2018), the issuance of 62,900,000 shares of our common stock in the IPO, and the issuance of 9,435,000 shares of our common stock sold pursuant to the underwriters’ option to purchase additional shares.
Note 14. Related Party Agreements and Transactions
Separation-Related Agreements with Lilly
As described in Note 1, in connection with the Separation Lilly transferred to us substantially all of its animal health businesses in exchange for approximately $4.2 billion. This is reflected as consideration to Lilly in our statement of equity. In addition, we entered into a master separation agreement and a transitional services agreement with Lilly.
Master Separation Agreement (MSA)
As stated in Note 1, Lilly transferred to us at the time of Separation, through a series of transactions, the businesses that will continue as part of Elanco. For a certain portion of our operations, the legal transfer of our net assets did not occur prior to the Separation due to certain regulatory requirements in each of these countries. Under the MSA entered into with Lilly, we are responsible for the business activities conducted by Lilly on our behalf and are subject to the risks and entitled to the benefits generated by these operations and assets. As a result, the related assets and liabilities and results of operations have been reported in our unaudited condensed consolidated and combined financial statements. The total net assets associated with these jurisdictions are $84.5 million and the annual profits are insignificant. Upon Separation, we retained $275.0 million, which is reflected as restricted cash, that will be used to fund the purchase of these operations from Lilly at the time of the local country closing and have an offsetting payable to Lilly. If the amount of local purchases is less than $275.0 million, we are required to repay the remaining amount to Lilly.
In addition, based on the MSA, we are required to distribute to Lilly any amount of cash in excess of $300.0 million held at September 30, 2018. As a result, we have reflected an additional $359.9 million of restricted cash on our balance sheet with an offsetting payable to Lilly at September 30, 2018.
Transitional Services Agreement (TSA)
Historically, Lilly has provided us significant shared services and resources related to corporate functions such as executive oversight, treasury, legal, finance, human resources, tax, internal audit, financial reporting, information technology and investor relations, which we refer to collectively as the "Lilly Services." Under the terms of the TSA, we will be able to use Lilly Services for a fixed term established on a service-by-service basis. We will pay Lilly mutually agreed-upon fees for the Lilly Services provided under the TSA, which will be based on Lilly's cost (including third-party costs) of providing the Lilly Services through March 31, 2021, and subject to a mark-up of 7% thereafter, with additional inflation-based escalation beginning January 1, 2020. The fees under the TSA become payable for all periods beginning after October 1, 2018.
We also entered into a TMA, an employee matters agreement, a toll manufacturing and supply agreement and a registration rights agreement with Lilly in connection with the Separation.



19


Transactions with Lilly Prior to Separation
We did not historically operate as a standalone business and had various relationships with Lilly whereby Lilly provided services to us.
Transfers to/from Lilly, net
As discussed in the basis of presentation, net parent company investment is primarily impacted by contributions from Lilly which are the result of treasury activity and net funding provided by or distributed to Lilly. For the three months ended September 30, 2018 and 2017, respectively, the net transfers (to)/from Lilly were $(116.8) million and $38.1 million. For the nine months ended September 30, 2018 and 2017, respectively, the net transfers (to)/from Lilly were $(226.3) million and $862.7 million, respectively. The most significant activity impacting the 2017 transfer was the financing by Lilly of our acquisition in the amount of $882.1 million for Boehringer Ingelheim Vetmedica, Inc.'s United States feline, canine, and rabies vaccine portfolio and other related assets in 2017. Other activities that impacted the net transfers (to)/from Lilly include corporate overhead and other allocations, income taxes, retirement benefits, and centralized cash management.
Corporate Overhead and Other Allocations
Lilly provides us certain services, including executive oversight, treasury, legal, finance, human resources, tax, internal audit, financial reporting, information technology and investor relations. We provide Lilly certain services related to manufacturing support. Our financial statements reflect an allocation of these costs. When specific identification is not practicable, the remainder have been allocated primarily on a proportional cost method on a basis of revenue or headcount.
The allocations of services from Lilly to us were reflected as follows in the unaudited condensed consolidated and combined statements of operations:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Cost of sales
$
7.0

 
$
7.7

 
$
21.8

 
$
23.0

Research and development
0.7

 
0.7

 
2.2

 
2.1

Marketing, selling and administrative
26.4

 
27.7

 
81.2

 
82.7

Total
$
34.1

 
$
36.1

 
$
105.2

 
$
107.8

We provide Lilly certain services related to manufacturing support. Allocations of manufacturing support from us to Lilly of $1.3 million and $1.5 million for the three months ended September 30, 2018 and 2017, respectively, as well as $3.7 million and $4.5 million for the nine months ended September 30, 2018 and 2017, respectively, reduced the cost of sales in the unaudited condensed consolidated and combined statements of operations.
The financial information herein may not necessarily reflect our consolidated financial position, results of operations and cash flows in the future or what they would have been if we had been a separate, standalone entity during the periods presented. Management believes that the methods used to allocate expenses are reasonable.
Stock-based Compensation
Our employees participate in Lilly stock-based compensation plans, the costs of which have been allocated to us and recorded in cost of sales, research and development, and marketing, selling and administrative expenses in the unaudited condensed consolidated and combined statements of operations. The costs of such plans related to our employees were $6.9 million and $6.2 million for the three months ended September 30, 2018 and 2017, respectively, as well as $20.2 million and $18.7 million for the nine months ended September 30, 2018 and 2017, respectively.
Retirement Benefits
Our employees participate in defined benefit pension and other post retirement plans sponsored by Lilly, the costs and benefits of which have been recorded in the unaudited condensed consolidated and combined statement of operations in cost of sales, research and development, and marketing, selling and administrative expenses. For the three and nine months ended September 30, 2018, the benefit of such plans related to our employees was $1.6 million and $0.3 million, respectively, and for the three and nine months ended September 30, 2017 the costs of such plans related to our employees were $1.7 million and $5.1 million, respectively.
Centralized Cash Management

20


Lilly uses a centralized approach to cash management and financing of operations. Until Separation, the majority of our business was party to Lilly’s cash pooling arrangements to maximize Lilly's availability of cash for general operating and investing purposes. Under these cash pooling arrangements, cash balances were swept regularly from our accounts. Cash transfers to and from Lilly’s cash concentration accounts and the resulting balances at the end of each reporting period were reflected in net parent company investment in the condensed consolidated and combined balance sheets.
Debt
Lilly’s third-party debt and the related interest expense have not been allocated to us for any of the periods presented as we were not the legal obligor of the debt and Lilly borrowings were not directly attributable to our business.
Commercial Operations
We sell certain products to and receives certain goods and services from a customer/vendor, whose chairman and Chief Executive Officer is a member of Lilly's Board of Directors. These product sales resulted in revenue of $4.2 million and $6.6 million for the three months ended September 30, 2018 and 2017, respectively, and of $16.4 million and $17.8 million for the nine months ended September 30, 2018 and 2017, respectively. The product sales resulted in accounts receivable of $1.9 million and $2.0 million at September 30, 2018 and December 31, 2017, respectively. The purchase of goods and services resulted in cost of sales and operating expenses of $1.4 million and $1.1 million for the three months ended September 30, 2018 and 2017, respectively, as well as $3.3 million and $5.3 million September 30, 2018 and 2017, respectively. The purchase of goods and services resulted in accounts payable of $0.4 million and $0.3 million at September 30, 2018 and December 31, 2017, respectively.

21


Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Management’s Discussion and Analysis of Financial Condition and Results of Operations
(Tables present dollars in millions, except per-share data)
The management’s discussion and analysis of financial condition and results of operations is intended to assist the reader in understanding and assessing significant changes and trends related to our results of operations and financial position. This discussion and analysis should be read in conjunction with the unaudited condensed consolidated and combined financial statements and accompanying footnotes in Item 1 of Part I of this Quarterly Report on Form 10-Q. Certain statements in this Item 2 of Part I of this Quarterly Report on Form 10-Q constitute forward-looking statements. Various risks and uncertainties, including those discussed in "Forward-Looking Statements" and in “Risk Factors” included in our final prospectus relating to our initial public offering filed on September 21, 2018 (IPO Prospectus), may cause our actual results, financial position, and cash generated from operations to differ materially from these forward-looking statements.
Overview
Founded in 1954 as part of Eli Lilly and Company, Elanco is a premier animal health company that innovates, develops, manufactures and markets products for companion and food animals. Headquartered in Greenfield, Indiana, we are the fourth largest animal health company in the world. We have one of the broadest portfolios of pet parasiticides in the companion animal sector. We offer a diverse portfolio of more than 125 brands that make us a trusted partner to veterinarians and food animal producers in more than 90 countries.
We operate our business in a single segment directed at fulfilling our vision of enriching the lives of people through food - making protein more accessible and affordable - and through pet companionship - helping pets live longer, healthier lives. We advance our vision by offering products in four primary categories:
Companion Animal Disease Prevention (CA Disease Prevention): We have one of the broadest parasiticide portfolios in the companion animal sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. Combining our parasiticide portfolio with our vaccines presence, we are a leader in the United States (U.S.) in the disease prevention category based on share of revenue.
Companion Animal Therapeutics (CA Therapeutics): We have a broad pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. Pet owners are increasingly treating osteoarthritis in their pets, and our Galliprant product is one of the fastest growing osteoarthritis treatments in the U.S. We also have treatments for otitis (ear infections), as well as cardiovascular and dermatology indications.
Food Animal Future Protein & Health (FA Future Protein & Health): Our portfolio in this category, which includes vaccines, nutritional enzymes and animal only antibiotics, serves the growing demand for protein and includes innovative products in poultry and aquaculture production, where demand for animal health products is outpacing overall industry growth. We are focused on developing functional nutritional health products that promote food animal health, including enzymes, probiotics and prebiotics. We are a leader in providing vaccines as alternatives to antibiotics to promote animal health based on share of revenue.
Food Animal Ruminants & Swine (FA Ruminants & Swine): We have developed a range of food animal products used extensively in ruminant (e.g., cattle, sheep and goats) and swine production.
On September 24, 2018, we completed an initial public offering resulting in the issuance of 72.3 million shares our common stock (IPO), which represented approximately 19.8% of our total outstanding shares. Our common stock began trading on the New York Stock Exchange under the symbol "ELAN" on September 20, 2018. Prior to and in connection with the IPO, we completed a $2.0 billion senior notes offering and entered into a $500.0 million term loan, and Lilly transferred to us substantially all of the assets and liabilities of their animal health business. Lilly continues to own the remaining 80.2% of our outstanding shares. Lilly has informed us that it may make a tax-free distribution to its shareholders of all or a portion of its remaining equity interest in us, which may include one or more distributions effected as a dividend to all Lilly shareholders, one or more distributions in exchange for Lilly shares or other securities, or any combination thereof. We refer to any such potential distribution as the Distribution. Lilly has no obligation to pursue or consummate any further dispositions of its ownership interest in us, including through the Distribution, by any specified date or at all.
For the three months ended September 30, 2018 and 2017, our revenue was $761.1 million and $697.1 million,

22


respectively. For the three months ended September 30, 2018 and 2017, our net income (loss) was $60.2 million and $(20.7) million, respectively.
For the nine months ended September 30, 2018 and 2017, our revenue was $2,267.5 million and $2,134.7 million, respectively, For the nine months ended September 30, 2018 and 2017 our net income (loss) was $70.1 million and $(149.2) million, respectively.
Factors Affecting Our Results of Operations
Product Development and New Product Launches
A key element of our targeted value creation strategy is to drive growth through portfolio development and product innovation, primarily in our three targeted growth categories of CA Disease Prevention, CA Therapeutics and FA Future Protein & Health. Since 2015, we've launched 11 new products, five of which were launched in 2017 and 2018. We continue to pursue the development of new chemical and biological molecules through our approach to innovation. Our future growth and success depends on both our pipeline of new products, including new products that we may develop through joint ventures and products that we are able to obtain through license or acquisition, and the expansion of the use of our existing products. We believe we are an industry leader in animal health research and development (R&D), with a track record of product innovation, business development and commercialization.
Productivity
Our results have benefited from our continued operational and productivity initiatives implemented following recent acquisitions and in response to changing market demand for antibiotics and other headwinds, such as competition with generics and innovation. We implemented a number of initiatives across manufacturing, R&D and marketing, selling and administrative, such as rationalization of stock keeping units, reduction of contract manufacturing organizations, implementation of lean manufacturing principles and procurement initiatives.
Foreign Exchange Rates
Significant portions of our revenue and costs are exposed to changes in foreign exchange rates. Our products are sold in more than 90 countries and, as a result, our revenue is influenced by changes in foreign exchange rates. During the nine months ended September 30, 2018 and 2017, approximately 51.1% and 50.6%, respectively, of our revenue was denominated in foreign currencies. As we operate in multiple foreign currencies, including the Euro, British pound, Brazilian real, Australian dollar, Japanese yen, Canadian dollar, Chinese yuan, and other currencies, changes in those currencies relative to the U.S. dollar impact our revenue, cost of goods and expenses, and consequently, net income. These fluctuations may also affect the ability to buy and sell our products between markets impacted by significant exchange rate variances. There has been limited impact on our results due to currency movements during the nine months ended September 30, 2018 and 2017.
Our Relationship with Lilly and Additional Standalone Costs
During the period prior to the IPO, our business operated as part of a division of Lilly. Our combined financial statements have been derived from Lilly’s consolidated financial statements and accounting records. Our combined financial statements reflect the financial position, results of operations and cash flows of the business that was transferred at the time of the Separation and do not purport to reflect what the results of operations, comprehensive income/(loss), financial position, equity or cash flows would have been had we operated as an independent, publicly traded company during the periods presented.
Our historical results reflect an allocation of costs for certain Lilly corporate costs, including, among others, executive oversight, treasury, legal, finance, human resources, tax, internal audit, financial reporting, information technology and investor relations. These allocations are not necessarily indicative of the expenses we may incur as a standalone public company. Although we entered into certain agreements with Lilly in connection with the IPO and the Separation, the amount and composition of our expenses may vary from historical levels since the fees charged for the services under these agreements may be higher or lower than the costs reflected in the historical allocations. In addition, we intend to replace these services over time with ones supplied either internally by our employees or by third parties, the cost of which may be higher or lower than the historical allocations. During the three and nine months ended September 30, 2018 and 2017, corporate overhead and other allocations were $34.1 million, $105.2 million, $36.1 million and $107.8 million, respectively. See Note 14: Related Party Agreements and Transactions in our unaudited condensed consolidated and combined financial statements.
We are currently investing in expanding our own administrative functions, including, but not limited to, information technology, facilities management, distribution, human resources and manufacturing, to replace services previously provided by Lilly. Because of initial stand up costs and overlaps with services previously provided by Lilly, we have incurred and expect to continue to incur certain temporary, duplicative expenses in connection with the

23


Separation. We have also incurred and expect to continue to incur costs related to the build out of processes and systems to support finance and global supply and logistics, among others. We currently estimate these costs taken together to be in a range from $240 million to $290 million, of which a portion will be capitalized and the remainder will be expensed.
In addition, our historical results do not reflect the impact of costs we have incurred and expect to continue to incur as a consequence of becoming a standalone company, including incremental costs associated with being a publicly traded company. These costs include a change in compensation expense as we institute competitive compensation policies and programs as a standalone public company, the costs of internal and external audit (including those related to Sarbanes-Oxley Act of 2002), investor relations, stock administration, stock exchange fees and regulatory compliance costs.
For the purposes of our financial statements for periods prior our IPO, our effective tax rate was computed on a separate company basis, as if we had operated as a standalone entity or a separate consolidated group in each material jurisdiction in which we operate. As a result of potential changes to our business model and due the fact that we are a standalone entity, income tax expense (benefit) included in the consolidated and combined financial statements may not be indicative of our future expected tax rate.
In connection with the IPO, we entered into $2.5 billion of long-term borrowings. Our historical results for the period prior to entering into such agreements do not reflect interest expense, which we estimate at approximately $110.0 million on an annual basis.
Asset Impairment, Restructuring and Other Special Charges
Our results have been impacted by asset impairment, restructuring and other special charges, including integration of acquired businesses, during the nine months ended September 30, 2018 and 2017. These charges primarily include severance costs resulting from actions taken to reduce our cost structure, asset impairment charges related to product rationalization, site closures, and integration costs related to acquired businesses. For more information on these charges, see Note 6: Asset Impairment, Restructuring and Other Special Charges in our unaudited condensed consolidated and combined financial statements.
Results of Operations
The following discussion and analysis of our results of operations should be read along with our unaudited condensed consolidated and combined financial statements and the notes thereto, which reflect the results of operations of the business transferred to us from Lilly.

24


 
Three Months Ended September 30,
 
%
 
Nine Months Ended September 30,
 
%
 
2018
 
2017
 
Change
 
2018
 
2017
 
Change
Revenue
$
761.1

 
$
697.1

 
9
 %
 
$
2,267.5

 
$
2,134.7

 
6
 %
Costs, expenses and other:
 
 
 
 
 
 
 
 
 
 
 
Cost of sales
369.8

 
376.2

 
(2
)%
 
1,161.3

 
1,088.9

 
7
 %
% of revenue
49
%
 
54
 %
 
(5
)%
 
51
%
 
51
 %
 
—
 %
Research and development
58.9

 
61.9

 
(5
)%
 
185.5

 
189.7

 
(2
)%
% of revenue
8
%
 
9
 %
 
(1
)%
 
8
%
 
9
 %
 
(1
)%
Marketing, selling and administrative
179.0

 
194.7

 
(8
)%
 
550.1

 
583.0

 
(6
)%
% of revenue
24
%
 
28
 %
 
(4
)%
 
24
%
 
27
 %
 
(3
)%
Amortization of intangible assets
48.7

 
51.6

 
(6
)%
 
147.3

 
161.0

 
(9
)%
% of revenue
6
%
 
7
 %
 
(1
)%
 
6
%
 
8
 %
 
(1
)%
Asset impairment, restructuring and other special charges
12.4

 
23.7

 
(48
)%
 
82.8

 
189.3

 
(56
)%
Other - (income) expense
13.5

 
(1.9
)
 
NM

 
24.2

 
—

 
NM

Income (loss) before taxes
78.8

 
(9.1
)
 
NM

 
116.3

 
(77.2
)
 
NM

% of revenue
10
%
 
(1
)%
 
11
 %
 
5
%
 
(4
)%
 
NM

Income tax expense
18.6

 
11.6

 
60
 %
 
46.2

 
72.0

 
(36
)%
Net income (loss)
$
60.2

 
$
(20.7
)
 
NM

 
$
70.1

 
$
(149.2
)
 
NM

Certain amounts and percentages may reflect rounding adjustments.
Revenue
On a global basis, our revenue within our product categories was as follows:
 
Three Months Ended September 30,
 
%
 
Nine Months Ended September 30,
 
%
 
2018
 
2017
 
Change
 
2018
 
2017
 
Change
CA Disease Prevention
$
188.6

 
$
140.4

 
34
 %
 
$
603.9

 
$
519.7

 
16
 %
CA Therapeutics
80.5

 
63.5

 
27
 %
 
211.1

 
181.8

 
16
 %
FA Future Protein & Health
162.8

 
164.5

 
(1
)%
 
502.1

 
456.0

 
10
 %
FA Ruminants & Swine
301.5

 
280.4

 
8
 %
 
881.1

 
857.3

 
3
 %
Subtotal
733.4

 
648.8

 
13
 %
 
2,198.2

 
2,014.8

 
9
 %
Strategic Exits (1)
27.7

 
48.3

 
(42
)%
 
69.3

 
119.9

 
(42
)%
Total
$
761.1

 
$
697.1

 
9
 %
 
$
2,267.5

 
$
2,134.7

 
6
 %
(1) Represents revenue from business activities we have either exited or made a strategic decision to exit. 

Total revenue
Three months ended September 30, 2018 vs. three months ended September 30, 2017
Total revenue increased $64.0 million or 9% for the three months ended September 30, 2018 as compared to the three months ended September 30, 2017, reflecting a 4% increase due to higher realized prices and a 7% increase due to higher volumes partially offset by a 2% unfavorable foreign exchange rate impact.
In summary, the total revenue increase was due primarily to:
•
an increase in revenue of $49.4 million or 35% from CA Disease Prevention products, excluding the impact of foreign exchange rates;


25


•
an increase in revenue of $17.5 million or 28% from CA Therapeutics products, excluding the impact of foreign exchange rates;
•
an increase in revenue of $2.8 million or 2% from FA Future Protein & Health products, excluding the impact foreign exchange rates; and
•
an increase in revenue of $26.3 million or 10% from FA Ruminants & Swine products, excluding the impact of foreign exchange rates;
partially offset by:
•
a decrease in revenue of $11.5 million due to the negative impact of foreign exchange rates; and
•
a decrease in revenue of $20.5 million from Strategic Exits, excluding the impact of foreign exchange rates.
The detailed change in revenue by product category was as follows:
•
CA Disease Prevention revenue increased by $48.2 million or 34% primarily driven by increases in volume and price, partially offset by an unfavorable impact from foreign exchange rates. Growth was primarily driven by higher realized price on Trifexis and a favorable comparison to prior year related to an anticipated stock out in third quarter of 2017 which shifted sales of Trifexis to the second quarter of 2017. Growth was also driven by the continued uptake of Interceptor Plus and Credelio, as well as increased sales of certain vaccines from new customer agreements.
•
CA Therapeutics revenue increased by $17.0 million or 27% due to volume and increased price, partially offset by the unfavorable impact of foreign exchange rates. Growth was primarily due to the re-introduction of Galliprant 100mg for dogs, continued uptake of the product and realized price increases across the category.
•
FA Future Protein & Health revenue decreased by $1.7 million or 1% due to unfavorable impact from foreign exchange rates and a decline in volume, partially offset by increased price. Volume growth in aqua, vaccines and nutritional health products was offset by international purchasing patterns in the current year for poultry which shifted sales from the third quarter of 2018 to the first half of 2018.
•
FA Ruminants & Swine revenue increased by $21.1 million or 8% due primarily to increases in volume partially offset by the unfavorable impact of foreign exchange rates. Growth was driven mainly by U.S. and international purchasing patterns in both the current and prior year which resulted in higher sales in third quarter of 2018.
•
Strategic Exits revenue decreased by $20.6 million or 42% due primarily to reduced revenue from a temporary contract manufacturing arrangement as part of the acquisition of the BI Vetmedica U.S. vaccines portfolio (BIVIVP), as well as the termination of two legacy U.S. distribution agreements acquired as part of our Novartis Animal Health acquisition.
Nine months ended September 30, 2018 vs. nine months ended September 30, 2017
Total revenue increased $132.8 million or 6% for the nine months ended September 30, 2018 as compared to the nine months ended September 30, 2017, reflecting a 1% favorable foreign exchange rate impact, a 3% increase due to higher realized prices and a 2% increase due to higher volumes.
In summary, the total revenue increase was due primarily to:
•
an increase in revenue of $22.9 million due to the positive impact of foreign exchange rates;
•
an increase in revenue of $79.6 million or 15% from CA Disease Prevention products, excluding the impact foreign exchange rates;
•
an increase in revenue of $24.3 million or 13% from CA Therapeutics products, excluding the impact of foreign exchange rates;
•
an increase in revenue of $39.4 million or 9% from FA Future Protein & Health products, excluding the impact of foreign exchange rates;
•
an increase in revenue of $17.7 million or 2% from FA Ruminants & Swine, excluding the

26


impact of foreign exchange rates; and
partially offset by:
•
a decrease in revenue of $51.1 million from Strategic Exits, excluding the impact of foreign exchange rates.
The detailed change in revenue by product category was as follows:
•
CA Disease Prevention revenue increased by $84.2 million or 16% due primarily to the continued uptake of Credelio and Interceptor Plus, as well as realized price increases primarily impacting Trifexis, Capstar and Comfortis, partially offset by competition in certain parasiticides, primarily impacting Trifexis and Comfortis.
•
CA Therapeutics revenue increased by $29.3 million or 16% due primarily to the continued uptake of Galliprant and Osurnia, as well as increased demand for Atopica and Onsior, partially offset by a temporary supply shortage of Percorten V used for the treatment of canine Addison’s Disease.
•
FA Future Protein & Health revenue increased by $46.1 million or 10% due primarily to the launch of Imvixa and the growth in poultry animal-only antibiotics and AviPro.
•
FA Ruminants & Swine revenue increased by $23.8 million or 3% due primarily to growth in animal-only and shared-class antibiotics, offset by competition from generic ractopamine based products.
•
Strategic Exits revenue decreased by $50.6 million or 42% due to reduced revenue from a temporary contract manufacturing arrangement as part of the acquisition of BIVIVP, as well as the termination in the third quarter of 2017 of a legacy U.S. distribution agreement acquired as part of our Novartis Animal Health acquisition.
Costs and Expenses and Other
Cost of sales
Three months ended September 30, 2018 vs. three months ended September 30, 2017
Cost of sales decreased $6.4 million in the three months ended September 30, 2018 as compared to three months ended September 30, 2017 due primarily to the mix of products sold, the results of the manufacturing productivity agenda and non-recurring costs in 2017 associated with purchase accounting charges from the acquisition of BIVIVP related to the fair value adjustments of inventory acquired that was subsequently sold, partially offset by costs related to increased volume of products sold and various cost increases.
Nine months ended September 30, 2018 vs. nine months ended September 30, 2017
Cost of sales increased $72.4 million in the nine months ended September 30, 2018 as compared to nine months ended September 30, 2017 primarily due to costs related to increased volume of products sold, the write-off of inventory primarily related to the suspension of activities for Imrestor and various cost increases, partially offset by non-recurring costs in 2017 associated with purchase accounting charges from the acquisition of BIVIVP related to the fair value adjustments of inventory acquired that was subsequently sold.
Research and development
Three months ended September 30, 2018 vs. months ended September 30, 2017
R&D expenses decreased $3.0 million for the three months ended September 30, 2018 as compared to the three months ended September 30, 2017 due primarily to normal project spend fluctuations and restructuring savings.
Nine months ended September 30, 2018 vs. nine months ended September 30, 2017
R&D expenses decreased $4.2 million for the nine months ended September 30, 2018 as compared to the nine months ended September 30, 2017 due primarily to site closures and headcount reductions in early 2017.
Marketing, selling and administrative
Three months ended September 30, 2018 vs. three months ended September 30, 2017
Marketing, selling and administrative expenses decreased $15.7 million for the three months ended September 30, 2018 as compared to the three months ended September 30, 2017 due primarily to productivity initiatives and cost control measures across these functions.

27


Nine months ended September 30, 2018 vs. nine months ended September 30, 2017
Marketing, selling and administrative expenses decreased $32.9 million for the nine months ended September 30, 2018 as compared to the nine months ended September 30, 2017 due primarily to productivity initiatives and reduced direct to consumer programs.
Amortization of intangible assets
Three months ended September 30, 2018 vs. three months ended September 30, 2017
Amortization of intangible assets decreased $2.9 million for the three months ended September 30 2018 as compared to the three months ended September 30, 2017 due primarily to the acceleration of amortization related to certain product exits in 2017.
Nine months ended September 30, 2018 vs. nine months ended September 30, 2017
Amortization of intangible assets decreased $13.7 million for the nine months ended September 30, 2018 as compared to the nine months ended September 30, 2017 due primarily to the acceleration of amortization related to certain product exits in 2017.
Asset impairment, restructuring and other special charges
For additional information regarding our asset impairment, restructuring and other special charges, see Note 6: Asset Impairment, Restructuring and Other Special Charges to our unaudited condensed consolidated and combined financial statements.
Three months ended September 30, 2018 vs. three months ended September 30, 2017
Asset impairment, restructuring and other special charges decreased $11.3 million for the three months ended September 30, 2018 as compared to the three months ended September 30, 2017 primarily due to decreased severance, integration and exit costs, partially offset by higher asset impairments.
Nine months ended September 30, 2018 vs. nine months ended September 30, 2017
Asset impairment, restructuring and other special charges decreased $106.5 million for the nine months ended September 30, 2018 as compared to the nine months ended September 30, 2017 primarily due to a decrease in severance, integration and exit costs, partially offset by an increase in asset impairments and a gain on disposal of a site that was previously closed as part of the acquisition and integration of Novartis Animal Health in 2017.
Income tax expense
Three months ended September 30, 2018 vs. three months ended September 30, 2017
Income tax expense increased $7.0 million for the three months ended September 30, 2018 as compared to the three months ended September 30, 2017 primarily due to an increase in pretax earnings offset by a decrease in the U.S. valuation allowance related to utilization of prior years' net operating losses.
Nine months ended September 30, 2018 vs. nine months ended September 30, 2017
Income tax expense decreased $25.8 million for the nine months ended September 30, 2018 as compared to the nine months ended September 30, 2017 primarily due to a decrease in the U.S. valuation allowance related to the utilization of prior years' net operating losses.
Liquidity and Capital
We historically participated in Lilly’s centralized treasury management system, including centralized cash pooling and overall financing arrangements. We have generated and expect to continue to generate positive cash flows from operations. In connection with the IPO, we entered into various long-term debt agreements as described below.
Our primary sources of liquidity are cash on hand, cash flows from operations and funds available under our Credit Facilities. As a significant portion of our business is conducted outside the U.S., we hold a significant portion of cash outside of the U.S. We monitor and adjust the amount of foreign cash based on projected cash flow requirements. Our ability to use foreign cash to fund cash flow requirements in the U.S. may be impacted by local regulations and, to a lesser extent, following U.S. tax reforms, the income taxes associated with transferring cash to the U.S. As our structure evolves as a standalone company, we may change that strategy, particularly to the extent we identify tax efficient reinvestment alternatives for our foreign earnings or change our cash management strategy.
Our principal liquidity needs going forward include funding existing marketed and pipeline products, capital

28


expenditures, business development in our targeted areas, interest expense and an anticipated dividend. We believe our cash and cash equivalents on hand, our operating cash flows and our existing financing arrangements will be sufficient to support our cash needs for the foreseeable future, including for at least the next 12 months.
Our ability to meet future funding requirements may be impacted by macroeconomic, business and financial volatility. As markets change, we will continue to monitor our liquidity position. However, a challenging economic environment or an economic downturn may impact our liquidity or ability to obtain future financing. See Forward-Looking Statements.
Cash Flows
The following table provides a summary of cash flows from operating, investing and financing activities for the periods presented:
 
Nine Months Ended September 30,
%
Net cash provided by (used in):
2018
 
2017
Change
Operating activities
$
347.8

 
$
167.1

108
 %
Investing activities
(78.9
)
 
(929.1
)
(92
)%
Financing activities
327.2

 
843.5

(61
)%
Effect of exchange-rate changes on cash and cash equivalents
15.4

 
3.3

367
 %
Net increase in cash, cash equivalents and restricted cash
$
611.5

 
$
84.8

621
 %
Operating activities
Our cash flow from operating activities increased by $180.7 million from $167.1 million for the nine months ended September 30, 2017 to $347.8 million for the nine months ended September 30, 2018.  The increase is a result of an increase in net income, which was partially offset by cash used to finance working capital. 
Investing activities
Our cash flow used in investing activities decreased from $929.1 million for the nine months ended September 30, 2017 to $78.9 million for the nine months ended September 30, 2018. Our cash used in investing activities for the nine months ended September 30, 2017 included $882.1 million related to the acquisition of BIVIVP. This decrease was offset by a net increase of $42.6 million in capital expenditures from 2017 to 2018.
Financing activities
Our cash provided by financing activities decreased from $843.5 million for the nine months ended September 30, 2017 to $327.2 million for the nine months ended September 30, 2018. The cash flows in 2017 relate to net cash provided by transactions with Lilly of $844.0 million compared to cash used in transactions with Lilly of $247.4 million in 2018, a reduction in financing of cash flows between periods of $1.1 billion. This was offset by the net cash provided from the financing transactions related to the Separation including the proceeds from long-term debt and our IPO, which was only partially offset by the consideration paid to Lilly in connection with the Separation. The remainder of the proceeds from the financing related to the Separation will be paid to Lilly in future periods and is reflected as restricted cash in our consolidated balance sheet.
Description of Indebtedness
During the three months ended September 30, 2018, we issued $2.0 billion of senior notes, entered into a $500.0 million three-year term loan, and entered into five-year $750.0 million senior unsecured revolving credit facility. For more information, see Note 8: Debt in our unaudited condensed consolidated and combined financial statements.
Off Balance Sheet Arrangements
We have no off balance sheet arrangements that currently have a material effect or that are reasonably likely to have a material future effect on our financial condition, changes in financial condition, revenue or expenses, results of operations, liquidity, capital expenditures or capital resources.
Critical Accounting Policies
The preparation of financial statements in accordance with GAAP requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. There are certain of our

29


accounting policies that are considered critical, as these policies are the most important to the depiction of our financial statements and require significant, difficult or complex judgments, often employing the use of estimates about the effects of matters that are inherently uncertain. Such policies are summarized in the Management’s Discussion and Analysis of Financial Condition and Results of Operations section in our IPO Prospectus. There have been no significant changes in the application of our critical accounting policies during 2018.
Contractual Obligations
See Contractual Obligations included in our IPO Prospectus. During the nine months ended September 30, 2018, we issued $2.0 billion of senior notes, entered into a $500.0 million three-year term loan, and entered into five-year $750.0 million senior unsecured revolving credit facility. For more information, see Note 8: Debt in our unaudited condensed consolidated and combined financial statements.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
Foreign Exchange Risk
We operate on a global basis and are exposed to the risk that our earnings, cash flows and equity could be adversely impacted by fluctuations in foreign exchange rates. We are primarily exposed to foreign exchange risk with respect to net assets denominated in the Euro, British pound, Canadian dollar, Australian dollar and Brazilian real. Lilly maintains a foreign currency risk management program through a central shared entity, which enters into derivative contracts to hedge foreign currency risk associated with forecasted transactions for the entire company, including historically for our operations. Gains and losses on derivative contracts entered into by Lilly have been allocated to our results to the extent they were to cover exposure related to our business and offset gains and losses on underlying foreign currency exposures. Following the Separation, we intend to implement our own foreign currency risk management program.
We also face currency exposure that arises from translating the results of our global operations to the U.S. dollar at exchange rates that have fluctuated from the beginning of the period. We may enter into foreign currency forward or option derivative contracts to reduce the effect of fluctuating currency exchange rates in future periods, but our historical results do not reflect the impact of any such derivatives related to our exposure to foreign currency impacts on translation.
We estimate that a hypothetical 10% adverse movement in all foreign currency exchange rates related to the translation of the results of our foreign operations would decrease our net income by approximately $12.0 million for the nine months ended September 30, 2018.
Interest Risk
We are exposed to interest rate risk on the long-term debt we entered into in connection with our IPO. Prior to our IPO, we did not have any interest rate exposure. We have cash flow risk associated with our $500.0 million of borrowings that pay interest based on variable rates. We actively monitor our exposure and will enter into financial instrument to fix the interest rate based on our assessment of the risk.
Recently Issued Accounting Pronouncements
For discussion of our new accounting standards, see Note 4: Implementation of New Financial Accounting Pronouncements to our unaudited condensed consolidated and combined financial statements.
Item 4. Controls and Procedures
(a)Evaluation of Disclosure Controls and Procedures. Under applicable SEC regulations, management of a reporting company, with the participation of the principal executive officer and principal financial officer, must periodically evaluate the company’s “disclosure controls and procedures,” which are defined generally as controls and other procedures of a reporting company designed to ensure that information required to be disclosed by the reporting company in its periodic reports filed with the SEC (such as this Form 10-Q) is recorded, processed, summarized, and reported on a timely basis.
Our management, with the participation of Jeff Simmons, president and chief executive officer, and Todd Young, executive vice president and chief financial officer, evaluated our disclosure controls and procedures as of September 30, 2018. Based on this evaluation, the chief executive officer and the chief financial officer concluded that the disclosure controls and procedures are effective.

30


(b)Changes in Internal Controls. During the third quarter of 2018, there were no changes in our internal control over financial reporting that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II. Other Information
Item 1. Legal Proceedings
(none)
Item 1A. Risk Factors
Our material risk factors are disclosed in our IPO Prospectus. There have been no material changes from the risk factors previously disclosed in our IPO Prospectus.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Use of Proceeds from Registered Securities
On September 24, 2018, we completed our IPO resulting in the issuance of 72.3 million shares of our common stock at a price to the public of $24.00 per share, which number of shares included the underwriters’ exercise in full of their option to purchase up to an additional 9.4 million shares of common stock at the IPO price, less underwriting discounts. The 72.3 million shares of our common stock sold in the IPO represent approximately 19.8% of our outstanding shares, while Lilly continues to own approximately 80.2% of our outstanding shares. The shares sold in the offering were registered under the Securities Act pursuant to a registration statement on Form S-1 (File No. 333-226536), which was declared effective by the SEC as of September 19, 2018. The aggregate offering price of our common stock registered and sold under the registration statement was approximately $1,736.0 million (including the shares issued pursuant to the underwriters’ option to purchase additional shares). Our proceeds from the IPO were approximately $1,659.7 million, after deducting underwriting discounts and commissions of approximately $76.4 million. Goldman, Sachs & Co. LLC, J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC served as joint book-running managers and as representatives of the underwriters for the IPO. The offering commenced on September 19, 2018 and did not terminate before all of the securities registered in the registration statement were sold.
As contemplated by the IPO Prospectus, we have paid, or will pay, to Lilly approximately $4.2 billion in connection with the Separation, which includes the net proceeds from the IPO. A portion of the aggregate payment to Lilly is currently retained by us and is reflected on our balance sheet as restricted cash.
There has been no material change in the planned use of the IPO proceeds as described in the IPO Prospectus.
Item 3. Defaults Upon Senior Securities
(none)
Item 4. Mine Safety Disclosures
(none)
Item 5. Other Information
(none)
Item 6. Exhibits
The following exhibits are either filed or furnished herewith (as applicable) or, if so indicated, incorporated by reference to the documents indicated in parentheses, which have previously been filed or furnished with the Securities and Exchange Commission.
Exhibit Number
Description
3.1
Amended and Restated Articles of Incorporation of Elanco Animal Health Incorporated, effective September 18, 2018 (incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed with the SEC on September 26, 2018).

31


3.2
Amended and Restated Bylaws of Elanco Animal Health Incorporated, effective September 19, 2018 (incorporated by reference to Exhibit 3.2 of the Current Report on Form 8-K filed with the SEC on September 26, 2018).
4.1
Form of Certificate of Common Stock (incorporated by reference to Exhibit 4.1 of Amendment No. 2 to Registration Statement on Form S-1 (Registration No. 333-226536) filed with the SEC on September 6, 2018).
4.2
Indenture, dated August 28, 2018, between Elanco Animal Health Incorporated and Deutsche Bank Trust Company Americas, as trustee (incorporated by reference to Exhibit 4.2 of Amendment No. 2 to Registration Statement on Form S-1 (Registration No. 333-226536) filed with the SEC on September 6, 2018).
4.3
First Supplemental Indenture, dated August 28, 2018, between Elanco Animal Health Incorporated and Deutsche Bank Trust Company Americas, as trustee (incorporated by reference to Exhibit 4.3 of Amendment No. 2 to Registration Statement on Form S-1 (Registration No. 333-226536) filed with the SEC on September 6, 2018).
10.1
Registration Rights Agreement, dated August 28, 2018, between Elanco Animal Health Incorporated and Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC, as representatives of the several initial purchasers (incorporated by reference to Exhibit 4.4 of Amendment No. 2 to Registration Statement on Form S-1 (Registration No. 333-226536) filed with the SEC on September 6, 2018).
10.2
Master Separation Agreement, dated September 24, 2018, between Eli Lilly and Company and Elanco Animal Health Incorporated (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the SEC on September 26, 2018).
10.3
Transitional Services Agreement, dated September 24, 2018, between Eli Lilly and Company and Elanco Animal Health Incorporated (incorporated by reference to Exhibit 10.2 of the Current Report on Form 8-K filed with the SEC on September 26, 2018).
10.4
Tax Matters Agreement, dated September 24, 2018, between Eli Lilly and Company and Elanco Animal Health Incorporated (incorporated by reference to Exhibit 10.3 of the Current Report on Form 8-K filed with the SEC on September 26, 2018).
10.5
Employee Matters Agreement, dated September 24, 2018, between Eli Lilly and Company and Elanco Animal Health Incorporated (incorporated by reference to Exhibit 10.4 of the Current Report on Form 8-K filed with the SEC on September 26, 2018).
10.6
Toll Manufacturing and Supply Agreement, dated September 24, 2018, between Eli Lilly Export S.A. and Elanco UK AH Limited (incorporated by reference to Exhibit 10.5 of the Current Report on Form 8-K filed with the SEC on September 26, 2018).
10.7
Registration Rights Agreement, dated September 24, 2018, between Eli Lilly and Company and Elanco Animal Health Incorporated (incorporated by reference to Exhibit 10.6 of the Current Report on Form 8-K filed with the SEC on September 26, 2018).
10.8
Transitional Trademark License Agreement, dated September 24, 2018, among Eli Lilly and Company, Elanco Animal Health Incorporated and Elanco US Inc. (incorporated by reference to Exhibit 10.7 of the Current Report on Form 8-K filed with the SEC on September 26, 2018).
10.9
Intellectual Property and Technology License Agreement, dated September 24, 2018, among Eli Lilly and Company, Elanco Animal Health Incorporated and Elanco US Inc. (incorporated by reference to Exhibit 10.8 of the Current Report on Form 8-K filed with the SEC on September 26, 2018).
10.10
Revolving Loan Credit Agreement, dated as of September 5, 2018, among Elanco Animal Health Incorporated, as borrower, JPMorgan Chase Bank, N.A., as administrative agent and the other Lenders party thereto (incorporated by reference to Exhibit 10.24 of Amendment No. 2 to Registration Statement on Form S-1 (Registration No. 333-226536) filed with the SEC on September 6, 2018).
10.11
Term Loan Credit Agreement, dated as of September 5, 2018, among Elanco Animal Health Incorporated, as borrower, JPMorgan Chase Bank, N.A., as administrative agent and the other Lenders party thereto (incorporated by reference to Exhibit 10.25 of Amendment No. 2 to Registration Statement on Form S-1 (Registration No. 333-226536) filed with the SEC on September 6, 2018).
10.12
2018 Elanco Stock Plan (incorporated by reference to Exhibit 4.3 of Registration Statement on Form S-8 (Registration No. 333-227447) filed with the SEC on September 20, 2018).
10.13
Elanco Animal Health Incorporated Directors’ Deferral Plan (incorporated by reference to Exhibit 4.4 of Registration Statement on Form S-8 (Registration No. 333-227447) filed with the SEC on September 20, 2018).
Section 302 Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).
Section 302 Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).

32


Certification of the Chief Executive Officer and the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (filed herewith).
101
Interactive Data Files.


33


Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
ELANCO ANIMAL HEALTH INCORPORATED
 
 
(Registrant)
 
 
 
Date:
November 8, 2018
/s/ Jeff Simmons
 
 
Jeff Simmons
 
 
President and Chief Executive Officer
Date:
November 8, 2018
/s/ James Meer
 
 
James Meer
 
 
Chief Accounting Officer

34
 EX-31.1 2 elanco-20180930exhibit311x.htm EX-31.1 Exhibit


EXHIBIT 31.1

CERTIFICATIONS
I, Jeff Simmons, certify that:
1.
I have reviewed this report on Form 10-Q of Elanco Animal Health Incorporated;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):
a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and
b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date:
 
November 8, 2018
 
 
 
 
By:
 
/s/
Jeff Simmons
 
 
 
Jeff Simmons
 
 
 
President, and Chief Executive Officer



 EX-31.2 3 elanco-20180930exhibit312x.htm EX-31.2 Exhibit


EXHIBIT 31.2

CERTIFICATIONS
I, Todd Young, certify that:
1.
I have reviewed this report on Form 10-Q of Elanco Animal Health Incorporated;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):
a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and
b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date:
 
November 8, 2018
 
 
 
 
By:
 
/s/
Todd Young
 
 
 
Todd Young
 
 
 
Executive Vice President and Chief Financial Officer



 EX-32 4 elanco-20180930exhibit32xs.htm EX-32 Exhibit


EXHIBIT 32
Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Elanco Animal Health Incorporated, an Indiana corporation (the “Company”), does hereby certify that, to the best of their knowledge:
The Quarterly Report on Form 10-Q for the quarter ended September 30, 2018 (the “Form 10-Q”) of the Company fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date:
November 8, 2018
/s/
Jeff Simmons
 
 
 
Jeff Simmons
 
 
 
President, and Chief Executive Officer
 
 
 
 
 
 
 
 
 
 
 
 
Date:
November 8, 2018
/s/
Todd Young
 
 
 
Todd Young
 
 
 
Executive Vice President and Chief Financial Officer



 EX-101.INS 5 elan-20180930.xml XBRL INSTANCE DOCUMENT 0001739104 2018-01-01 2018-09-30 0001739104 2018-11-06 0001739104 2018-07-01 2018-09-30 0001739104 2017-01-01 2017-09-30 0001739104 2017-07-01 2017-09-30 0001739104 2018-09-30 0001739104 2017-12-31 0001739104 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-09-30 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-09-30 0001739104 elan:NetParentCompanyInvestmentMember 2018-09-30 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2017-09-30 0001739104 elan:NetParentCompanyInvestmentMember 2017-12-31 0001739104 us-gaap:AdditionalPaidInCapitalMember 2017-09-30 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2018-09-30 0001739104 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-01-01 2017-09-30 0001739104 elan:NetParentCompanyInvestmentMember 2017-09-30 0001739104 2016-12-31 0001739104 elan:NetParentCompanyInvestmentMember 2018-01-01 2018-09-30 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2018-01-01 2018-09-30 0001739104 us-gaap:CommonStockMember 2016-12-31 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2017-01-01 2017-09-30 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-09-30 0001739104 us-gaap:CommonStockMember 2017-12-31 0001739104 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-09-30 0001739104 us-gaap:CommonStockMember 2018-09-30 0001739104 us-gaap:CommonStockMember 2018-01-01 2018-09-30 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-09-30 0001739104 us-gaap:CommonStockMember 2017-09-30 0001739104 2017-09-30 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2017-12-31 0001739104 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2016-12-31 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-12-31 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-01-01 2018-09-30 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-30 0001739104 elan:NetParentCompanyInvestmentMember 2016-12-31 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2016-12-31 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-09-30 0001739104 elan:NetParentCompanyInvestmentMember 2017-01-01 2017-09-30 0001739104 us-gaap:IPOMember 2018-09-24 2018-09-24 0001739104 us-gaap:IPOMember 2018-09-30 0001739104 us-gaap:IPOMember 2018-08-01 2018-09-30 0001739104 us-gaap:IPOMember 2018-09-24 0001739104 srt:ScenarioPreviouslyReportedMember elan:RebatesRelatedToProductHeldInWholesalersPipelineMember 2017-12-31 0001739104 srt:ScenarioPreviouslyReportedMember elan:RebatesRelatedToProductHeldInWholesalersPipelineMember 2016-12-31 0001739104 srt:RestatementAdjustmentMember elan:RebatesRelatedToProductHeldInWholesalersPipelineMember 2017-12-31 0001739104 srt:RestatementAdjustmentMember elan:RebatesRelatedToProductHeldInWholesalersPipelineMember 2016-12-31 0001739104 us-gaap:SeniorNotesMember 2018-08-28 0001739104 elan:EliLillyandCompanyMember elan:ElancoAnimalHealthIncorporatedAndSubsidiariesMember 2018-09-30 0001739104 2018-09-24 2018-09-24 0001739104 elan:TermCreditFacilityMember us-gaap:LineOfCreditMember 2018-09-24 0001739104 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2018-09-24 0001739104 us-gaap:AccountingStandardsUpdate201616Member 2018-09-30 0001739104 country:US elan:ContractWithCustomerLiabilityMember us-gaap:GeographicConcentrationRiskMember 2017-01-01 2017-09-30 0001739104 us-gaap:NonUsMember elan:ContractWithCustomerLiabilityMember us-gaap:GeographicConcentrationRiskMember 2017-01-01 2017-09-30 0001739104 us-gaap:RevenueFromContractWithCustomerMember elan:ProductReturnConcentrationRiskMember 2018-07-01 2018-09-30 0001739104 us-gaap:NonUsMember elan:ContractWithCustomerLiabilityMember us-gaap:GeographicConcentrationRiskMember 2018-01-01 2018-09-30 0001739104 country:US elan:ContractWithCustomerLiabilityMember us-gaap:GeographicConcentrationRiskMember 2018-01-01 2018-09-30 0001739104 elan:CompanionAnimalDiseasePreventionMember 2018-01-01 2018-09-30 0001739104 elan:CompanionAnimalOtherMember 2018-01-01 2018-09-30 0001739104 elan:FoodAnimalRuminantsAndSwineMember 2018-07-01 2018-09-30 0001739104 elan:FoodAnimalRuminantsAndSwineMember 2018-01-01 2018-09-30 0001739104 elan:CompanionAnimalTherapeuticsMember 2017-07-01 2017-09-30 0001739104 elan:CompanionAnimalDiseasePreventionMember 2017-07-01 2017-09-30 0001739104 elan:CompanionAnimalOtherMember 2018-07-01 2018-09-30 0001739104 elan:FoodAnimalFutureProteinAndHealthMember 2018-07-01 2018-09-30 0001739104 elan:FoodAnimalFutureProteinAndHealthMember 2018-01-01 2018-09-30 0001739104 elan:CompanionAnimalDiseasePreventionMember 2018-07-01 2018-09-30 0001739104 elan:FoodAnimalFutureProteinAndHealthMember 2017-01-01 2017-09-30 0001739104 elan:CompanionAnimalTherapeuticsMember 2018-07-01 2018-09-30 0001739104 elan:CompanionAnimalOtherMember 2017-01-01 2017-09-30 0001739104 elan:FoodAnimalRuminantsAndSwineMember 2017-01-01 2017-09-30 0001739104 elan:CompanionAnimalTherapeuticsMember 2018-01-01 2018-09-30 0001739104 elan:CompanionAnimalTherapeuticsMember 2017-01-01 2017-09-30 0001739104 elan:CompanionAnimalDiseasePreventionMember 2017-01-01 2017-09-30 0001739104 elan:FoodAnimalRuminantsAndSwineMember 2017-07-01 2017-09-30 0001739104 elan:FoodAnimalFutureProteinAndHealthMember 2017-07-01 2017-09-30 0001739104 elan:CompanionAnimalOtherMember 2017-07-01 2017-09-30 0001739104 2017-06-30 0001739104 2018-06-30 0001739104 us-gaap:RevenueFromContractWithCustomerMember elan:ProductReturnConcentrationRiskMember 2018-01-01 2018-09-30 0001739104 us-gaap:RevenueFromContractWithCustomerMember elan:ProductReturnConcentrationRiskMember 2017-07-01 2017-09-30 0001739104 us-gaap:RevenueFromContractWithCustomerMember elan:ProductReturnConcentrationRiskMember 2017-01-01 2017-09-30 0001739104 us-gaap:FacilityClosingMember 2018-01-01 2018-09-30 0001739104 us-gaap:EmployeeSeveranceMember 2018-01-01 2018-09-30 0001739104 us-gaap:FacilityClosingMember 2016-12-31 0001739104 us-gaap:FacilityClosingMember 2017-01-01 2017-09-30 0001739104 us-gaap:EmployeeSeveranceMember 2017-12-31 0001739104 us-gaap:EmployeeSeveranceMember 2017-09-30 0001739104 us-gaap:EmployeeSeveranceMember 2017-01-01 2017-09-30 0001739104 us-gaap:EmployeeSeveranceMember 2018-09-30 0001739104 us-gaap:FacilityClosingMember 2017-09-30 0001739104 us-gaap:EmployeeSeveranceMember 2016-12-31 0001739104 us-gaap:FacilityClosingMember 2017-12-31 0001739104 us-gaap:FacilityClosingMember 2018-09-30 0001739104 us-gaap:NotesPayableOtherPayablesMember 2018-09-30 0001739104 elan:TermCreditFacilityMember us-gaap:LineOfCreditMember 2018-09-30 0001739104 elan:A3.912SeniorNotesDue2021Member us-gaap:SeniorNotesMember 2018-09-30 0001739104 elan:A4.272SeniorNotesDue2023Member us-gaap:SeniorNotesMember 2018-09-30 0001739104 elan:A4.9SeniorNotesDue2028Member us-gaap:SeniorNotesMember 2018-09-30 0001739104 elan:TermCreditFacilityMember us-gaap:LineOfCreditMember 2018-09-05 0001739104 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2018-09-05 0001739104 elan:A3.912SeniorNotesDue2021Member us-gaap:SeniorNotesMember 2018-08-28 0001739104 elan:TermCreditFacilityMember us-gaap:LineOfCreditMember 2018-09-05 2018-09-05 0001739104 elan:A4.272SeniorNotesDue2023Member us-gaap:SeniorNotesMember 2018-08-28 0001739104 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2017-12-31 0001739104 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2018-09-05 2018-09-05 0001739104 elan:A4.9SeniorNotesDue2028Member us-gaap:SeniorNotesMember 2018-08-28 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001739104 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-09-30 0001739104 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-09-30 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2018-09-30 0001739104 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2018-09-30 0001739104 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-09-30 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2018-09-30 0001739104 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-09-30 0001739104 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2018-09-30 0001739104 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-09-30 0001739104 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001739104 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001739104 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-09-30 0001739104 elan:AratanaTherapeuticsInc.Member 2018-04-01 2018-06-30 0001739104 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2018-09-30 0001739104 us-gaap:ForeignCountryMember 2018-09-30 0001739104 us-gaap:StateAndLocalJurisdictionMember 2018-09-30 0001739104 elan:OtherForeignCountriesNotSeparatelyDisclosedMember 2018-09-30 0001739104 elan:OtherForeignCountriesNotSeparatelyDisclosedMember 2017-12-31 0001739104 country:GB 2018-09-30 0001739104 country:US 2018-09-30 0001739104 country:GB 2017-12-31 0001739104 country:US 2017-12-31 0001739104 elan:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2017-01-01 2017-09-30 0001739104 us-gaap:ProductMember 2018-09-30 0001739104 elan:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-09-30 0001739104 elan:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-07-01 2018-09-30 0001739104 elan:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2017-07-01 2017-09-30 0001739104 us-gaap:ProductMember 2017-12-31 0001739104 us-gaap:NonUsMember 2017-07-01 2017-09-30 0001739104 country:US 2017-07-01 2017-09-30 0001739104 us-gaap:NonUsMember 2018-01-01 2018-09-30 0001739104 country:US 2018-07-01 2018-09-30 0001739104 us-gaap:NonUsMember 2017-01-01 2017-09-30 0001739104 us-gaap:NonUsMember 2018-07-01 2018-09-30 0001739104 country:US 2017-01-01 2017-09-30 0001739104 country:US 2018-01-01 2018-09-30 0001739104 elan:EliLillyandCompanyMember elan:ElancoAnimalHealthIncorporatedAndSubsidiariesMember 2018-09-18 0001739104 2018-09-19 2018-09-19 0001739104 us-gaap:OverAllotmentOptionMember 2018-09-24 2018-09-24 0001739104 elan:IPOExcludingOverAllotmentOptionMember 2018-09-24 2018-09-24 0001739104 us-gaap:ResearchAndDevelopmentExpenseMember elan:TransitionalServicesAgreementMember us-gaap:MajorityShareholderMember 2018-07-01 2018-09-30 0001739104 elan:TransitionalServicesAgreementMember us-gaap:MajorityShareholderMember 2018-01-01 2018-09-30 0001739104 us-gaap:CostOfSalesMember elan:TransitionalServicesAgreementMember us-gaap:MajorityShareholderMember 2017-07-01 2017-09-30 0001739104 elan:TransitionalServicesAgreementMember us-gaap:MajorityShareholderMember 2017-01-01 2017-09-30 0001739104 us-gaap:SellingGeneralAndAdministrativeExpensesMember elan:TransitionalServicesAgreementMember us-gaap:MajorityShareholderMember 2018-07-01 2018-09-30 0001739104 us-gaap:ResearchAndDevelopmentExpenseMember elan:TransitionalServicesAgreementMember us-gaap:MajorityShareholderMember 2018-01-01 2018-09-30 0001739104 us-gaap:SellingGeneralAndAdministrativeExpensesMember elan:TransitionalServicesAgreementMember us-gaap:MajorityShareholderMember 2018-01-01 2018-09-30 0001739104 us-gaap:SellingGeneralAndAdministrativeExpensesMember elan:TransitionalServicesAgreementMember us-gaap:MajorityShareholderMember 2017-01-01 2017-09-30 0001739104 us-gaap:CostOfSalesMember elan:TransitionalServicesAgreementMember us-gaap:MajorityShareholderMember 2017-01-01 2017-09-30 0001739104 us-gaap:CostOfSalesMember elan:TransitionalServicesAgreementMember us-gaap:MajorityShareholderMember 2018-07-01 2018-09-30 0001739104 elan:TransitionalServicesAgreementMember us-gaap:MajorityShareholderMember 2018-07-01 2018-09-30 0001739104 us-gaap:CostOfSalesMember elan:TransitionalServicesAgreementMember us-gaap:MajorityShareholderMember 2018-01-01 2018-09-30 0001739104 us-gaap:ResearchAndDevelopmentExpenseMember elan:TransitionalServicesAgreementMember us-gaap:MajorityShareholderMember 2017-07-01 2017-09-30 0001739104 us-gaap:ResearchAndDevelopmentExpenseMember elan:TransitionalServicesAgreementMember us-gaap:MajorityShareholderMember 2017-01-01 2017-09-30 0001739104 us-gaap:SellingGeneralAndAdministrativeExpensesMember elan:TransitionalServicesAgreementMember us-gaap:MajorityShareholderMember 2017-07-01 2017-09-30 0001739104 elan:TransitionalServicesAgreementMember us-gaap:MajorityShareholderMember 2017-07-01 2017-09-30 0001739104 elan:CommercialOperationsMember us-gaap:DirectorMember 2018-01-01 2018-09-30 0001739104 elan:CommercialOperationsMember us-gaap:DirectorMember 2017-07-01 2017-09-30 0001739104 elan:CommercialOperationsMember us-gaap:DirectorMember 2017-01-01 2017-09-30 0001739104 elan:MasterSeparationAgreementMember us-gaap:MajorityShareholderMember 2018-09-30 0001739104 us-gaap:MajorityShareholderMember 2017-01-01 2017-09-30 0001739104 elan:ManufacturingSupportMember us-gaap:MajorityShareholderMember 2017-07-01 2017-09-30 0001739104 us-gaap:MajorityShareholderMember 2018-01-01 2018-09-30 0001739104 elan:BoehringerIngelheimVetmedicaInc.Member 2017-01-01 2017-09-30 0001739104 elan:CommercialOperationsMember us-gaap:DirectorMember 2018-09-30 0001739104 elan:CommercialOperationsMember us-gaap:DirectorMember 2018-07-01 2018-09-30 0001739104 elan:ManufacturingSupportMember us-gaap:MajorityShareholderMember 2017-01-01 2017-09-30 0001739104 elan:CommercialOperationsMember us-gaap:DirectorMember 2017-12-31 0001739104 elan:ManufacturingSupportMember us-gaap:MajorityShareholderMember 2018-01-01 2018-09-30 0001739104 us-gaap:MajorityShareholderMember 2018-07-01 2018-09-30 0001739104 us-gaap:MajorityShareholderMember 2017-07-01 2017-09-30 0001739104 elan:ManufacturingSupportMember us-gaap:MajorityShareholderMember 2018-07-01 2018-09-30 xbrli:pure iso4217:USD xbrli:shares xbrli:shares elan:brand elan:segment elan:country iso4217:USD false --12-31 Q3 2018 2018-09-30 10-Q 0001739104 365625000 false Non-accelerated Filer Elanco Animal Health Inc. false 4194900000 4194900000 43800000 102500000 49600000 183300000 49100000 165500000 P6M -10500000 7484800000 8036900000 -10500000 8047400000 0 -300000 293290000 100 125 3600000000 0 3559100000 844000000 -247400000 359900000 300000000.0 0.07 84500000 275000000 23700000 161500000 6200000 18900000 0 43800000 6200000 63900000 4200000000 -7882600000 7882600000 58300000 58300000 2200000 56100000 56100000 38100000 862700000 862700000 -116800000 -226300000 -226300000 203800000 202700000 300000 400000 567400000 88000000 606100000 79500000 2000000 1900000 834100000 894500000 -256600000 -210300000 0 5347400000 6200000 18700000 6900000 20200000 9800000 8800000 51600000 161000000 48700000 147300000 0 43800000 6200000 63900000 8940300000 9211500000 2123700000 2703700000 8500000 6400000 75100000 4900000 10500000 11500000 24300000 1500000 11200000 343600000 323400000 300000000 258800000 343600000 323400000 934900000 84800000 611500000 5000000000 5000000000 365625000 365625000 365625000 365625000 0 0 -24700000 82600000 154700000 60300000 0.094 0.01 0.119 0.71 0.06 0.01 0.111 0.01 0.115 0.70 0.08 0.01 116100000 118700000 117700000 114800000 10500000 155000000 99100000 103500000 165500000 147900000 48600000 184900000 53500000 154200000 376200000 1088900000 369800000 1161300000 706200000 2211900000 682300000 2151200000 -300000 -300000 0 500000000 500000000 750000000 750000000 200000 500000000 750000000 750000000 2000000000 0.03912 0.04272 0.04900 0.03912 0.04272 0.049 P3Y P5Y 21700000 -7000000 12600000 251900000 125000000 190000000 6200000 -1600000 -300000 231300000 222300000 0 634900000 -0.06 -0.41 0.16 0.19 3300000 15400000 0.236 0.397 89300000 81300000 0 16000000 0 0 16000000 0 2969200000 2968800000 19900000 44000000 -9100000 -77200000 78800000 116300000 11600000 72000000 18600000 46200000 -31200000 -42700000 83400000 2672800000 2514800000 452000000 408100000 1102400000 1051800000 40100000 43100000 1062300000 1008700000 70400000 71400000 580000000 572300000 38600000 12300000 14900000 1160000000 10500000 1149500000 4074400000 8940300000 9211500000 643100000 10500000 632600000 1245400000 0.0350 500000000 750000000 500000000 750000000 0 0 2478500000 0 2500000000 0 2478500000 0.802 843500000 327200000 -929100000 -78900000 167100000 347800000 -20700000 -149200000 -149200000 60200000 70100000 70100000 999300000 204400000 604700000 190200000 975900000 195900000 589500000 190500000 0 0 17400000 17400000 17400000 0 0 41400000 41400000 41400000 0 0 1300000 1300000 1300000 0 0 45200000 45200000 45200000 1900000 0 -13500000 -24200000 90 1 242000000 100000000 -4000000 231800000 3700000 231800000 228100000 94500000 -9800000 10800000 -9800000 -20600000 184500000 178600000 126000000 89500000 2800000 3500000 34500000 30800000 15300000 4600000 69400000 61800000 7600000 33500000 22600000 10900000 882100000 882100000 0 31700000 74300000 139000000 136000000 1700000 5100000 136100000 123200000 0 1659700000 0 2477700000 -500000 -3700000 920300000 909300000 7700000 700000 27700000 36100000 23000000 2100000 82700000 107800000 7000000 700000 26400000 34100000 21800000 2200000 81200000 105200000 1100000 5300000 1400000 3300000 61900000 189700000 58900000 185500000 275000000 0 0 634900000 86400000 62100000 24300000 8400000 -2800000 11200000 38100000 26600000 11500000 55100000 26900000 28200000 78000000 43100000 34900000 47000000 17700000 29300000 -5900000 0 -5900000 23700000 189300000 12400000 82800000 697100000 140400000 48300000 63500000 164500000 280400000 2134700000 519700000 119900000 181800000 456000000 857300000 761100000 188600000 27700000 80500000 162800000 301500000 2267500000 603900000 69300000 211100000 502100000 881100000 697100000 321400000 375700000 2134700000 1054600000 1080100000 761100000 382200000 378900000 2267500000 1108600000 1158900000 6600000 1500000 17800000 4500000 4200000 1300000 16400000 3700000 Payment terms differ by jurisdiction and customer, but payment terms in most of our major jurisdictions typically range from 30 to 100 days from date of shipment. 1700000000 62900000 72300000 9435000 0.198 24 194700000 583000000 179000000 550100000 5800000 62100000 -200000 -2800000 18700000 20200000 0 0 0 365600000 365600000 1659700000 1659700000 7017400000 -10500000 7027900000 7474300000 -19600000 -456900000 -437300000 0 0 7962700000 8187800000 -15900000 -225100000 -209200000 0 0 7780300000 -10500000 7790800000 8036900000 -29400000 -256600000 -227200000 0 0 5137100000 0 -18600000 -210300000 -191700000 5347400000 0 2932900 365600000 365600000 365600000 365600000 365265000 365265000 365625000 365265000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Note 4. Implementation of New Financial Accounting Pronouncements</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table provides a brief description of accounting standards that were effective January 1, 2018 and were adopted on that date:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:29%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:35%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:34%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Standard</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Effect on the financial statements or other significant matters</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accounting Standards Update 2014-09 and various other related updates, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This standard replaced existing revenue recognition standards and requires entities to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. An entity can apply the new revenue standard retrospectively to each prior reporting period presented or with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. We applied the latter approach.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Application of the new standard to applicable contracts had no impact to net parent company investment as of January 1, 2018. Disclosures required by the new standard are included in Note 5.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accounting Standards Update 2016-16, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Income Taxes: Intra-Entity Transfers of Assets Other Than Inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:13px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This standard requires entities to recognize the income tax consequences of intra-entity transfers of assets other than inventory at the time of transfer. This standard requires a modified retrospective approach to adoption.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Upon adoption, the cumulative effect of applying the standard resulted in a decrease to net parent company investment of approximately $0.3 million. Adoption of this standard did not result in a material change in net income for the three and nine months ended September 30, 2018.</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accounting Standards Update 2017-07, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Compensation-Retirement Benefits: Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This standard was issued to improve the transparency and comparability among organizations by requiring entities to separate their net periodic pension cost and net periodic postretirement benefit cost into a service cost component and other components. Previously, the costs of the other components along with the service cost component were classified based upon the function of the employee. This standard requires entities to classify the service cost component in the same financial statement line item or items as other compensation costs arising from services rendered by pertinent employees. The other components of net benefit cost are now presented separately from the line items that include the service cost component. When applicable, the service cost component is now the only component eligible for capitalization. An entity should apply the new standard retrospectively for the classification of the service cost and other components and prospectively for the capitalization of the service cost component. </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Upon adoption of this standard, pension and postretirement benefit cost components other than service costs are presented in other&#8211;net, (income) expense. Retrospective application was not material to the combined statement of operations for the three and nine months ended September 30, 2017. We do not expect application of the new standard to have a material impact on an ongoing basis. </font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table provides a brief description of the accounting standard that has not yet been adopted and could have a material effect on the consolidated financial statements:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:37%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:31%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Standard</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Effective Date</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Effect on the financial statements or other significant matters</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accounting Standards Update 2016-02, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Leases</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This standard was issued to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities, including leases classified as operating leases under current GAAP, on the balance sheet and requiring additional disclosures about leasing arrangements. An entity can apply the new leases standard retrospectively to each prior reporting period presented or with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. We plan to use the latter approach.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This standard is effective January 1, 2019, with early adoption permitted. We intend to adopt this standard on that date.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We are in the process of determining the impact on our consolidated financial statements. We have selected a software solution to be compatible with our enterprise software system. Development of our selected solution is ongoing, as it is not yet fully compliant with the requirements of the standard. The timely readiness of the lease software system is critical to ensure an efficient and effective adoption of the standard.</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Note 2. Basis of Presentation</font><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We have prepared the accompanying unaudited condensed consolidated and combined financial statements in accordance with the requirements of Form 10-Q and, therefore, they do not include all information and footnotes necessary for a fair presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States (GAAP). In our opinion, the financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for a fair presentation of the results of operations for the periods shown. In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Certain reclassifications have been made to prior periods in the unaudited condensed consolidated and combined financial statements and accompanying notes to conform with current presentation. In addition, during the period ended September 30, 2018, certain combined balance sheet amounts related to the prior year have been revised to correct the sales rebates and discounts liability, which did not correctly reflect an accrual for rebates related to product held in the wholesalers' pipeline. &#160;In accordance with Securities and Exchange Commission Staff Accounting Bulletin No. 99, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Materiality</font><font style="font-family:Arial;font-size:10pt;">, and Accounting Standards Codification (ASC) 250,</font><font style="font-family:Arial;font-size:10pt;font-style:italic;"> Presentation of Financial Statements</font><font style="font-family:Arial;font-size:10pt;">, we assessed the materiality of this correction and concluded that the accrual for the rebate related to product held in the wholesalers' pipeline was not material to prior periods, and therefore, amendments of previously filed reports are not required.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As such, in accordance with ASC 250, we revised the previously reported combined balance sheet and combined statements of equity. The adjustment, which originates in periods prior to those presented, resulted in a &#160;</font><font style="font-family:Arial;font-size:10pt;">$10.5 million</font><font style="font-family:Arial;font-size:10pt;"> increase as of December 31, 2017 in the accrual for sales rebates and discounts of </font><font style="font-family:Arial;font-size:10pt;">$155.0 million</font><font style="font-family:Arial;font-size:10pt;">, total current liabilities of </font><font style="font-family:Arial;font-size:10pt;">$632.6 million</font><font style="font-family:Arial;font-size:10pt;"> and total liabilities of </font><font style="font-family:Arial;font-size:10pt;">$1,149.5 million</font><font style="font-family:Arial;font-size:10pt;">. In addition, previously reported amounts at December 31, 2017 and December 31, 2016 of net parent company investment of </font><font style="font-family:Arial;font-size:10pt;">$8,047.4 million</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$7,484.8 million</font><font style="font-family:Arial;font-size:10pt;">, respectively, and total equity of </font><font style="font-family:Arial;font-size:10pt;">$7,790.8 million</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$7,027.9 million</font><font style="font-family:Arial;font-size:10pt;">, respectively, have been reduced by </font><font style="font-family:Arial;font-size:10pt;">$10.5 million</font><font style="font-family:Arial;font-size:10pt;"> to reflect the correction above. &#160;</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our combined financial statements and accompanying notes as of and for the three years ended December 31, 2017 included in our final prospectus relating to our IPO filed on September 21 2018 (IPO Prospectus) with the Securities and Exchange Commission (SEC).</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">For the periods after Separation, the financial statements are prepared on a consolidated basis. For periods prior to the Separation, our financial statements are combined, have been prepared on a standalone basis, and are derived from Lilly's consolidated financial statements and accounting records. The unaudited condensed combined financial statements reflect the financial position, results of operations and cash flows related to the animal health businesses that were transferred to Elanco Parent and are prepared in conformity with GAAP. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The unaudited condensed combined financial statements include the attribution of certain assets and liabilities that historically have been held at the Lilly corporate level but which are specifically identifiable or attributable to the businesses that have been transferred to Elanco Parent. All intercompany transactions and accounts within Elanco have been eliminated. All transactions between us and Lilly are considered to be effectively settled in the unaudited condensed combined financial statements at the time the intercompany transaction is recorded. The total net effect of the settlement of these intercompany transactions is reflected in the unaudited condensed combined statements of cash flows as a financing activity and in the condensed combined balance sheets as net parent company investment.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">These unaudited condensed combined financial statements include an allocation of expenses related to certain Lilly corporate functions, including executive oversight, treasury, legal, finance, human resources, tax, internal audit, financial reporting, information technology and investor relations. These expenses have been allocated to us based on direct usage or benefit where specifically identifiable, with the remainder allocated primarily on a pro rata basis of revenue, headcount and other measures. We consider the expenses methodology and results to be reasonable for all periods presented. However, the allocations may not be indicative of the actual expense that would have been incurred had we operated as an independent, publicly traded company for the periods presented. It is impractical to estimate what the standalone costs of Elanco would have been in the historical periods.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The income tax amounts in the unaudited condensed combined financial statements have been calculated based on a separate return methodology and presented as if our operations were separate taxpayers in the respective jurisdictions. We file income tax returns in the United States (U.S.) federal jurisdiction and various state, local and non-U.S. jurisdictions. Certain of these income tax returns are filed on a consolidated or combined basis with Eli Lilly and Company and/or its subsidiaries.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Lilly maintains various benefit and combined stock-based compensation plans at a corporate level and other benefit plans at a country level. Our employees participate in such programs and the portion of the cost of those plans related to our employees is included in our financial statements. However, the condensed combined balance sheets do not include any equity issued related to stock-based compensation plans or any net benefit plan obligations unless the benefit plan covers only our dedicated employees or where the legal obligation associated with the benefit plan will transfer to Elanco.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Prior to Separation, the equity balance in the unaudited condensed combined financial statements represents the excess of total assets over liabilities, including intercompany balances between us and Lilly (net parent company investment) and accumulated other comprehensive loss. Net parent company investment is primarily impacted by contributions from Lilly which are the result of treasury activities and net funding provided by or distributed to Lilly. See Note 14 for further information.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We have prepared the accompanying unaudited condensed consolidated and combined financial statements in accordance with the requirements of Form 10-Q and, therefore, they do not include all information and footnotes necessary for a fair presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States (GAAP). In our opinion, the financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for a fair presentation of the results of operations for the periods shown. In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Lilly maintains various benefit and combined stock-based compensation plans at a corporate level and other benefit plans at a country level. Our employees participate in such programs and the portion of the cost of those plans related to our employees is included in our financial statements. However, the condensed combined balance sheets do not include any equity issued related to stock-based compensation plans or any net benefit plan obligations unless the benefit plan covers only our dedicated employees or where the legal obligation associated with the benefit plan will transfer to Elanco.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">For the periods after Separation, the financial statements are prepared on a consolidated basis. For periods prior to the Separation, our financial statements are combined, have been prepared on a standalone basis, and are derived from Lilly's consolidated financial statements and accounting records. The unaudited condensed combined financial statements reflect the financial position, results of operations and cash flows related to the animal health businesses that were transferred to Elanco Parent and are prepared in conformity with GAAP. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The unaudited condensed combined financial statements include the attribution of certain assets and liabilities that historically have been held at the Lilly corporate level but which are specifically identifiable or attributable to the businesses that have been transferred to Elanco Parent. All intercompany transactions and accounts within Elanco have been eliminated. All transactions between us and Lilly are considered to be effectively settled in the unaudited condensed combined financial statements at the time the intercompany transaction is recorded. The total net effect of the settlement of these intercompany transactions is reflected in the unaudited condensed combined statements of cash flows as a financing activity and in the condensed combined balance sheets as net parent company investment.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table summarizes the activity in the sales rebates and discounts liability in the U.S.:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:42%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">99.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">118.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">114.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">116.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Reduction of revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">53.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">48.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">154.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">184.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(49.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(49.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(165.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(183.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">103.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">117.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">103.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">117.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Note 8. Debt</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Long-term debt as of September 30, 2018 consisted of the following:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:79%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Term credit facility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">500.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3.912% Senior Notes due 2021</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">500.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4.272% Senior Notes due 2023</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">750.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4.900% Senior Notes due 2028</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">750.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other obligations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Unamortized debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(21.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total long-term debt</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,478.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Less current portion of long-term debt</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,478.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Long-term debt as of December 31, 2017 was not material.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Revolving and Term Credit Facilities</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On </font><font style="font-family:Arial;font-size:10pt;">September&#160;5, 2018</font><font style="font-family:Arial;font-size:10pt;">, we entered into a revolving credit agreement with a syndicate of banks providing for a </font><font style="font-family:Arial;font-size:10pt;">five</font><font style="font-family:Arial;font-size:10pt;">-year </font><font style="font-family:Arial;font-size:10pt;">$750.0 million</font><font style="font-family:Arial;font-size:10pt;"> senior unsecured revolving credit facility (Revolving Facility). The Revolving Facility bears interest at a variable rate plus specified margin as defined in the agreement and is payable quarterly. There were </font><font style="font-family:Arial;font-size:10pt;">no</font><font style="font-family:Arial;font-size:10pt;"> borrowings outstanding under the Revolving Facility at </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;">. The Revolving Facility is payable in full at the end of the term.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:0px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On </font><font style="font-family:Arial;font-size:10pt;">September&#160;5, 2018</font><font style="font-family:Arial;font-size:10pt;"> we also entered into a </font><font style="font-family:Arial;font-size:10pt;">$500.0 million</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">three</font><font style="font-family:Arial;font-size:10pt;">-year term loan under a term credit facility with a syndicate of banks (the Term Facility and collectively with the Revolving Facility, the Credit Facilities.) The Term Facility bears interest at a variable rate plus margin as defined in Term Facility (</font><font style="font-family:Arial;font-size:10pt;">3.50%</font><font style="font-family:Arial;font-size:10pt;"> at September 30, 2018) and is payable quarterly. The Term Facility is payable in full at the end of the term. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:0px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Credit Facilities are subject to various financial and other covenants including restrictions on the level of borrowings based on a consolidated leverage ratio and a consolidated interest coverage ratio. We were in compliance with all such covenants as of </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Senior Notes</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On </font><font style="font-family:Arial;font-size:10pt;">August&#160;28, 2018</font><font style="font-family:Arial;font-size:10pt;">, we issued </font><font style="font-family:Arial;font-size:10pt;">$2.0 billion</font><font style="font-family:Arial;font-size:10pt;"> of senior notes (Senior Notes) in a private placement. The Senior Notes comprised of </font><font style="font-family:Arial;font-size:10pt;">$500.0 million</font><font style="font-family:Arial;font-size:10pt;"> of </font><font style="font-family:Arial;font-size:10pt;">3.912%</font><font style="font-family:Arial;font-size:10pt;"> Senior Notes due </font><font style="font-family:Arial;font-size:10pt;">August&#160;27, 2021</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">$750.0 million</font><font style="font-family:Arial;font-size:10pt;"> of </font><font style="font-family:Arial;font-size:10pt;">4.272%</font><font style="font-family:Arial;font-size:10pt;"> Senior Notes due </font><font style="font-family:Arial;font-size:10pt;">August&#160;28, 2023</font><font style="font-family:Arial;font-size:10pt;">, and </font><font style="font-family:Arial;font-size:10pt;">$750.0 million</font><font style="font-family:Arial;font-size:10pt;"> of </font><font style="font-family:Arial;font-size:10pt;">4.900%</font><font style="font-family:Arial;font-size:10pt;"> Senior Notes due </font><font style="font-family:Arial;font-size:10pt;">August&#160;28, 2028</font><font style="font-family:Arial;font-size:10pt;">. The interest rate payable on each series of Senior Notes is subject to adjustment if Moody's Investor Services, Inc. or Standard &amp; Poor's Financial Services LLC downgrades, or subsequently upgrades, its ratings on the respective series of Senior Notes.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The indenture that governs the Senior Notes contains covenants, including limitations on our ability, and certain of our subsidiaries, to incur liens or engage in sale-leaseback transactions. The indenture also contains restrictions on our ability to consolidate, merge or sell substantially all of our assets, in addition, to other customary terms. We were in compliance with all such covenants under the indenture governing the Senior Notes as of September 30, 2018.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We have entered into an agreement that requires us to use commercially reasonable efforts to cause a registration statement to become effective with the SEC by August 28, 2019, relating to an offer to exchange the Senior Notes for registered Senior Notes having substantially identical terms, or, in certain cases, to register the Senior Notes for resale. If we do not register or exchange the Senior Notes pursuant to the terms of the registration rights agreement, we will be required to pay additional interest to the holders of the Senior Notes under certain circumstances.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table summarizes our revenue disaggregated by product category:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.4375%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:43%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Companion Animal Disease Prevention</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">188.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">140.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">603.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">519.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Companion Animal Therapeutics</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">80.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">63.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">211.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">181.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Companion Animal Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">27.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">48.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">69.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">119.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Food Animal Future Protein &amp; Health</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">162.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">164.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">502.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">456.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Food Animal Ruminants &amp; Swine</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">301.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">280.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">881.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">857.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">761.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">697.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,267.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,134.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Note 13. Earnings Per Share</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We have calculated earnings per share assuming </font><font style="font-family:Arial;font-size:10pt;">365,625,000</font><font style="font-family:Arial;font-size:10pt;"> shares were outstanding for all periods presented. This represents an aggregate of </font><font style="font-family:Arial;font-size:10pt;">293,290,000</font><font style="font-family:Arial;font-size:10pt;"> shares of our common stock held by Lilly (which represents the </font><font style="font-family:Arial;font-size:10pt;">100</font><font style="font-family:Arial;font-size:10pt;"> shares held by Lilly prior to giving effect to the </font><font style="font-family:Arial;font-size:10pt;">2,932,900</font><font style="font-family:Arial;font-size:10pt;">-for-1 stock split that occurred on September 19, 2018), the issuance of </font><font style="font-family:Arial;font-size:10pt;">62,900,000</font><font style="font-family:Arial;font-size:10pt;"> shares of our common stock in the IPO, and the issuance of </font><font style="font-family:Arial;font-size:10pt;">9,435,000</font><font style="font-family:Arial;font-size:10pt;"> shares of our common stock sold pursuant to the underwriters&#8217; option to purchase additional shares.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Note 9. Financial Instruments and Fair Value</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Financial instruments that are potentially subject to credit risk consist principally of trade receivables. Collateral is generally not required. The risk associated with this concentration is mitigated by our ongoing credit-review procedures and insurance.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">A large portion of our cash is held by a few major financial institutions. We monitor the exposure with these institutions and do not expect any of these institutions to fail to meet their obligations. All highly liquid investments with a maturity of three months or less from the date of purchase are considered to be cash equivalents. The cost of these investments approximates fair value. We also consider the carrying value of restricted cash balances to be representative of its fair value.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As of </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">December 31, 2017</font><font style="font-family:Arial;font-size:10pt;">, we had </font><font style="font-family:Arial;font-size:10pt;">$14.9 million</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;background-color:#ffffff;">and</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;background-color:#ffffff;">$12.3 million</font><font style="font-family:Arial;font-size:10pt;background-color:#ffffff;">, respectively, of cost and equity method investments.</font><font style="font-family:Arial;font-size:10pt;"> </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;background-color:#ffffff;">The following table summarizes the fair value information at </font><font style="font-family:Arial;font-size:10pt;background-color:#ffffff;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;background-color:#ffffff;"> and </font><font style="font-family:Arial;font-size:10pt;background-color:#ffffff;">December 31, 2017</font><font style="font-family:Arial;font-size:10pt;background-color:#ffffff;"> for contingent consideration liabilities measured at fair value on a recurring basis in the respective balance sheet line items: </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:27%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Fair Value Measurements Using</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Financial statement line item</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Carrying</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Quoted Prices in Active Markets for Identical Assets</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Significant</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other Observable Inputs</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Significant</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Unobservable</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Inputs</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(Level 3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Fair</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other current liabilities- contingent consideration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">17.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">17.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">17.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other noncurrent liabilities- contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">41.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">41.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">41.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2017</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other current liabilities- contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other noncurrent liabilities- contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">45.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">45.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">45.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Contingent consideration liabilities relate to </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Galliprant</font><font style="font-family:Arial;font-size:10pt;"> for which the fair value was estimated using a discounted cash flow analysis and Level 3 inputs, including projections representative of a market participant view for the probability of achieving potential future payments to Aratana Therapeutics, Inc. and an estimated discount rate. The amount to be paid is dependent upon certain development, success-based regulatory, and sales-based milestones. In addition, the amount of royalties to be paid is calculated as a percentage of net sales dependent upon the timing and geography and will, therefore, vary directly with increases and decreases in net sales of </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Galliprant</font><font style="font-family:Arial;font-size:10pt;">. There is no cap on the amount that may be paid pursuant to this arrangement. During the second quarter of 2018, as a result of an increase in the projected cash flows related to </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Galliprant,</font><font style="font-family:Arial;font-size:10pt;"> we increased the fair value of the contingent consideration liabilities by </font><font style="font-family:Arial;font-size:10pt;">$8.5 million</font><font style="font-family:Arial;font-size:10pt;">. The additional expense was recognized in other-net (income) expense.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We have long term debt of </font><font style="font-family:Arial;font-size:10pt;">$2.5 billion</font><font style="font-family:Arial;font-size:10pt;"> that is recorded at amortized cost in our condensed consolidated balance sheet as of September 30, 2018. We consider the carrying value of the long term debt to be representative of its fair value as of September 30, 2018. The fair value of this long term debt is estimated based on quoted market prices of similar liabilities and is classified as Level 2. As of </font><font style="font-family:Arial;font-size:10pt;">December 31, 2017</font><font style="font-family:Arial;font-size:10pt;">, long term debt was not material.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;background-color:#ffffff;">The following table summarizes the fair value information at </font><font style="font-family:Arial;font-size:10pt;background-color:#ffffff;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;background-color:#ffffff;"> and </font><font style="font-family:Arial;font-size:10pt;background-color:#ffffff;">December 31, 2017</font><font style="font-family:Arial;font-size:10pt;background-color:#ffffff;"> for contingent consideration liabilities measured at fair value on a recurring basis in the respective balance sheet line items: </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:27%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Fair Value Measurements Using</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Financial statement line item</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Carrying</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Quoted Prices in Active Markets for Identical Assets</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Significant</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other Observable Inputs</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Significant</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Unobservable</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Inputs</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(Level 3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Fair</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other current liabilities- contingent consideration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">17.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">17.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">17.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other noncurrent liabilities- contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">41.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">41.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">41.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2017</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other current liabilities- contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other noncurrent liabilities- contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">45.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">45.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">45.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Note 10. Income Taxes</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Prior to Separation</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">During the periods presented in the unaudited condensed consolidated and combined financial statements, our operations were generally included in the tax grouping of other Lilly entities within the respective entity's tax jurisdiction; however, in certain jurisdictions, we filed separate tax returns. Prior to the Separation, the income tax expense included in these financial statements has been calculated using the separate return basis as if Elanco filed separate tax returns. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">For the three and nine months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;">, we incurred </font><font style="font-family:Arial;font-size:10pt;">$18.6 million</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$46.2 million</font><font style="font-family:Arial;font-size:10pt;">, respectively, of income tax expense. </font><font style="font-family:Arial;font-size:10pt;">For the three and nine months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;">, the effective tax rate of </font><font style="font-family:Arial;font-size:10pt;">23.6%</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">39.7%</font><font style="font-family:Arial;font-size:10pt;">, respectively, was primarily attributable to a net operating loss in the U.S. for which no tax benefit was recognized and a valuation allowance was recorded. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">For the three and nine months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Arial;font-size:10pt;">, despite reporting a loss before taxes of </font><font style="font-family:Arial;font-size:10pt;">$9.1 million</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$77.2 million</font><font style="font-family:Arial;font-size:10pt;">, respectively, we incurred </font><font style="font-family:Arial;font-size:10pt;">$11.6 million</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$72.0 million</font><font style="font-family:Arial;font-size:10pt;"> of income tax expense. The tax expense recorded related primarily to income generated in certain foreign jurisdictions as no tax benefit was recorded for U.S. net operating losses.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In December 2017, the President of the U.S. signed into law the Tax Cuts and Jobs Act (2017 Tax Act), which includes significant changes to the U.S. corporate income tax system, including a reduction in the corporate income tax rate, transition to a territorial tax system, and modifications to the international tax provisions. At </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;">, our accounting for the 2017 Tax Act is incomplete; however, we expect to complete our accounting by December 2018. As discussed in our combined financial statements and accompanying notes as of and for the year ended December 31, 2017 included in our IPO Prospectus, we recorded provisional adjustments for effects that we were able to reasonably estimate. Those effects included the one-time repatriation transition tax (also known as the Toll Tax), re-measurement of deferred tax assets and liabilities, unremitted earnings, executive compensation, and uncertain tax positions.&#160;At </font><font style="font-family:Arial;font-size:10pt;">December 31, 2017</font><font style="font-family:Arial;font-size:10pt;">, we were not able to make reasonable estimates for Global Intangible Low-Taxed Income (GILTI) deferred taxes or changes to the valuation allowances; therefore, we did not record provisional amounts. We are still evaluating the effects of the GILTI provisions and assessing our valuation allowances, and we have not yet concluded upon our accounting policy election with respect to GILTI deferred taxes or the application of intra entity transfers of inventory; therefore, the estimated annual effective tax rate reflects GILTI as a period expense. </font><font style="font-family:Arial;font-size:10pt;">For the three and nine months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;">, we have not made any additional measurement-period adjustments related to provisional amounts as we are continuing to collect and analyze additional information as well as evaluate the interpretations and assumptions made. Updates to the calculations may result in material changes to the provisional adjustments recorded at </font><font style="font-family:Arial;font-size:10pt;">December 31, 2017</font><font style="font-family:Arial;font-size:10pt;"> and the estimated annual effective tax rate.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As part of Lilly, we are included in Lilly's U.S. tax examinations by the Internal Revenue Service (IRS). The IRS examination of tax years 2013-2015 began in 2016. While we believe it is reasonably possible that this audit could reach a resolution within the next twelve months, the IRS examination of tax years 2013-2015 remains ongoing. For periods prior to the Separation, Lilly will retain the liabilities related to such IRS audit resolutions.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Impact of Separation</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In connection with the Separation, we entered into a tax matters agreement (TMA) with Lilly that, among other things, formalized our agreement related to the responsibility for historical tax positions for the periods prior to the Separation for jurisdictions where our business was included in the consolidated or combined tax returns of Lilly. The TMA also established a tax sharing agreement for jurisdictions where our business will continue to be included in Lilly's consolidated or combined tax returns for a period of time.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Based on the TMA, Lilly retained the tax benefits and liabilities associated with all periods prior to the Separation date for any jurisdiction where we were included in a consolidated or combined tax return. The financial statements for periods prior to Separation included certain deferred tax assets related to tax credit and net operating loss carryovers that resulted from our tax expense being calculated on a separate return basis that will not transfer to us either because they were used by Lilly or are retained by Lilly and reflected certain tax liabilities that will be retained by Lilly. We recorded an adjustment to our consolidated balance sheet at the date of Separation to reflect our tax positions based on the TMA. This resulted in a decrease in tax liabilities by </font><font style="font-family:Arial;font-size:10pt;">$31.2 million</font><font style="font-family:Arial;font-size:10pt;"> as these tax liabilities will be retained by Lilly. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">At </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;">, we have net operating losses for international tax purposes of approximately </font><font style="font-family:Arial;font-size:10pt;">$190 million</font><font style="font-family:Arial;font-size:10pt;"> which will expire between 2022 and 2028. These net operating losses are partially reserved. Deferred tax assets related to state net operating losses are </font><font style="font-family:Arial;font-size:10pt;">$6.2 million</font><font style="font-family:Arial;font-size:10pt;">. The state net operating losses will generally expire between 2035 and 2037.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The income tax amounts in the unaudited condensed combined financial statements have been calculated based on a separate return methodology and presented as if our operations were separate taxpayers in the respective jurisdictions. We file income tax returns in the United States (U.S.) federal jurisdiction and various state, local and non-U.S. jurisdictions. Certain of these income tax returns are filed on a consolidated or combined basis with Eli Lilly and Company and/or its subsidiaries.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Note 7. Inventories</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We state all inventories at the lower of cost or market. We use the last-in, first-out (LIFO) method for a portion of our inventories located in the continental U.S. Other inventories are valued by the first-in, first-out (FIFO) method. FIFO cost approximates current replacement cost.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Inventories consisted of the following:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Finished products</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">408.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">452.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">572.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">580.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Raw materials and supplies</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">71.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">70.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total (approximates replacement cost)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,051.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,102.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Decrease to LIFO cost</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(43.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(40.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Inventories</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,008.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,062.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">During the nine months ended September 30, 2018, we recognized </font><font style="font-family:Arial;font-size:10pt;">$38.6 million</font><font style="font-family:Arial;font-size:10pt;"> of inventory write-offs in cost of sales primarily related to the suspension of commercial activities for Imrestor.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Note 11. Contingencies</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We are party to various legal actions in the normal course of business. We record a liability if there is a claim for which it is probable a payment will be made and the amount is estimable. At </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">December 31, 2017</font><font style="font-family:Arial;font-size:10pt;">, we had </font><font style="font-family:Arial;font-size:10pt;">no</font><font style="font-family:Arial;font-size:10pt;"> liabilities established related to litigation as there are no claims which were probable and estimable. We have not historically had any significant litigation expense and are not currently subject to any claim.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Long-lived assets </font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">United States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">589.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">604.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">United Kingdom</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">195.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">204.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other foreign countries</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">190.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">190.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Long-lived assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">975.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">999.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:0px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Long-lived assets consist of property and equipment, net, and certain noncurrent assets.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table provides a brief description of accounting standards that were effective January 1, 2018 and were adopted on that date:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:29%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:35%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:34%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Standard</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Effect on the financial statements or other significant matters</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accounting Standards Update 2014-09 and various other related updates, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This standard replaced existing revenue recognition standards and requires entities to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. An entity can apply the new revenue standard retrospectively to each prior reporting period presented or with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. We applied the latter approach.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Application of the new standard to applicable contracts had no impact to net parent company investment as of January 1, 2018. Disclosures required by the new standard are included in Note 5.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accounting Standards Update 2016-16, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Income Taxes: Intra-Entity Transfers of Assets Other Than Inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:13px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This standard requires entities to recognize the income tax consequences of intra-entity transfers of assets other than inventory at the time of transfer. This standard requires a modified retrospective approach to adoption.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Upon adoption, the cumulative effect of applying the standard resulted in a decrease to net parent company investment of approximately $0.3 million. Adoption of this standard did not result in a material change in net income for the three and nine months ended September 30, 2018.</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accounting Standards Update 2017-07, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Compensation-Retirement Benefits: Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This standard was issued to improve the transparency and comparability among organizations by requiring entities to separate their net periodic pension cost and net periodic postretirement benefit cost into a service cost component and other components. Previously, the costs of the other components along with the service cost component were classified based upon the function of the employee. This standard requires entities to classify the service cost component in the same financial statement line item or items as other compensation costs arising from services rendered by pertinent employees. The other components of net benefit cost are now presented separately from the line items that include the service cost component. When applicable, the service cost component is now the only component eligible for capitalization. An entity should apply the new standard retrospectively for the classification of the service cost and other components and prospectively for the capitalization of the service cost component. </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Upon adoption of this standard, pension and postretirement benefit cost components other than service costs are presented in other&#8211;net, (income) expense. Retrospective application was not material to the combined statement of operations for the three and nine months ended September 30, 2017. We do not expect application of the new standard to have a material impact on an ongoing basis. </font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table provides a brief description of the accounting standard that has not yet been adopted and could have a material effect on the consolidated financial statements:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:37%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:31%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Standard</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Effective Date</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Effect on the financial statements or other significant matters</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accounting Standards Update 2016-02, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Leases</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This standard was issued to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities, including leases classified as operating leases under current GAAP, on the balance sheet and requiring additional disclosures about leasing arrangements. An entity can apply the new leases standard retrospectively to each prior reporting period presented or with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. We plan to use the latter approach.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This standard is effective January 1, 2019, with early adoption permitted. We intend to adopt this standard on that date.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We are in the process of determining the impact on our consolidated financial statements. We have selected a software solution to be compatible with our enterprise software system. Development of our selected solution is ongoing, as it is not yet fully compliant with the requirements of the standard. The timely readiness of the lease software system is critical to ensure an efficient and effective adoption of the standard.</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Note 1. Nature of Business and Organization</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Nature of Business</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Elanco Animal Health Incorporated (Elanco Parent) and its subsidiaries (collectively, Elanco, the Company, we, us or our) was formed as a wholly-owned subsidiary of Eli Lilly and Company (Lilly). Elanco is a global animal health company that innovates, develops, manufactures and markets products for companion and food animals. We offer a diverse portfolio of more than </font><font style="font-family:Arial;font-size:10pt;">125</font><font style="font-family:Arial;font-size:10pt;"> brands to veterinarians and food animal producers in more than </font><font style="font-family:Arial;font-size:10pt;">90</font><font style="font-family:Arial;font-size:10pt;"> countries.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Organization </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Elanco Parent was formed in 2018, as a wholly-owned subsidiary of Lilly, to serve as the ultimate parent company of substantially all of the animal health businesses of Lilly.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On September 24, 2018, Elanco Parent completed an initial public offering resulting in the issuance of </font><font style="font-family:Arial;font-size:10pt;">72.3</font><font style="font-family:Arial;font-size:10pt;"> million shares of its common stock (including shares issued pursuant to the underwriters&#8217; option to purchase additional shares), which represents </font><font style="font-family:Arial;font-size:10pt;">19.8%</font><font style="font-family:Arial;font-size:10pt;"> of the outstanding shares, at </font><font style="font-family:Arial;font-size:10pt;">$24</font><font style="font-family:Arial;font-size:10pt;"> per share (IPO) for a total net proceeds, after underwriting discounts and commissions, of </font><font style="font-family:Arial;font-size:10pt;">$1.7 billion</font><font style="font-family:Arial;font-size:10pt;">.&#160; In connection with the completion of the IPO, through a series of equity and other transactions, Lilly transferred to Elanco Parent the animal health businesses that form its business going forward.&#160;In exchange Elanco Parent has paid, or will pay, to Lilly approximately </font><font style="font-family:Arial;font-size:10pt;">$4.2 billion</font><font style="font-family:Arial;font-size:10pt;">, which includes the net proceeds from the IPO, the net proceeds from the debt offering completed by Elanco Parent in August 2018 and the term loan facility entered into by Elanco Parent in September 2018 (see Note 8).&#160;As of September 30, 2018, Elanco Parent has paid Lilly </font><font style="font-family:Arial;font-size:10pt;">$3.6 billion</font><font style="font-family:Arial;font-size:10pt;">. These transactions are collectively referred to herein as the Separation.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Certain reclassifications have been made to prior periods in the unaudited condensed consolidated and combined financial statements and accompanying notes to conform with current presentation.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Note 14. Related Party Agreements and Transactions</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Separation-Related Agreements with Lilly</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As described in Note 1, in connection with the Separation Lilly transferred to us substantially all of its animal health businesses in exchange for approximately </font><font style="font-family:Arial;font-size:10pt;">$4.2 billion</font><font style="font-family:Arial;font-size:10pt;">. This is reflected as consideration to Lilly in our statement of equity. In addition, we entered into a master separation agreement and a transitional services agreement with Lilly. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Master Separation Agreement (MSA)</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As stated in Note 1, Lilly transferred to us at the time of Separation, through a series of transactions, the businesses that will continue as part of Elanco. For a certain portion of our operations, the legal transfer of our net assets did not occur prior to the Separation due to certain regulatory requirements in each of these countries. Under the MSA entered into with Lilly, we are responsible for the business activities conducted by Lilly on our behalf and are subject to the risks and entitled to the benefits generated by these operations and assets. As a result, the related assets and liabilities and results of operations have been reported in our unaudited condensed consolidated and combined financial statements. The total net assets associated with these jurisdictions are </font><font style="font-family:Arial;font-size:10pt;">$84.5 million</font><font style="font-family:Arial;font-size:10pt;"> and the annual profits are insignificant. Upon Separation, we retained </font><font style="font-family:Arial;font-size:10pt;">$275.0 million</font><font style="font-family:Arial;font-size:10pt;">, which is reflected as restricted cash, that will be used to fund the purchase of these operations from Lilly at the time of the local country closing and have an offsetting payable to Lilly. If the amount of local purchases is less than </font><font style="font-family:Arial;font-size:10pt;">$275.0 million</font><font style="font-family:Arial;font-size:10pt;">, we are required to repay the remaining amount to Lilly.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In addition, based on the MSA, we are required to distribute to Lilly any amount of cash in excess of </font><font style="font-family:Arial;font-size:10pt;">$300.0 million</font><font style="font-family:Arial;font-size:10pt;"> held at </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;">. As a result, we have reflected an additional </font><font style="font-family:Arial;font-size:10pt;">$359.9 million</font><font style="font-family:Arial;font-size:10pt;"> of restricted cash on our balance sheet with an offsetting payable to Lilly at </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Transitional Services Agreement (TSA)</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Historically, Lilly has provided us significant shared services and resources related to corporate functions such as executive oversight, treasury, legal, finance, human resources, tax, internal audit, financial reporting, information technology and investor relations, which we refer to collectively as the "Lilly Services." Under the terms of the TSA, we will be able to use Lilly Services for a fixed term established on a service-by-service basis. We will pay Lilly mutually agreed-upon fees for the Lilly Services provided under the TSA, which will be based on Lilly's cost (including third-party costs) of providing the Lilly Services through </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2021</font><font style="font-family:Arial;font-size:10pt;">, and subject to a mark-up of </font><font style="font-family:Arial;font-size:10pt;">7%</font><font style="font-family:Arial;font-size:10pt;"> thereafter, with additional inflation-based escalation beginning </font><font style="font-family:Arial;font-size:10pt;">January&#160;1, 2020</font><font style="font-family:Arial;font-size:10pt;">. The fees under the TSA become payable for all periods beginning after </font><font style="font-family:Arial;font-size:10pt;">October&#160;1, 2018</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We also entered into a TMA, an employee matters agreement, a toll manufacturing and supply agreement and a registration rights agreement with Lilly in connection with the Separation.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Transactions with Lilly Prior to Separation</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We did not historically operate as a standalone business and had various relationships with Lilly whereby Lilly provided services to us.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Transfers to/from Lilly, net</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As discussed in the basis of presentation, net parent company investment is primarily impacted by contributions from Lilly which are the result of treasury activity and net funding provided by or distributed to Lilly. For the three months ended </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">, respectively, the net transfers (to)/from Lilly were </font><font style="font-family:Arial;font-size:10pt;">$(116.8) million</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$38.1 million</font><font style="font-family:Arial;font-size:10pt;">. For the </font><font style="font-family:Arial;font-size:10pt;">nine months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">, respectively, the net transfers (to)/from Lilly were </font><font style="font-family:Arial;font-size:10pt;">$(226.3) million</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$862.7 million</font><font style="font-family:Arial;font-size:10pt;">, respectively. The most significant activity impacting the 2017 transfer was the financing by Lilly of our acquisition in the amount of </font><font style="font-family:Arial;font-size:10pt;">$882.1 million</font><font style="font-family:Arial;font-size:10pt;"> for Boehringer Ingelheim Vetmedica, Inc.'s United States feline, canine, and rabies vaccine portfolio and other related assets in 2017.&#160;Other activities that impacted the net transfers (to)/from Lilly include corporate overhead and other allocations, income taxes, retirement benefits, and centralized cash management.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Corporate Overhead and Other Allocations</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Lilly provides us certain services, including executive oversight, treasury, legal, finance, human resources, tax, internal audit, financial reporting, information technology and investor relations. We provide Lilly certain services related to manufacturing support. Our financial statements reflect an allocation of these costs. When specific identification is not practicable, the remainder have been allocated primarily on a proportional cost method on a basis of revenue or headcount.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The allocations of services from Lilly to us were reflected as follows in the unaudited condensed consolidated and combined statements of operations:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cost of sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">21.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">23.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Research and development </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Marketing, selling and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">26.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">27.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">81.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">82.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">34.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">36.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">105.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">107.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We provide Lilly certain services related to manufacturing support. Allocations of manufacturing support from us to Lilly of </font><font style="font-family:Arial;font-size:10pt;">$1.3 million</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$1.5 million</font><font style="font-family:Arial;font-size:10pt;"> for the three months ended </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">, respectively, as well as </font><font style="font-family:Arial;font-size:10pt;">$3.7 million</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$4.5 million</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">for the nine months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">, respectively, reduced the cost of sales in the unaudited condensed consolidated and combined statements of operations.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The financial information herein may not necessarily reflect our consolidated financial position, results of operations and cash flows in the future or what they would have been if we had been a separate, standalone entity during the periods presented. Management believes that the methods used to allocate expenses are reasonable.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Stock-based Compensation</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our employees participate in Lilly stock-based compensation plans, the costs of which have been allocated to us and recorded in cost of sales, research and development, and marketing, selling and administrative expenses in the unaudited condensed consolidated and combined statements of operations. The costs of such plans related to our employees were </font><font style="font-family:Arial;font-size:10pt;">$6.9 million</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$6.2 million</font><font style="font-family:Arial;font-size:10pt;"> for the three months ended </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">, respectively, as well as </font><font style="font-family:Arial;font-size:10pt;">$20.2 million</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$18.7 million</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">for the nine months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Retirement Benefits</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our employees participate in defined benefit pension and other post retirement plans sponsored by Lilly, the costs and benefits of which have been recorded in the unaudited condensed consolidated and combined statement of operations in cost of sales, research and development, and marketing, selling and administrative expenses. </font><font style="font-family:Arial;font-size:10pt;">For the three and nine months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;">, the benefit of such plans related to our employees was </font><font style="font-family:Arial;font-size:10pt;">$1.6 million</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$0.3 million</font><font style="font-family:Arial;font-size:10pt;">, respectively, and </font><font style="font-family:Arial;font-size:10pt;">for the three and nine months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Arial;font-size:10pt;"> the costs of such plans related to our employees were </font><font style="font-family:Arial;font-size:10pt;">$1.7 million</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$5.1 million</font><font style="font-family:Arial;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Centralized Cash Management</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Lilly uses a centralized approach to cash management and financing of operations. Until Separation, the majority of our business was party to Lilly&#8217;s cash pooling arrangements to maximize Lilly's availability of cash for general operating and investing purposes. Under these cash pooling arrangements, cash balances were swept regularly from our accounts. Cash transfers to and from Lilly&#8217;s cash concentration accounts and the resulting balances at the end of each reporting period were reflected in net parent company investment in the condensed consolidated and combined balance sheets.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Debt</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Lilly&#8217;s third-party debt and the related interest expense have not been allocated to us for any of the periods presented as we were not the legal obligor of the debt and Lilly borrowings were not directly attributable to our business.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Commercial Operations</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We sell certain products to and receives certain goods and services from a customer/vendor, whose chairman and Chief Executive Officer is a member of Lilly's Board of Directors. These product sales resulted in revenue of </font><font style="font-family:Arial;font-size:10pt;">$4.2 million</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$6.6 million</font><font style="font-family:Arial;font-size:10pt;"> for the three months ended </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">, respectively, and of </font><font style="font-family:Arial;font-size:10pt;">$16.4 million</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$17.8 million</font><font style="font-family:Arial;font-size:10pt;"> for the nine months ended </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">, respectively. The product sales resulted in accounts receivable of </font><font style="font-family:Arial;font-size:10pt;">$1.9 million</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$2.0 million</font><font style="font-family:Arial;font-size:10pt;"> at </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">December 31, 2017</font><font style="font-family:Arial;font-size:10pt;">, respectively. The purchase of goods and services resulted in cost of sales and operating expenses of </font><font style="font-family:Arial;font-size:10pt;">$1.4 million</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$1.1 million</font><font style="font-family:Arial;font-size:10pt;"> for the three months ended </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">, respectively, as well as </font><font style="font-family:Arial;font-size:10pt;">$3.3 million</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$5.3 million</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">, respectively. The purchase of goods and services resulted in accounts payable of </font><font style="font-family:Arial;font-size:10pt;">$0.4 million</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$0.3 million</font><font style="font-family:Arial;font-size:10pt;"> at </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">December 31, 2017</font><font style="font-family:Arial;font-size:10pt;">, respectively.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Note 6. Asset Impairment, Restructuring and Other Special Charges</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We have historically participated in Lilly's cost-reduction initiatives. Our total charges related to asset impairment, restructuring and other special charges, including integration of acquired businesses, in the unaudited condensed consolidated and combined statements of operations consisted of the following:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cash expense:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Severance </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(0.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(2.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">62.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Integration and other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">75.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Exit costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">24.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total cash expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">23.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">18.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">161.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Non-cash expense</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Asset impairment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">63.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">43.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total non-cash expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">63.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">43.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Gain on sale of fixed assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(16.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">12.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">23.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">82.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">189.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Severance costs represent costs incurred as a result of actions taken to reduce our cost structure.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Integration and other costs primarily represent costs related to our integration efforts as a result of our acquired businesses.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Exit costs primarily represent contract termination costs and reserves for costs related to facilities which we have exited.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Asset impairment recognized during the nine months ended </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;"> resulted from </font><font style="font-family:Arial;font-size:10pt;">$19.9 million</font><font style="font-family:Arial;font-size:10pt;"> of intangible asset impairments and </font><font style="font-family:Arial;font-size:10pt;">$44.0 million</font><font style="font-family:Arial;font-size:10pt;"> of fixed asset impairments. The intangible asset impairments primarily related to revised projections of fair value due to product rationalization. The fixed asset impairments were primarily due to the decision to dispose of a manufacturing facility in the U.S. and to the suspension of commercial activities for Imrestor&#174;.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Asset impairment recognized during the nine months ended </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Arial;font-size:10pt;"> resulted primarily from intangible asset impairments related to revised projections of fair value due to product rationalization and to a lessor extent competitive pressures. The fair value measurements utilized to determine the intangible asset impairments in </font><font style="font-family:Arial;font-size:10pt;">2018</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;"> represent Level 3 fair value measurements.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Gain on sale of fixed assets for the nine months ended </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Arial;font-size:10pt;"> represents a gain on the disposal of a site that was previously closed as part of the acquisition and integration of Novartis Animal Health.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table summarizes the activity in our reserves established in connection with these restructuring activities:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:50%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Exit costs </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Severance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Balance at December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">26.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">38.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:18px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Charges</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">24.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">62.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">86.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:18px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cash paid</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(7.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(61.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(69.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Balance at September&#160;30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">28.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">26.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">55.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Balance at December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">34.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">43.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">78.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:18px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Charges</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(2.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">8.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:18px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Separation adjustment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(5.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(5.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:18px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cash paid</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(10.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(22.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(33.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Balance at September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">29.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">17.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">47.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Substantially all of the reserves are expected to be paid in the next twelve months. We believe that the reserves are adequate.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Note 5. Revenue</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Effective January 1, 2018, we adopted Accounting Standards Update 2014-09, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:Arial;font-size:10pt;"> (ASU 2014-09) and other related updates. The new standard has been applied to contracts for which performance had not been completed as of the date of adoption. Revenue presented for periods prior to 2018 were accounted for under previous standards and has not been adjusted. Revenue and net income for the </font><font style="font-family:Arial;font-size:10pt;">three and nine months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;"> do not differ materially from amounts that would have resulted from application of the previous standards.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Product Sales</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We recognize revenue primarily from product sales to customers. Revenue from sales of products is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation, which generally is at the time we ship the product to the customer. </font><font style="font-family:Arial;font-size:10pt;">Payment terms differ by jurisdiction and customer, but payment terms in most of our major jurisdictions typically range from 30 to 100 days from date of shipment.</font><font style="font-family:Arial;font-size:10pt;"> Revenue for our product sales has not been adjusted for the effects of a financing component as we expect, at contract inception, that the period between when we transfer control of the product and when we receive payment will be one year or less. Any exceptions are either not material or we collect interest for payments made after the due date. Provisions for rebates and discounts, and returns are established in the same period the related sales are recognized. We generally, ship product shortly after orders are received; therefore, we generally only have a few days of orders received but not yet shipped at the end of any reporting period. Shipping and handling activities are considered to be fulfillment activities and are not considered to be a separate performance obligation. We exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are imposed on our sales of product and collected from a customer.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Significant judgments must be made in determining the transaction price for sales of products related to anticipated rebates and discounts, and returns. The following describe the most significant of these judgments:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Sales Rebates and Discounts - Background and Uncertainties</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Most of our products are sold to wholesale distributors. We initially invoice our customers contractual list prices. Contracts with direct and indirect customers may provide for various rebates and discounts that may differ in each contract. As a consequence, to determine the appropriate transaction price for our product sales at the time we recognize a sale to a direct customer, we must estimate any rebates or discounts that ultimately will be due to the direct customer and other customers in the distribution chain under the terms of our contracts. Significant judgments are required in making these estimates.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The rebate and discount amounts are recorded as a deduction to arrive at our net product sales. We estimate these accruals using an expected value approach.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In determining the appropriate accrual amount, we consider our historical experience with similar incentives programs and current sales data to estimate the impact of such programs on revenue and continually monitor the impact of this experience and adjust as necessary. Although we accrue a liability for rebates related to these programs at the time the sale is recorded, the rebate related to that sale is typically paid up to </font><font style="font-family:Arial;font-size:10pt;">six months</font><font style="font-family:Arial;font-size:10pt;"> after rebate or incentive period expires. Because of this time lag, in any particular period rebate adjustments may incorporate revisions of accruals for several periods.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our sales rebates and discounts are based on specific agreements and the majority relate to sales in the U.S. As of </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">, liability for sales rebates and discounts in the U.S. represents approximately </font><font style="font-family:Arial;font-size:10pt;">70%</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">71%</font><font style="font-family:Arial;font-size:10pt;">, respectively, of our total liability with the next largest country representing approximately </font><font style="font-family:Arial;font-size:10pt;">8%</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">6%</font><font style="font-family:Arial;font-size:10pt;">, respectively, of our total liability. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table summarizes the activity in the sales rebates and discounts liability in the U.S.:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:42%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">99.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">118.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">114.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">116.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Reduction of revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">53.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">48.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">154.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">184.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(49.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(49.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(165.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(183.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">103.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">117.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">103.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">117.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Adjustments to revenue recognized as a result of changes in estimates for the judgments described above during the </font><font style="font-family:Arial;font-size:10pt;">three and nine months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;"> for product shipped in previous periods were not material.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Sales Returns - Background and Uncertainties</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We estimate a reserve for future product returns related to product sales using an expected value approach. This estimate is based on several factors, including: local returns policies and practices; returns as a percentage of revenue; an understanding of the reasons for past returns; estimated shelf life by product; and estimate of the amount of time between shipment and return. Adjustments to the returns reserve have been and may in the future be required based on revised estimates to our assumptions, which would have an impact on our consolidated results of operations. We record the return amounts as a deduction to arrive at our net product sales.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Actual product returns have been approximately </font><font style="font-family:Arial;font-size:10pt;">1%</font><font style="font-family:Arial;font-size:10pt;"> of net revenue for the </font><font style="font-family:Arial;font-size:10pt;">three and nine months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;"> and have not fluctuated significantly as a percentage of revenue.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Disaggregation of Revenue </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table summarizes our revenue disaggregated by product category:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.4375%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:43%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Companion Animal Disease Prevention</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">188.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">140.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">603.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">519.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Companion Animal Therapeutics</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">80.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">63.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">211.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">181.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Companion Animal Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">27.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">48.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">69.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">119.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Food Animal Future Protein &amp; Health</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">162.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">164.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">502.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">456.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Food Animal Ruminants &amp; Swine</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">301.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">280.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">881.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">857.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">761.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">697.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,267.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,134.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:0px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Revenue is attributed to the countries based on the location of the customer.</font></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Selected geographic area information was as follows:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:43%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Revenue&#8212;to unaffiliated customers </font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">United States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">382.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">321.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,108.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,054.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">International</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">378.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">375.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,158.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,080.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">761.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">697.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,267.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,134.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Long-term debt as of September 30, 2018 consisted of the following:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:79%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Term credit facility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">500.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3.912% Senior Notes due 2021</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">500.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4.272% Senior Notes due 2023</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">750.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4.900% Senior Notes due 2028</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">750.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other obligations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Unamortized debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(21.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total long-term debt</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,478.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Less current portion of long-term debt</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,478.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Inventories consisted of the following:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Finished products</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">408.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">452.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">572.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">580.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Raw materials and supplies</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">71.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">70.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total (approximates replacement cost)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,051.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,102.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Decrease to LIFO cost</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(43.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(40.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Inventories</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,008.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,062.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table provides a brief description of accounting standards that were effective January 1, 2018 and were adopted on that date:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:29%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:35%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:34%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Standard</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Effect on the financial statements or other significant matters</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accounting Standards Update 2014-09 and various other related updates, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This standard replaced existing revenue recognition standards and requires entities to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. An entity can apply the new revenue standard retrospectively to each prior reporting period presented or with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. We applied the latter approach.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Application of the new standard to applicable contracts had no impact to net parent company investment as of January 1, 2018. Disclosures required by the new standard are included in Note 5.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accounting Standards Update 2016-16, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Income Taxes: Intra-Entity Transfers of Assets Other Than Inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:13px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This standard requires entities to recognize the income tax consequences of intra-entity transfers of assets other than inventory at the time of transfer. This standard requires a modified retrospective approach to adoption.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Upon adoption, the cumulative effect of applying the standard resulted in a decrease to net parent company investment of approximately $0.3 million. Adoption of this standard did not result in a material change in net income for the three and nine months ended September 30, 2018.</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accounting Standards Update 2017-07, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Compensation-Retirement Benefits: Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This standard was issued to improve the transparency and comparability among organizations by requiring entities to separate their net periodic pension cost and net periodic postretirement benefit cost into a service cost component and other components. Previously, the costs of the other components along with the service cost component were classified based upon the function of the employee. This standard requires entities to classify the service cost component in the same financial statement line item or items as other compensation costs arising from services rendered by pertinent employees. The other components of net benefit cost are now presented separately from the line items that include the service cost component. When applicable, the service cost component is now the only component eligible for capitalization. An entity should apply the new standard retrospectively for the classification of the service cost and other components and prospectively for the capitalization of the service cost component. </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Upon adoption of this standard, pension and postretirement benefit cost components other than service costs are presented in other&#8211;net, (income) expense. Retrospective application was not material to the combined statement of operations for the three and nine months ended September 30, 2017. We do not expect application of the new standard to have a material impact on an ongoing basis. </font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table provides a brief description of the accounting standard that has not yet been adopted and could have a material effect on the consolidated financial statements:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:37%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:31%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Standard</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Effective Date</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Effect on the financial statements or other significant matters</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accounting Standards Update 2016-02, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Leases</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This standard was issued to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities, including leases classified as operating leases under current GAAP, on the balance sheet and requiring additional disclosures about leasing arrangements. An entity can apply the new leases standard retrospectively to each prior reporting period presented or with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. We plan to use the latter approach.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This standard is effective January 1, 2019, with early adoption permitted. We intend to adopt this standard on that date.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We are in the process of determining the impact on our consolidated financial statements. We have selected a software solution to be compatible with our enterprise software system. Development of our selected solution is ongoing, as it is not yet fully compliant with the requirements of the standard. The timely readiness of the lease software system is critical to ensure an efficient and effective adoption of the standard.</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The allocations of services from Lilly to us were reflected as follows in the unaudited condensed consolidated and combined statements of operations:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cost of sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">21.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">23.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Research and development </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Marketing, selling and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">26.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">27.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">81.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">82.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">34.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">36.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">105.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">107.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our total charges related to asset impairment, restructuring and other special charges, including integration of acquired businesses, in the unaudited condensed consolidated and combined statements of operations consisted of the following:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cash expense:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Severance </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(0.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(2.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">62.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Integration and other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">75.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Exit costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">24.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total cash expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">23.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">18.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">161.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Non-cash expense</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Asset impairment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">63.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">43.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total non-cash expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">63.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">43.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Gain on sale of fixed assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(16.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">12.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">23.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">82.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">189.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table summarizes the activity in our reserves established in connection with these restructuring activities:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:50%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Exit costs </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Severance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Balance at December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">26.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">38.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:18px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Charges</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">24.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">62.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">86.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:18px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cash paid</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(7.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(61.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(69.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Balance at September&#160;30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">28.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">26.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">55.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Balance at December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">34.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">43.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">78.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:18px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Charges</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(2.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">8.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:18px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Separation adjustment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(5.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(5.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:18px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cash paid</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(10.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(22.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(33.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Balance at September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">29.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">17.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">47.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We operate as a single operating segment engaged in the development, manufacturing, marketing and sales of animal health products worldwide for both food animals and companion animals. Consistent with our operational structure, our President and Chief Executive Officer (CEO), as the chief operating decision maker, makes resource allocation and business process decisions globally across our consolidated business. Strategic decisions are managed globally with global functional leaders responsible for determining significant cost/investments and with regional leaders responsible for overseeing the execution of the global strategy. Our global research and development organization is responsible for development of new products. Our manufacturing organization is responsible for the manufacturing and supply of products and for the optimization of our supply chain. Regional leaders are responsible for the distribution and sale of our products and for local direct costs. The business is also supported by global corporate staff functions. Managing and allocating resources at the global corporate level enables our CEO to assess the overall level of resources available and how to best deploy these resources across functions, product types, regional commercial organizations and research and development projects in line with our overarching long-term corporate-wide strategic goals, rather than on a product or geographic basis. Consistent with this decision-making process, our CEO uses consolidated, single-segment financial information for purposes of evaluating performance, allocating resources, setting incentive compensation targets, as well as forecasting future period financial results.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our products include Rumensin</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;">, Optaflexx</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;">, Denagard</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;">, Tylan</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;">, Maxiban</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;"> and other products for livestock and poultry, as well as Trifexis</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;">, Interceptor</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;">, Comfortis</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;"> and other products for companion animals. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We have a single customer who accounted for </font><font style="font-family:Arial;font-size:10pt;">11.1%</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">9.4%</font><font style="font-family:Arial;font-size:10pt;"> of revenue for the three months ended </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">, respectively, and for </font><font style="font-family:Arial;font-size:10pt;">11.5%</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">11.9%</font><font style="font-family:Arial;font-size:10pt;"> of revenue for the </font><font style="font-family:Arial;font-size:10pt;">nine months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">, respectively. The product sales resulted in accounts receivable with this customer of </font><font style="font-family:Arial;font-size:10pt;">$79.5 million</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$88.0 million</font><font style="font-family:Arial;font-size:10pt;"> as of </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">December 31, 2017</font><font style="font-family:Arial;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We are exposed to the risk of changes in social, political and economic conditions inherent in foreign operations and our results of operations and the value of its foreign assets are affected by fluctuations in foreign currency exchange rates.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Selected geographic area information was as follows:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:43%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Revenue&#8212;to unaffiliated customers </font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">United States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">382.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">321.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,108.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,054.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">International</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">378.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">375.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,158.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,080.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">761.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">697.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,267.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,134.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Long-lived assets </font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">United States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">589.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">604.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">United Kingdom</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">195.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">204.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other foreign countries</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">190.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">190.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Long-lived assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">975.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">999.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:19.53125%;border-collapse:collapse;text-align:left;"><tr><td colspan="1" rowspan="1"></td></tr><tr><td style="width:100%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:0px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)&#160;&#160;&#160;&#160;</sup></font><font style="font-family:Arial;font-size:8pt;">Revenue is attributed to the countries based on the location of the customer.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:0px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)&#160;&#160;&#160;&#160;</sup></font><font style="font-family:Arial;font-size:8pt;">Long-lived assets consist of property and equipment, net, and certain noncurrent assets.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">These unaudited condensed combined financial statements include an allocation of expenses related to certain Lilly corporate functions, including executive oversight, treasury, legal, finance, human resources, tax, internal audit, financial reporting, information technology and investor relations. These expenses have been allocated to us based on direct usage or benefit where specifically identifiable, with the remainder allocated primarily on a pro rata basis of revenue, headcount and other measures. We consider the expenses methodology and results to be reasonable for all periods presented. However, the allocations may not be indicative of the actual expense that would have been incurred had we operated as an independent, publicly traded company for the periods presented. It is impractical to estimate what the standalone costs of Elanco would have been in the historical periods.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In connection with the Separation, we issued </font><font style="font-family:Arial;font-size:10pt;">$2.0 billion</font><font style="font-family:Arial;font-size:10pt;"> aggregate principal amount of senior notes in a private placement, and we also entered into a </font><font style="font-family:Arial;font-size:10pt;">$750.0 million</font><font style="font-family:Arial;font-size:10pt;"> senior unsecured revolving credit facility and </font><font style="font-family:Arial;font-size:10pt;">$500.0 million</font><font style="font-family:Arial;font-size:10pt;"> senior unsecured term credit facility. See Note 8 for further information.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In connection with the Separation, we entered into various agreements with Lilly, including a master separation agreement. In connection with the terms of the Separation, there were certain&#160;assets and liabilities included in the pre-Separation balance sheet that were retained by Lilly and there were certain assets not included in the pre-Separation balance sheet that were transferred to us.&#160;The cumulative adjustment to the historical balance sheet increased net assets and total equity by approximately </font><font style="font-family:Arial;font-size:10pt;">$58.3 million</font><font style="font-family:Arial;font-size:10pt;">.&#160;The impact on net assets primarily represent the elimination of certain income tax assets and liabilities and the contribution of additional fixed assets. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">After Separation, Lilly owns approximately </font><font style="font-family:Arial;font-size:10pt;">80.2%</font><font style="font-family:Arial;font-size:10pt;"> of the outstanding shares of our common stock. Lilly has informed us that it may make a tax-free distribution to its shareholders of all or a portion of its remaining equity interest, which may include one or more distributions effected as a dividend to all Lilly shareholders, one or more distributions in exchange for Lilly shares or other securities, or any combination thereof. Lilly does not have any obligation to pursue or consummate any further dispositions of its ownership interest in us by any specified date or at all. In connection with the Separation, we will continue to have certain ongoing relationships with Lilly as described in Note 14.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Prior to Separation, the equity balance in the unaudited condensed combined financial statements represents the excess of total assets over liabilities, including intercompany balances between us and Lilly (net parent company investment) and accumulated other comprehensive loss. Net parent company investment is primarily impacted by contributions from Lilly which are the result of treasury activities and net funding provided by or distributed to Lilly.</font></div></div> EX-101.SCH 6 elan-20180930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2106100 - Disclosure - Asset Impairment, Restructuring and Other Special Charges link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - Asset Impairment, Restructuring and Other Special Charges - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2406404 - Disclosure - Asset Impairment, Restructuring and Other Special Charges - Summary of Activity in Reserves (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Asset Impairment, Restructuring and Other Special Charges (Tables) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Asset Impairment, Restructuring and Other Special Charges - Total Charges Related to Asset Impairment, Restructuring and Other Special Charges (Details) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 2402402 - Disclosure - Basis of Presentation (Details) link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Basis of Presentation (Policies) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Condensed Consolidated and Combined Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1003501 - Statement - Condensed Consolidated and Combined Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - Contingencies link:presentationLink link:calculationLink link:definitionLink 2411401 - Disclosure - Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - Debt - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Debt - Schedule of Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Debt - Schedule of Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2137100 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 2437401 - Disclosure - Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - Financial Instruments and Fair Value link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - Financial Instruments and Fair Value - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - Financial Instruments and Fair Value - Summary of Fair Value Information (Details) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - Financial Instruments and Fair Value (Tables) link:presentationLink link:calculationLink link:definitionLink 2131100 - Disclosure - Geographic Information link:presentationLink link:calculationLink link:definitionLink 2431404 - Disclosure - Geographic Information - Long-lived Assets by Selected Geographic Area Information (Details) link:presentationLink link:calculationLink link:definitionLink 2431402 - Disclosure - Geographic Information - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2431403 - Disclosure - Geographic Information - Revenue by Selected Geographic Area Information (Details) link:presentationLink link:calculationLink link:definitionLink 2331301 - Disclosure - Geographic Information (Tables) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Impact of Separation link:presentationLink link:calculationLink link:definitionLink 2403401 - Disclosure - Impact of Separation (Details) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Implementation of New Financial Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Implementation of New Financial Accounting Pronouncements (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Implementation of New Financial Accounting Pronouncements (Tables) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2410401 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - Inventories - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Inventories - Schedule of Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Nature of Business and Organization link:presentationLink link:calculationLink link:definitionLink 2401401 - Disclosure - Nature of Business and Organization (Details) link:presentationLink link:calculationLink link:definitionLink 2140100 - Disclosure - Related Party Agreements and Transactions link:presentationLink link:calculationLink link:definitionLink 2440403 - Disclosure - Related Party Agreements and Transactions - Allocations of Services (Details) link:presentationLink link:calculationLink link:definitionLink 2440402 - Disclosure - Related Party Agreements and Transactions - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2340301 - Disclosure - Related Party Agreements and Transactions (Tables) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 2405404 - Disclosure - Revenue - Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Revenue - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2405403 - Disclosure - Revenue - Summary of Activity in Sales Rebates and Discounts Liability (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Unaudited Condensed Consolidated and Combined of Cash Flows link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Unaudited Condensed Consolidated and Combined Statements of Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Unaudited Condensed Consolidated and Combined Statements of Equity link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Unaudited Condensed Consolidated and Combined Statements of Operations link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 elan-20180930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 elan-20180930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 elan-20180930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Revenue from Contract with Customer [Abstract] Summary of Activity in Sales Rebates and Discounts Liability Contract with Customer, Asset and Liability [Table Text Block] Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Equity [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Senior Notes Senior Notes [Member] Credit Facility Line of Credit [Member] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Senior Unsecured Revolving Credit Facility Revolving Credit Facility [Member] Senior Unsecured Term Credit Facility Term Credit Facility [Member] Term Credit Facility [Member] Ownership [Axis] Ownership [Axis] Ownership [Domain] Ownership [Domain] Elanco Elanco Animal Health Incorporated And Subsidiaries [Member] Elanco Animal Health Incorporated And Subsidiaries [Member] Legal Entity [Axis] Legal Entity [Axis] Entity [Domain] Entity [Domain] Lilly Eli Lilly and Company [Member] Eli Lilly and Company [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Aggregate principal amount Debt Instrument, Face Amount Credit facility, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Increase in net assets Stockholders' Equity, Separation Adjustments Stockholders' Equity, Separation Adjustments Ownership percentage of outstanding Common stock Noncontrolling Interest, Ownership Percentage by Parent Related Party Transactions [Abstract] Related Party Agreements and Transactions Related Party Transactions Disclosure [Text Block] Debt Disclosure [Abstract] Schedule of Long-term Debt Schedule of Long-term Debt Instruments [Table Text Block] Segment Reporting [Abstract] Number of operating segments Number of Operating Segments Concentration Risk [Table] Concentration Risk [Table] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Customer Concentration Risk Customer Concentration Risk [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Revenue Sales Revenue, Net [Member] Customer [Axis] Customer [Axis] Customer [Domain] Customer [Domain] Single Customer Customer A [Member] Customer A [Member] Product and Service [Axis] Product and Service [Axis] Product and Service [Domain] Product and Service [Domain] Product Sales Product [Member] Concentration Risk [Line Items] Concentration Risk [Line Items] Concentration risk Concentration Risk, Percentage Accounts receivable Accounts Receivable, Net, Current Accounting Changes and Error Corrections [Abstract] Description of Accounting Standards Adopted and Not Yet Adopted Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block] Implementation of New Financial Accounting Pronouncements Accounting Changes and Error Corrections [Text Block] Geographic Information Segment Reporting Disclosure [Text Block] Statement of Cash Flows [Abstract] Cash Flows from Operating Activities Net Cash Provided by (Used in) Operating Activities [Abstract] Net income (loss) Net Income (Loss) Attributable to Parent Adjustments to Reconcile Net Income (Loss) to Cash Flows from Operating Activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization Change in deferred income taxes Deferred Income Tax Expense (Benefit) Stock-based compensation expense Share-based Compensation Asset impairment charges Asset Impairment Charges, Including Inventory Write-Down Asset Impairment Charges, Including Inventory Write-Down Gain on sale of assets Gain (Loss) on Disposition of Assets Other changes in operating assets and liabilities, net of acquisitions and divestitures Increase (Decrease) in Other Operating Assets and Liabilities, Net Other non-cash operating activities, net Other Operating Activities, Cash Flow Statement Net Cash Provided by Operating Activities Net Cash Provided by (Used in) Operating Activities Cash Flows from Investing Activities Net Cash Provided by (Used in) Investing Activities [Abstract] Net purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Cash paid for acquisitions, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Other investing activities, net Payments for (Proceeds from) Other Investing Activities Net Cash Used for Investing Activities Net Cash Provided by (Used in) Investing Activities Cash Flows from Financing Activities Net Cash Provided by (Used in) Financing Activities [Abstract] Proceeds from issuance of long-term debt (Note 8) Proceeds from Issuance of Senior Long-term Debt Proceeds from issuance of common stock (Note 1) Proceeds from Issuance of Common Stock Consideration paid to Lilly in connection with the Separation (Note 1) Payments Of Separation Related Costs, Financing Activities Payments Of Separation Related Costs, Financing Activities Other financing activities, net Proceeds from (Payments for) Other Financing Activities Other net transactions with Lilly Proceeds From (Payments To) Transactions With Parent Proceeds From (Payments To) Transactions With Parent Net Cash Provided by Financing Activities Net Cash Provided by (Used in) Financing Activities Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Net increase in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, cash equivalents and restricted cash at beginning of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash, cash equivalents and restricted cash at end of period Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Restricted cash (Note 14) Restricted Cash, Current Cash, cash equivalents and restricted cash at end of period Change In Contract With Customer, Liability [Roll Forward] Change In Contract With Customer, Liability [Roll Forward] Change In Contract With Customer, Liability [Roll Forward] Beginning balance Contract with Customer, Liability Reduction of revenue Contract with Customer, Liability, Revenue Recognized Payments Contract With Customer, Liability, Increase From Cash Receipts Contract With Customer, Liability, Increase From Cash Receipts Ending balance Organization, Consolidation and Presentation of Financial Statements [Abstract] Number of brands in diverse portfolio (more than) Number Of Brands In Entity's Portfolio Number Of Brands In Entity's Portfolio Number of countries in which entity operates (more than) Number of Countries in which Entity Operates Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Sale of Stock [Axis] Sale of Stock [Axis] Sale of Stock [Domain] Sale of Stock [Domain] IPO IPO [Member] Subsidiary, Sale of Stock [Line Items] Subsidiary, Sale of Stock [Line Items] Number of shares issued Sale of Stock, Number of Shares Issued in Transaction Percentage of total outstanding shares Sale of Stock, Percentage of Ownership before Transaction Price per share (usd per share) Sale of Stock, Price Per Share Total net proceeds, after underwriting discounts and commissions Sale of Stock, Consideration Received on Transaction Payments made to date Separation Related Costs, Financing Activities, Payments Made To Date Separation Related Costs, Financing Activities, Payments Made To Date Amount transferred to parent Restructuring and Related Activities [Abstract] Asset Impairment, Restructuring and Other Special Charges Restructuring, Impairment, and Other Activities Disclosure [Text Block] Fair Value Disclosures [Abstract] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Measurement Frequency [Axis] Measurement Frequency [Axis] Fair Value, Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Recurring Fair Value, Measurements, Recurring [Member] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Other current liabilities- contingent consideration Other Current Liabilities [Member] Other noncurrent liabilities- contingent consideration Other Noncurrent Liabilities [Member] Measurement Basis [Axis] Measurement Basis [Axis] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Carrying Amount Reported Value Measurement [Member] Fair Value Estimate of Fair Value Measurement [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Contingent consideration liabilities Nonfinancial Liabilities Fair Value Disclosure Summary of Fair Value Information Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Statement of Comprehensive Income [Abstract] Other comprehensive income (loss), net of tax Other Comprehensive Income (Loss), Net of Tax Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock Common Stock [Member] Additional Paid-in Capital Additional Paid-in Capital [Member] Net Parent Company Investment Net Parent Company Investment [Member] Net Parent Company Investment [Member] Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Foreign Currency Translation Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Defined Benefit Pension and Retiree Health Benefit Plans Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Statement [Line Items] Statement [Line Items] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Balance at beginning of period (in shares) Shares, Outstanding Balance at beginning of period Stockholders' Equity Attributable to Parent Adoption of Accounting Standards Update 2016-16 Cumulative Effect of New Accounting Principle in Period of Adoption Other comprehensive income (loss), net of tax Transfers (to)/from Lilly, net Stockholders' Equity, Transfers (To) From Parent Stockholders' Equity, Transfers (To) From Parent Separation adjustments Issuance of common stock (in shares) Stock Issued During Period, Shares, New Issues Issuance of common stock Stock Issued During Period, Value, New Issues Consideration to Lilly in connection with the Separation Adjustments To Additional Paid In Capital, Separation Payment To Parent Adjustments To Additional Paid In Capital, Separation Payment To Parent Reclassification of net parent company investment Stockholders' Equity, Reclassification Of Net Parent Company Investment Stockholders' Equity, Reclassification Of Net Parent Company Investment Balance at end of period (in shares) Balance at end of period Commitments and Contingencies Disclosure [Abstract] Contingencies Legal Matters and Contingencies [Text Block] Inventory Disclosure [Abstract] Inventories Inventory Disclosure [Text Block] Statement of Financial Position [Abstract] Assets Assets [Abstract] Current Assets Assets, Current [Abstract] Cash and cash equivalents Accounts receivable, net of allowances of $8.8 (2018) and $9.8 (2017) Other receivables Other Receivables, Net, Current Inventories (Note 7) Inventory, Net Prepaid expenses and other Prepaid Expense and Other Assets, Current Restricted cash (Note 14) Total current assets Assets, Current Noncurrent Assets Assets, Noncurrent [Abstract] Investments (Note 9) Investments Goodwill Goodwill Other intangibles, net Intangible Assets, Net (Excluding Goodwill) Other noncurrent assets Other Assets, Noncurrent Property and equipment, net of accumulated depreciation $894.5 (2018) and $834.1 (2017) Property, Plant and Equipment, Net Total assets Assets Liabilities and Equity Liabilities and Equity [Abstract] Current Liabilities Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Employee compensation Employee-related Liabilities, Current Sales rebates and discounts Contract with Customer, Liability, Current Other current liabilities Other Liabilities, Current Payable to Lilly (Note 14) Due to Related Parties, Noncurrent Total current liabilities Liabilities, Current Noncurrent Liabilities Liabilities, Noncurrent [Abstract] Long-term debt (Note 8) Long-term Debt, Excluding Current Maturities Accrued retirement benefits Liability, Defined Benefit Plan, Noncurrent Deferred taxes Deferred Income Tax Liabilities, Net Other noncurrent liabilities Other Liabilities, Noncurrent Total liabilities Liabilities Commitments and Contingencies (Note 11) Commitments and Contingencies Equity Stockholders' Equity Attributable to Parent [Abstract] Net parent company investment Net Parent Company Investment Net Parent Company Investment Common stock, no par value, 5,000,000,000 shares authorized 365,625,000 shares issued and outstanding as of September 30, 2018 Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Total equity Total liabilities and equity Liabilities and Equity Financial Instruments and Fair Value Fair Value Disclosures [Text Block] Income Statement [Abstract] Revenue Revenue from Contract with Customer, Including Assessed Tax Costs, expenses and other: Costs and Expenses [Abstract] Cost of sales Cost of Goods and Services Sold Research and development Research and Development Expense Marketing, selling and administrative Selling, General and Administrative Expense Amortization of intangible assets Amortization of Intangible Assets Asset impairments, restructuring and other special charges (Note 6) Restructuring, Settlement and Impairment Provisions Other–net, (income) expense Nonoperating Income (Expense) Costs, expenses and other Costs and Expenses Income (loss) before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income tax expense Income Tax Expense (Benefit) Net income (loss) Earnings (loss) per share: Earnings Per Share [Abstract] Basic and diluted (usd per share) Earnings Per Share, Basic and Diluted Weighted average shares outstanding: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Basic and diluted (in shares) Weighted Average Number of Shares Outstanding, Basic and Diluted Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Reclassifications Reclassification, Policy [Policy Text Block] Consolidation Consolidation, Policy [Policy Text Block] Expenses Related to Certain Corporate Functions Selling, General and Administrative Expenses, Policy [Policy Text Block] Income Tax Income Tax, Policy [Policy Text Block] Benefit and Combined Stock-Based Compensation Plans Compensation Related Costs, Policy [Policy Text Block] Equity Balance Stockholders' Equity, Policy [Policy Text Block] New Financial Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Other obligations Notes Payable, Other Payables [Member] Term credit facility Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] 3.912% Senior Notes due 2021 3.912% Senior Notes Due 2021 [Member] 3.912% Senior Notes Due 2021 [Member] 4.272% Senior Notes due 2023 4.272% Senior Notes Due 2023 [Member] 4.272% Senior Notes Due 2023 [Member] 4.900% Senior Notes due 2028 4.9% Senior Notes Due 2028 [Member] 4.9% Senior Notes Due 2028 [Member] Interest rate Debt Instrument, Interest Rate, Stated Percentage Long-term debt, gross Long-term Debt, Gross Unamortized debt issuance costs Debt Issuance Costs, Net Total long-term debt Long-term Debt Less current portion of long-term debt Long-term Debt, Current Maturities Total long-term debt, excluding current portion Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Companion Animal Disease Prevention Companion Animal Disease Prevention [Member] Companion Animal Disease Prevention [Member] Companion Animal Therapeutics Companion Animal Therapeutics [Member] Companion Animal Therapeutics [Member] Companion Animal Other Companion Animal Other [Member] Companion Animal Other [Member] Food Animal Future Protein & Health Food Animal Future Protein And Health [Member] Food Animal Future Protein And Health [Member] Food Animal Ruminants & Swine Food Animal Ruminants And Swine [Member] Food Animal Ruminants And Swine [Member] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Revenue Revenue from Contract with Customer, Excluding Assessed Tax Income Tax Disclosure [Abstract] Income Taxes Income Tax Disclosure [Text Block] Schedule of Error Corrections and Prior Period Adjustment Restatement [Table] Schedule of Error Corrections and Prior Period Adjustment Restatement [Table] Adjustments for Error Corrections [Axis] Adjustments for Error Corrections [Axis] Adjustments for Error Correction [Domain] Adjustments for Error Correction [Domain] Rebates Related to Product Held in Wholesalers Pipeline Rebates Related To Product Held In Wholesalers Pipeline [Member] Rebates Related To Product Held In Wholesalers Pipeline [Member] Restatement [Axis] Restatement [Axis] Restatement [Domain] Restatement [Domain] Adjustment Restatement Adjustment [Member] Previously Reported Previously Reported [Member] Error Corrections and Prior Period Adjustments Restatement [Line Items] Error Corrections and Prior Period Adjustments Restatement [Line Items] Sales rebates and discounts liability Total current liabilities Total liabilities Total equity Cost and equity method investments Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table] Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Aratana Therapeutics, Inc. Aratana Therapeutics, Inc. [Member] Aratana Therapeutics, Inc. [Member] Amortized Cost Business Acquisition, Contingent Consideration [Line Items] Business Acquisition, Contingent Consideration [Line Items] Increase in fair value of contingent consideration liabilities Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Long term debt Long-term Debt, Fair Value Intangible asset impairments Impairment of Intangible Assets (Excluding Goodwill) Fixed asset impairments Impairment of Long-Lived Assets to be Disposed of Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Related Party [Axis] Related Party [Axis] Related Party [Domain] Related Party [Domain] Lilly Majority Shareholder [Member] Related Party Transaction [Axis] Related Party Transaction [Axis] Related Party Transaction [Domain] Related Party Transaction [Domain] Transitional Services Agreement Transitional Services Agreement [Member] Transitional Services Agreement [Member] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Cost of sales Cost of Sales [Member] Research and development Research and Development Expense [Member] Marketing, selling and administrative Selling, General and Administrative Expenses [Member] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Allocation of services Related Party Transaction, Expenses from Transactions with Related Party New Accounting Pronouncements or Change in Accounting Principle [Table] New Accounting Pronouncements or Change in Accounting Principle [Table] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Accounting Standards Update 2016-16 Accounting Standards Update 2016-16 [Member] New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Net parent company investment Schedule of Inventories Schedule of Inventory, Current [Table Text Block] Receivables, Net, Current [Abstract] Accounts receivable, allowances Allowance for Doubtful Accounts Receivable, Current Property and equipment, accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Common stock, shares authorized Common Stock, Shares Authorized Common stock, shares issued Common Stock, Shares, Issued Common stock, shares outstanding Common Stock, Shares, Outstanding Geographic Concentration Risk Geographic Concentration Risk [Member] Product Return Concentration Risk Product Return Concentration Risk [Member] Product Return Concentration Risk [Member] Contract With Customer Liability Contract With Customer, Liability [Member] Contract With Customer, Liability [Member] Net Revenue Revenue from Contract with Customer [Member] Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] United States UNITED STATES Next Largest Country Non-US [Member] Payment terms Revenue, Performance Obligation, Description of Timing Rebate period Contract With Customer, Rebate Period Contract With Customer, Rebate Period Nature of Business and Organization Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Finished products Inventory, Finished Goods, Gross Work in process Inventory, Work in Process, Gross Raw materials and supplies Inventory, Raw Materials and Supplies, Gross Total (approximates replacement cost) Inventory, Gross Decrease to LIFO cost Inventory, LIFO Reserve Inventories IPO, excluding Underwriters' Option IPO, Excluding Over-Allotment Option [Member] IPO, Excluding Over-Allotment Option [Member] Underwriters' Option Over-Allotment Option [Member] Number of shares outstanding Weighted Average Number of Shares Outstanding, Basic Common shares outstanding Noncontrolling Interest, Number Of Shares Owned By Parent Noncontrolling Interest, Number Of Shares Owned By Parent Stock split ratio Stockholders' Equity Note, Stock Split, Conversion Ratio Revenue Revenue from Contract with Customer [Text Block] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Schedule of Revenues from External Customers and Long-Lived Assets [Table] United Kingdom UNITED KINGDOM Other foreign countries Other Foreign Countries Not Separately Disclosed [Member] Other Foreign Countries Not Separately Disclosed [Member] Revenues from External Customers and Long-Lived Assets [Line Items] Revenues from External Customers and Long-Lived Assets [Line Items] Long-lived assets Long-Lived Assets Liabilities related to litigation Estimated Litigation Liability Revenue by Selected Geographic Area Information Revenue from External Customers by Geographic Areas [Table Text Block] Long-lived Assets by Selected Geographic Area Information Long-lived Assets by Geographic Areas [Table Text Block] Total Charges Related to Asset Impairment, Restructuring and Other Special Charges Restructuring and Related Costs [Table Text Block] Summary of Activity in Reserves Schedule of Restructuring Reserve by Type of Cost [Table Text Block] International Revenue—to unaffiliated customers Debt Debt Disclosure [Text Block] Cash expense: Restructuring, Settlement and Impairment Provisions [Abstract] Severance Severance Costs Integration and other Business Combination, Integration Related Costs Exit costs Business Exit Costs Total cash expense Restructuring, Settlement And Impairment Provisions, Excluding Noncash Restructuring, Settlement And Impairment Provisions, Excluding Noncash Non-cash expense Asset Impairment Charges [Abstract] Asset impairment Asset Impairment Charges Total non-cash expense Restructuring, Settlement And Impairment Provisions, Noncash Restructuring, Settlement And Impairment Provisions, Noncash Gain on sale of fixed assets Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property Total cash expense Income tax expense (benefit) Income (loss) before income taxes Effective tax rate Effective Income Tax Rate Reconciliation, Percent Decrease in tax liabilities Increase (Decrease) in Income Taxes Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Income Tax Authority [Axis] Income Tax Authority [Axis] Income Tax Authority [Domain] Income Tax Authority [Domain] International Foreign Tax Authority [Member] State State and Local Jurisdiction [Member] Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Net operating loss carryforwards that expire Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration Revolving credit facility Credit facility term Debt Instrument, Term Borrowings outstanding Interest rate at period end Line of Credit Facility, Interest Rate at Period End Director Director [Member] MSA Master Separation Agreement [Member] Master Separation Agreement [Member] TSA Manufacturing Support Manufacturing Support [Member] Manufacturing Support [Member] Commercial Operations Commercial Operations [Member] Commercial Operations [Member] Boehringer Ingelheim Vetmedica, Inc. Boehringer Ingelheim Vetmedica, Inc. [Member] Boehringer Ingelheim Vetmedica, Inc. [Member] Amount transferred to parent Total net assets Related Party Transaction, Net Assets Related Party Transaction, Net Assets Restricted cash retained Restricted Cash Local purchases minimum Related Party Transaction, Required Local Purchases, Minimum Required Related Party Transaction, Required Local Purchases, Minimum Required Cash to be distributed in excess of Related Party Transaction, Excess Distribution Threshold, Minimum Related Party Transaction, Excess Distribution Threshold, Minimum Additional restricted cash Related Party Transaction, Additional Restricted Cash For Excess Distribution Related Party Transaction, Additional Restricted Cash For Excess Distribution Mark-up rate Related Party Transaction, Mark-Up Rate Related Party Transaction, Mark-Up Rate Net transfers (to)/from Lilly Acquisition amount Revenue from related parties Revenue from Related Parties Stock-based compensation Allocated Share-based Compensation Expense Benefit of defined benefit pension plan Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Costs of defined benefit pension plan Pension Cost (Reversal of Cost) Accounts receivable Accounts Receivable, Related Parties Purchases of goods and services Related Party Transaction, Purchases from Related Party Accounts payable Accounts Payable, Related Parties Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Emerging Growth Company Entity Emerging Growth Company Entity Small Business Entity Small Business Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Restructuring Type [Axis] Restructuring Type [Axis] Type of Restructuring [Domain] Type of Restructuring [Domain] Exit costs Facility Closing [Member] Severance Employee Severance [Member] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Balance at beginning of period Restructuring Reserve Charges Restructuring Charges Separation adjustment Restructuring Reserve, Accrual Adjustment Cash paid Payments for Restructuring Balance at end of period Allocations of Services Schedule of Related Party Transactions [Table Text Block] Earnings Per Share Earnings Per Share [Text Block] Basis of Presentation Basis of Accounting [Text Block] Inventory write-offs Inventory Write-down Impact of Separation Stockholders' Equity Note Disclosure [Text Block] EX-101.PRE 10 elan-20180930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.10.0.1
Document and Entity Information - shares
 9 Months Ended
Sep. 30, 2018
Nov. 06, 2018
Document And Entity Information [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Sep. 30, 2018  
Document Fiscal Year Focus 2018  
Document Fiscal Period Focus Q3  
Entity Registrant Name Elanco Animal Health Inc.  
Entity Central Index Key 0001739104  
Current Fiscal Year End Date --12-31  
Entity Filer Category Non-accelerated Filer  
Entity Emerging Growth Company false  
Entity Small Business false  
Entity Common Stock, Shares Outstanding   365,625,000
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.10.0.1
Unaudited Condensed Consolidated and Combined Statements of Operations - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Income Statement [Abstract]        
Revenue $ 761.1 $ 697.1 $ 2,267.5 $ 2,134.7
Costs, expenses and other:        
Cost of sales 369.8 376.2 1,161.3 1,088.9
Research and development 58.9 61.9 185.5 189.7
Marketing, selling and administrative 179.0 194.7 550.1 583.0
Amortization of intangible assets 48.7 51.6 147.3 161.0
Asset impairments, restructuring and other special charges (Note 6) 12.4 23.7 82.8 189.3
Other–net, (income) expense 13.5 (1.9) 24.2 0.0
Costs, expenses and other 682.3 706.2 2,151.2 2,211.9
Income (loss) before income taxes 78.8 (9.1) 116.3 (77.2)
Income tax expense 18.6 11.6 46.2 72.0
Net income (loss) $ 60.2 $ (20.7) $ 70.1 $ (149.2)
Earnings (loss) per share:        
Basic and diluted (usd per share) $ 0.16 $ (0.06) $ 0.19 $ (0.41)
Weighted average shares outstanding:        
Basic and diluted (in shares) 365.6 365.6 365.6 365.6
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.10.0.1
Unaudited Condensed Consolidated and Combined Statements of Comprehensive Income (Loss) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Statement of Comprehensive Income [Abstract]        
Net income (loss) $ 60.2 $ (20.7) $ 70.1 $ (149.2)
Other comprehensive income (loss), net of tax 94.5 (4.0) (9.8) 231.8
Comprehensive income (loss) $ 154.7 $ (24.7) $ 60.3 $ 82.6
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated and Combined Balance Sheets - USD ($)
$ in Millions
Sep. 30, 2018
Dec. 31, 2017
Current Assets    
Cash and cash equivalents $ 300.0 $ 323.4
Accounts receivable, net of allowances of $8.8 (2018) and $9.8 (2017) 606.1 567.4
Other receivables 30.8 34.5
Inventories (Note 7) 1,008.7 1,062.3
Prepaid expenses and other 123.2 136.1
Restricted cash (Note 14) 634.9 0.0
Total current assets 2,703.7 2,123.7
Noncurrent Assets    
Investments (Note 9) 14.9 12.3
Goodwill 2,968.8 2,969.2
Other intangibles, net 2,514.8 2,672.8
Other noncurrent assets 100.0 242.0
Property and equipment, net of accumulated depreciation $894.5 (2018) and $834.1 (2017) 909.3 920.3
Total assets 9,211.5 8,940.3
Current Liabilities    
Accounts payable 202.7 203.8
Employee compensation 81.3 89.3
Sales rebates and discounts 147.9 165.5
Other current liabilities 178.6 184.5
Payable to Lilly (Note 14) 634.9 0.0
Total current liabilities 1,245.4 643.1
Noncurrent Liabilities    
Long-term debt (Note 8) 2,478.5 0.0
Accrued retirement benefits 136.0 139.0
Deferred taxes 125.0 251.9
Other noncurrent liabilities 89.5 126.0
Total liabilities 4,074.4 1,160.0
Commitments and Contingencies (Note 11)
Equity    
Net parent company investment 0.0 8,036.9
Common stock, no par value, 5,000,000,000 shares authorized 365,625,000 shares issued and outstanding as of September 30, 2018 0.0 0.0
Additional paid-in capital 5,347.4 0.0
Accumulated other comprehensive loss (210.3) (256.6)
Total equity 5,137.1 7,780.3
Total liabilities and equity $ 9,211.5 $ 8,940.3
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated and Combined Balance Sheets (Parenthetical) - USD ($)
$ in Millions
Sep. 30, 2018
Dec. 31, 2017
Receivables, Net, Current [Abstract]    
Accounts receivable, allowances $ 8.8 $ 9.8
Property and equipment, accumulated depreciation $ 894.5 $ 834.1
Common stock, shares authorized 5,000,000,000 5,000,000,000
Common stock, shares issued 365,625,000 365,625,000
Common stock, shares outstanding 365,625,000 365,625,000
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.10.0.1
Unaudited Condensed Consolidated and Combined Statements of Equity - USD ($)
shares in Millions, $ in Millions
Total
Common Stock
Additional Paid-in Capital
Net Parent Company Investment
Accumulated Other Comprehensive Income (Loss)
Foreign Currency Translation
Defined Benefit Pension and Retiree Health Benefit Plans
Balance at beginning of period (in shares) at Dec. 31, 2016   0.0          
Balance at beginning of period at Dec. 31, 2016 $ 7,017.4 $ 0.0 $ 0.0 $ 7,474.3 $ (456.9) $ (437.3) $ (19.6)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income (loss) (149.2)     (149.2)      
Other comprehensive income (loss), net of tax 231.8       231.8 228.1 3.7
Transfers (to)/from Lilly, net 862.7     862.7      
Balance at end of period (in shares) at Sep. 30, 2017   0.0          
Balance at end of period at Sep. 30, 2017 7,962.7 $ 0.0 0.0 8,187.8 (225.1) (209.2) (15.9)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Adoption of Accounting Standards Update 2016-16 (0.3)     (0.3)      
Balance at beginning of period (in shares) at Dec. 31, 2017   0.0          
Balance at beginning of period at Dec. 31, 2017 7,780.3 $ 0.0 0.0 8,036.9 (256.6) (227.2) (29.4)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income (loss) 70.1     70.1      
Other comprehensive income (loss), net of tax (9.8)       (9.8) (20.6) 10.8
Transfers (to)/from Lilly, net (226.3)     (226.3)      
Separation adjustments 58.3     2.2 56.1 56.1  
Issuance of common stock (in shares)   365.6          
Issuance of common stock 1,659.7   1,659.7        
Consideration to Lilly in connection with the Separation (4,194.9)   (4,194.9)        
Reclassification of net parent company investment     7,882.6 (7,882.6)      
Balance at end of period (in shares) at Sep. 30, 2018   365.6          
Balance at end of period at Sep. 30, 2018 $ 5,137.1 $ 0.0 $ 5,347.4 $ 0.0 $ (210.3) $ (191.7) $ (18.6)
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.10.0.1
Unaudited Condensed Consolidated and Combined of Cash Flows - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Cash Flows from Operating Activities    
Net income (loss) $ 70.1 $ (149.2)
Adjustments to Reconcile Net Income (Loss) to Cash Flows from Operating Activities:    
Depreciation and amortization 222.3 231.3
Change in deferred income taxes 12.6 (7.0)
Stock-based compensation expense 20.2 18.7
Asset impairment charges 102.5 43.8
Gain on sale of assets 0.0 (16.0)
Other changes in operating assets and liabilities, net of acquisitions and divestitures (83.4) 42.7
Other non-cash operating activities, net 3.5 2.8
Net Cash Provided by Operating Activities 347.8 167.1
Cash Flows from Investing Activities    
Net purchases of property and equipment (74.3) (31.7)
Cash paid for acquisitions, net of cash acquired 0.0 (882.1)
Other investing activities, net (4.6) (15.3)
Net Cash Used for Investing Activities (78.9) (929.1)
Cash Flows from Financing Activities    
Proceeds from issuance of long-term debt (Note 8) 2,477.7 0.0
Proceeds from issuance of common stock (Note 1) 1,659.7 0.0
Consideration paid to Lilly in connection with the Separation (Note 1) (3,559.1) 0.0
Other financing activities, net (3.7) (0.5)
Other net transactions with Lilly (247.4) 844.0
Net Cash Provided by Financing Activities 327.2 843.5
Effect of exchange rate changes on cash and cash equivalents 15.4 3.3
Net increase in cash, cash equivalents and restricted cash 611.5 84.8
Cash, cash equivalents and restricted cash at beginning of period 323.4 258.8
Cash, cash equivalents and restricted cash at end of period 934.9 343.6
Cash, cash equivalents and restricted cash at end of period $ 323.4 $ 258.8
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.10.0.1
Nature of Business and Organization
 9 Months Ended
Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Nature of Business and Organization
Note 1. Nature of Business and Organization
Nature of Business
Elanco Animal Health Incorporated (Elanco Parent) and its subsidiaries (collectively, Elanco, the Company, we, us or our) was formed as a wholly-owned subsidiary of Eli Lilly and Company (Lilly). Elanco is a global animal health company that innovates, develops, manufactures and markets products for companion and food animals. We offer a diverse portfolio of more than 125 brands to veterinarians and food animal producers in more than 90 countries.
Organization
Elanco Parent was formed in 2018, as a wholly-owned subsidiary of Lilly, to serve as the ultimate parent company of substantially all of the animal health businesses of Lilly.
On September 24, 2018, Elanco Parent completed an initial public offering resulting in the issuance of 72.3 million shares of its common stock (including shares issued pursuant to the underwriters’ option to purchase additional shares), which represents 19.8% of the outstanding shares, at $24 per share (IPO) for a total net proceeds, after underwriting discounts and commissions, of $1.7 billion.  In connection with the completion of the IPO, through a series of equity and other transactions, Lilly transferred to Elanco Parent the animal health businesses that form its business going forward. In exchange Elanco Parent has paid, or will pay, to Lilly approximately $4.2 billion, which includes the net proceeds from the IPO, the net proceeds from the debt offering completed by Elanco Parent in August 2018 and the term loan facility entered into by Elanco Parent in September 2018 (see Note 8). As of September 30, 2018, Elanco Parent has paid Lilly $3.6 billion. These transactions are collectively referred to herein as the Separation.
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.10.0.1
Basis of Presentation
 9 Months Ended
Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation
Note 2. Basis of Presentation
We have prepared the accompanying unaudited condensed consolidated and combined financial statements in accordance with the requirements of Form 10-Q and, therefore, they do not include all information and footnotes necessary for a fair presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States (GAAP). In our opinion, the financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for a fair presentation of the results of operations for the periods shown. In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates.
Certain reclassifications have been made to prior periods in the unaudited condensed consolidated and combined financial statements and accompanying notes to conform with current presentation. In addition, during the period ended September 30, 2018, certain combined balance sheet amounts related to the prior year have been revised to correct the sales rebates and discounts liability, which did not correctly reflect an accrual for rebates related to product held in the wholesalers' pipeline.  In accordance with Securities and Exchange Commission Staff Accounting Bulletin No. 99, Materiality, and Accounting Standards Codification (ASC) 250, Presentation of Financial Statements, we assessed the materiality of this correction and concluded that the accrual for the rebate related to product held in the wholesalers' pipeline was not material to prior periods, and therefore, amendments of previously filed reports are not required.
As such, in accordance with ASC 250, we revised the previously reported combined balance sheet and combined statements of equity. The adjustment, which originates in periods prior to those presented, resulted in a  $10.5 million increase as of December 31, 2017 in the accrual for sales rebates and discounts of $155.0 million, total current liabilities of $632.6 million and total liabilities of $1,149.5 million. In addition, previously reported amounts at December 31, 2017 and December 31, 2016 of net parent company investment of $8,047.4 million and $7,484.8 million, respectively, and total equity of $7,790.8 million and $7,027.9 million, respectively, have been reduced by $10.5 million to reflect the correction above.  
The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our combined financial statements and accompanying notes as of and for the three years ended December 31, 2017 included in our final prospectus relating to our IPO filed on September 21 2018 (IPO Prospectus) with the Securities and Exchange Commission (SEC).
For the periods after Separation, the financial statements are prepared on a consolidated basis. For periods prior to the Separation, our financial statements are combined, have been prepared on a standalone basis, and are derived from Lilly's consolidated financial statements and accounting records. The unaudited condensed combined financial statements reflect the financial position, results of operations and cash flows related to the animal health businesses that were transferred to Elanco Parent and are prepared in conformity with GAAP.
The unaudited condensed combined financial statements include the attribution of certain assets and liabilities that historically have been held at the Lilly corporate level but which are specifically identifiable or attributable to the businesses that have been transferred to Elanco Parent. All intercompany transactions and accounts within Elanco have been eliminated. All transactions between us and Lilly are considered to be effectively settled in the unaudited condensed combined financial statements at the time the intercompany transaction is recorded. The total net effect of the settlement of these intercompany transactions is reflected in the unaudited condensed combined statements of cash flows as a financing activity and in the condensed combined balance sheets as net parent company investment.
These unaudited condensed combined financial statements include an allocation of expenses related to certain Lilly corporate functions, including executive oversight, treasury, legal, finance, human resources, tax, internal audit, financial reporting, information technology and investor relations. These expenses have been allocated to us based on direct usage or benefit where specifically identifiable, with the remainder allocated primarily on a pro rata basis of revenue, headcount and other measures. We consider the expenses methodology and results to be reasonable for all periods presented. However, the allocations may not be indicative of the actual expense that would have been incurred had we operated as an independent, publicly traded company for the periods presented. It is impractical to estimate what the standalone costs of Elanco would have been in the historical periods.
The income tax amounts in the unaudited condensed combined financial statements have been calculated based on a separate return methodology and presented as if our operations were separate taxpayers in the respective jurisdictions. We file income tax returns in the United States (U.S.) federal jurisdiction and various state, local and non-U.S. jurisdictions. Certain of these income tax returns are filed on a consolidated or combined basis with Eli Lilly and Company and/or its subsidiaries.
Lilly maintains various benefit and combined stock-based compensation plans at a corporate level and other benefit plans at a country level. Our employees participate in such programs and the portion of the cost of those plans related to our employees is included in our financial statements. However, the condensed combined balance sheets do not include any equity issued related to stock-based compensation plans or any net benefit plan obligations unless the benefit plan covers only our dedicated employees or where the legal obligation associated with the benefit plan will transfer to Elanco.
Prior to Separation, the equity balance in the unaudited condensed combined financial statements represents the excess of total assets over liabilities, including intercompany balances between us and Lilly (net parent company investment) and accumulated other comprehensive loss. Net parent company investment is primarily impacted by contributions from Lilly which are the result of treasury activities and net funding provided by or distributed to Lilly. See Note 14 for further information.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.10.0.1
Impact of Separation
 9 Months Ended
Sep. 30, 2018
Equity [Abstract]  
Impact of Separation
In connection with the Separation, we issued $2.0 billion aggregate principal amount of senior notes in a private placement, and we also entered into a $750.0 million senior unsecured revolving credit facility and $500.0 million senior unsecured term credit facility. See Note 8 for further information.
In connection with the Separation, we entered into various agreements with Lilly, including a master separation agreement. In connection with the terms of the Separation, there were certain assets and liabilities included in the pre-Separation balance sheet that were retained by Lilly and there were certain assets not included in the pre-Separation balance sheet that were transferred to us. The cumulative adjustment to the historical balance sheet increased net assets and total equity by approximately $58.3 million. The impact on net assets primarily represent the elimination of certain income tax assets and liabilities and the contribution of additional fixed assets.
After Separation, Lilly owns approximately 80.2% of the outstanding shares of our common stock. Lilly has informed us that it may make a tax-free distribution to its shareholders of all or a portion of its remaining equity interest, which may include one or more distributions effected as a dividend to all Lilly shareholders, one or more distributions in exchange for Lilly shares or other securities, or any combination thereof. Lilly does not have any obligation to pursue or consummate any further dispositions of its ownership interest in us by any specified date or at all. In connection with the Separation, we will continue to have certain ongoing relationships with Lilly as described in Note 14.
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.10.0.1
Implementation of New Financial Accounting Pronouncements
 9 Months Ended
Sep. 30, 2018
Accounting Changes and Error Corrections [Abstract]  
Implementation of New Financial Accounting Pronouncements
Note 4. Implementation of New Financial Accounting Pronouncements
The following table provides a brief description of accounting standards that were effective January 1, 2018 and were adopted on that date:
Standard
 
Description
 
Effect on the financial statements or other significant matters
Accounting Standards Update 2014-09 and various other related updates, Revenue from Contracts with Customers
 
This standard replaced existing revenue recognition standards and requires entities to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. An entity can apply the new revenue standard retrospectively to each prior reporting period presented or with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. We applied the latter approach.
 
Application of the new standard to applicable contracts had no impact to net parent company investment as of January 1, 2018. Disclosures required by the new standard are included in Note 5.
Accounting Standards Update 2016-16, Income Taxes: Intra-Entity Transfers of Assets Other Than Inventory
 
This standard requires entities to recognize the income tax consequences of intra-entity transfers of assets other than inventory at the time of transfer. This standard requires a modified retrospective approach to adoption.
 
Upon adoption, the cumulative effect of applying the standard resulted in a decrease to net parent company investment of approximately $0.3 million. Adoption of this standard did not result in a material change in net income for the three and nine months ended September 30, 2018.
Accounting Standards Update 2017-07, Compensation-Retirement Benefits: Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost
 
This standard was issued to improve the transparency and comparability among organizations by requiring entities to separate their net periodic pension cost and net periodic postretirement benefit cost into a service cost component and other components. Previously, the costs of the other components along with the service cost component were classified based upon the function of the employee. This standard requires entities to classify the service cost component in the same financial statement line item or items as other compensation costs arising from services rendered by pertinent employees. The other components of net benefit cost are now presented separately from the line items that include the service cost component. When applicable, the service cost component is now the only component eligible for capitalization. An entity should apply the new standard retrospectively for the classification of the service cost and other components and prospectively for the capitalization of the service cost component.
 
Upon adoption of this standard, pension and postretirement benefit cost components other than service costs are presented in other–net, (income) expense. Retrospective application was not material to the combined statement of operations for the three and nine months ended September 30, 2017. We do not expect application of the new standard to have a material impact on an ongoing basis.
The following table provides a brief description of the accounting standard that has not yet been adopted and could have a material effect on the consolidated financial statements:
Standard
 
Description
 
Effective Date
 
Effect on the financial statements or other significant matters
Accounting Standards Update 2016-02, Leases
 
This standard was issued to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities, including leases classified as operating leases under current GAAP, on the balance sheet and requiring additional disclosures about leasing arrangements. An entity can apply the new leases standard retrospectively to each prior reporting period presented or with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. We plan to use the latter approach.
 
This standard is effective January 1, 2019, with early adoption permitted. We intend to adopt this standard on that date.
 
We are in the process of determining the impact on our consolidated financial statements. We have selected a software solution to be compatible with our enterprise software system. Development of our selected solution is ongoing, as it is not yet fully compliant with the requirements of the standard. The timely readiness of the lease software system is critical to ensure an efficient and effective adoption of the standard.
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.10.0.1
Revenue
 9 Months Ended
Sep. 30, 2018
Revenue from Contract with Customer [Abstract]  
Revenue
Note 5. Revenue
Effective January 1, 2018, we adopted Accounting Standards Update 2014-09, Revenue from Contracts with Customers (ASU 2014-09) and other related updates. The new standard has been applied to contracts for which performance had not been completed as of the date of adoption. Revenue presented for periods prior to 2018 were accounted for under previous standards and has not been adjusted. Revenue and net income for the three and nine months ended September 30, 2018 do not differ materially from amounts that would have resulted from application of the previous standards.
Product Sales
We recognize revenue primarily from product sales to customers. Revenue from sales of products is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation, which generally is at the time we ship the product to the customer. Payment terms differ by jurisdiction and customer, but payment terms in most of our major jurisdictions typically range from 30 to 100 days from date of shipment. Revenue for our product sales has not been adjusted for the effects of a financing component as we expect, at contract inception, that the period between when we transfer control of the product and when we receive payment will be one year or less. Any exceptions are either not material or we collect interest for payments made after the due date. Provisions for rebates and discounts, and returns are established in the same period the related sales are recognized. We generally, ship product shortly after orders are received; therefore, we generally only have a few days of orders received but not yet shipped at the end of any reporting period. Shipping and handling activities are considered to be fulfillment activities and are not considered to be a separate performance obligation. We exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are imposed on our sales of product and collected from a customer.
Significant judgments must be made in determining the transaction price for sales of products related to anticipated rebates and discounts, and returns. The following describe the most significant of these judgments:
Sales Rebates and Discounts - Background and Uncertainties
•
Most of our products are sold to wholesale distributors. We initially invoice our customers contractual list prices. Contracts with direct and indirect customers may provide for various rebates and discounts that may differ in each contract. As a consequence, to determine the appropriate transaction price for our product sales at the time we recognize a sale to a direct customer, we must estimate any rebates or discounts that ultimately will be due to the direct customer and other customers in the distribution chain under the terms of our contracts. Significant judgments are required in making these estimates.
•
The rebate and discount amounts are recorded as a deduction to arrive at our net product sales. We estimate these accruals using an expected value approach.
•
In determining the appropriate accrual amount, we consider our historical experience with similar incentives programs and current sales data to estimate the impact of such programs on revenue and continually monitor the impact of this experience and adjust as necessary. Although we accrue a liability for rebates related to these programs at the time the sale is recorded, the rebate related to that sale is typically paid up to six months after rebate or incentive period expires. Because of this time lag, in any particular period rebate adjustments may incorporate revisions of accruals for several periods.
Our sales rebates and discounts are based on specific agreements and the majority relate to sales in the U.S. As of September 30, 2018 and 2017, liability for sales rebates and discounts in the U.S. represents approximately 70% and 71%, respectively, of our total liability with the next largest country representing approximately 8% and 6%, respectively, of our total liability.
The following table summarizes the activity in the sales rebates and discounts liability in the U.S.:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,

2018
 
2017
 
2018
 
2017
Beginning balance
$
99.1

 
$
118.7

 
$
114.8

 
$
116.1

Reduction of revenue
53.5

 
48.6

 
154.2

 
184.9

Payments
(49.1
)
 
(49.6
)
 
(165.5
)
 
(183.3
)
Ending balance
$
103.5

 
$
117.7

 
$
103.5

 
$
117.7


Adjustments to revenue recognized as a result of changes in estimates for the judgments described above during the three and nine months ended September 30, 2018 for product shipped in previous periods were not material.
Sales Returns - Background and Uncertainties
•
We estimate a reserve for future product returns related to product sales using an expected value approach. This estimate is based on several factors, including: local returns policies and practices; returns as a percentage of revenue; an understanding of the reasons for past returns; estimated shelf life by product; and estimate of the amount of time between shipment and return. Adjustments to the returns reserve have been and may in the future be required based on revised estimates to our assumptions, which would have an impact on our consolidated results of operations. We record the return amounts as a deduction to arrive at our net product sales.
•
Actual product returns have been approximately 1% of net revenue for the three and nine months ended September 30, 2018 and 2017 and have not fluctuated significantly as a percentage of revenue.
Disaggregation of Revenue
The following table summarizes our revenue disaggregated by product category:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Companion Animal Disease Prevention
$
188.6

 
$
140.4

 
$
603.9

 
$
519.7

Companion Animal Therapeutics
80.5

 
63.5

 
211.1

 
181.8

Companion Animal Other
27.7

 
48.3

 
69.3

 
119.9

Food Animal Future Protein & Health
162.8

 
164.5

 
502.1

 
456.0

Food Animal Ruminants & Swine
301.5

 
280.4

 
881.1

 
857.3

Revenue
$
761.1

 
$
697.1

 
$
2,267.5

 
$
2,134.7
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.10.0.1
Asset Impairment, Restructuring and Other Special Charges
 9 Months Ended
Sep. 30, 2018
Restructuring and Related Activities [Abstract]  
Asset Impairment, Restructuring and Other Special Charges
Note 6. Asset Impairment, Restructuring and Other Special Charges
We have historically participated in Lilly's cost-reduction initiatives. Our total charges related to asset impairment, restructuring and other special charges, including integration of acquired businesses, in the unaudited condensed consolidated and combined statements of operations consisted of the following:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Cash expense:
 
 
 
 
 
 
 
Severance
$
(0.2
)
 
$
5.8

 
$
(2.8
)
 
$
62.1

Integration and other
4.9

 
6.4

 
10.5

 
75.1

Exit costs
1.5

 
11.5

 
11.2

 
24.3

Total cash expense
6.2

 
23.7

 
18.9

 
161.5

Non-cash expense
 
 
 
 
 
 
 
Asset impairment
6.2

 
—

 
63.9

 
43.8

Total non-cash expense
6.2

 
—

 
63.9

 
43.8

Gain on sale of fixed assets
—

 
—

 
—

 
(16.0
)
Total
$
12.4

 
$
23.7

 
$
82.8

 
$
189.3


Severance costs represent costs incurred as a result of actions taken to reduce our cost structure.
Integration and other costs primarily represent costs related to our integration efforts as a result of our acquired businesses.
Exit costs primarily represent contract termination costs and reserves for costs related to facilities which we have exited.
Asset impairment recognized during the nine months ended September 30, 2018 resulted from $19.9 million of intangible asset impairments and $44.0 million of fixed asset impairments. The intangible asset impairments primarily related to revised projections of fair value due to product rationalization. The fixed asset impairments were primarily due to the decision to dispose of a manufacturing facility in the U.S. and to the suspension of commercial activities for Imrestor®.
Asset impairment recognized during the nine months ended September 30, 2017 resulted primarily from intangible asset impairments related to revised projections of fair value due to product rationalization and to a lessor extent competitive pressures. The fair value measurements utilized to determine the intangible asset impairments in 2018 and 2017 represent Level 3 fair value measurements.
Gain on sale of fixed assets for the nine months ended September 30, 2017 represents a gain on the disposal of a site that was previously closed as part of the acquisition and integration of Novartis Animal Health.
The following table summarizes the activity in our reserves established in connection with these restructuring activities:
 
Exit costs
 
Severance
 
Total
Balance at December 31, 2016
$
11.5

 
$
26.6

 
$
38.1

Charges
24.3

 
62.1

 
86.4

Cash paid
(7.6
)
 
(61.8
)
 
(69.4
)
Balance at September 30, 2017
$
28.2

 
$
26.9

 
$
55.1

 
 
 
 
 
 
Balance at December 31, 2017
$
34.9

 
$
43.1

 
$
78.0

Charges
11.2

 
(2.8
)
 
8.4

Separation adjustment
(5.9
)

—


(5.9
)
Cash paid
(10.9
)
 
(22.6
)
 
(33.5
)
Balance at September 30, 2018
$
29.3

 
$
17.7

 
$
47.0

Substantially all of the reserves are expected to be paid in the next twelve months. We believe that the reserves are adequate.
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.10.0.1
Inventories
 9 Months Ended
Sep. 30, 2018
Inventory Disclosure [Abstract]  
Inventories
Note 7. Inventories
We state all inventories at the lower of cost or market. We use the last-in, first-out (LIFO) method for a portion of our inventories located in the continental U.S. Other inventories are valued by the first-in, first-out (FIFO) method. FIFO cost approximates current replacement cost.
Inventories consisted of the following:
 
September 30, 2018
 
December 31, 2017
Finished products
$
408.1

 
$
452.0

Work in process
572.3

 
580.0

Raw materials and supplies
71.4

 
70.4

Total (approximates replacement cost)
1,051.8

 
1,102.4

Decrease to LIFO cost
(43.1
)
 
(40.1
)
Inventories
$
1,008.7

 
$
1,062.3


During the nine months ended September 30, 2018, we recognized $38.6 million of inventory write-offs in cost of sales primarily related to the suspension of commercial activities for Imrestor.
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.10.0.1
Debt
 9 Months Ended
Sep. 30, 2018
Debt Disclosure [Abstract]  
Debt
Note 8. Debt
Long-term debt as of September 30, 2018 consisted of the following:
 
September 30, 2018

Term credit facility
$
500.0

3.912% Senior Notes due 2021
500.0

4.272% Senior Notes due 2023
750.0

4.900% Senior Notes due 2028
750.0

Other obligations
0.2

Unamortized debt issuance costs
(21.7
)
Total long-term debt
2,478.5

Less current portion of long-term debt
—

 
$
2,478.5


Long-term debt as of December 31, 2017 was not material.
Revolving and Term Credit Facilities
On September 5, 2018, we entered into a revolving credit agreement with a syndicate of banks providing for a five-year $750.0 million senior unsecured revolving credit facility (Revolving Facility). The Revolving Facility bears interest at a variable rate plus specified margin as defined in the agreement and is payable quarterly. There were no borrowings outstanding under the Revolving Facility at September 30, 2018. The Revolving Facility is payable in full at the end of the term.
On September 5, 2018 we also entered into a $500.0 million three-year term loan under a term credit facility with a syndicate of banks (the Term Facility and collectively with the Revolving Facility, the Credit Facilities.) The Term Facility bears interest at a variable rate plus margin as defined in Term Facility (3.50% at September 30, 2018) and is payable quarterly. The Term Facility is payable in full at the end of the term.
The Credit Facilities are subject to various financial and other covenants including restrictions on the level of borrowings based on a consolidated leverage ratio and a consolidated interest coverage ratio. We were in compliance with all such covenants as of September 30, 2018.
Senior Notes
On August 28, 2018, we issued $2.0 billion of senior notes (Senior Notes) in a private placement. The Senior Notes comprised of $500.0 million of 3.912% Senior Notes due August 27, 2021, $750.0 million of 4.272% Senior Notes due August 28, 2023, and $750.0 million of 4.900% Senior Notes due August 28, 2028. The interest rate payable on each series of Senior Notes is subject to adjustment if Moody's Investor Services, Inc. or Standard & Poor's Financial Services LLC downgrades, or subsequently upgrades, its ratings on the respective series of Senior Notes.
The indenture that governs the Senior Notes contains covenants, including limitations on our ability, and certain of our subsidiaries, to incur liens or engage in sale-leaseback transactions. The indenture also contains restrictions on our ability to consolidate, merge or sell substantially all of our assets, in addition, to other customary terms. We were in compliance with all such covenants under the indenture governing the Senior Notes as of September 30, 2018.
We have entered into an agreement that requires us to use commercially reasonable efforts to cause a registration statement to become effective with the SEC by August 28, 2019, relating to an offer to exchange the Senior Notes for registered Senior Notes having substantially identical terms, or, in certain cases, to register the Senior Notes for resale. If we do not register or exchange the Senior Notes pursuant to the terms of the registration rights agreement, we will be required to pay additional interest to the holders of the Senior Notes under certain circumstances.
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.10.0.1
Financial Instruments and Fair Value
 9 Months Ended
Sep. 30, 2018
Fair Value Disclosures [Abstract]  
Financial Instruments and Fair Value
Note 9. Financial Instruments and Fair Value
Financial instruments that are potentially subject to credit risk consist principally of trade receivables. Collateral is generally not required. The risk associated with this concentration is mitigated by our ongoing credit-review procedures and insurance.
A large portion of our cash is held by a few major financial institutions. We monitor the exposure with these institutions and do not expect any of these institutions to fail to meet their obligations. All highly liquid investments with a maturity of three months or less from the date of purchase are considered to be cash equivalents. The cost of these investments approximates fair value. We also consider the carrying value of restricted cash balances to be representative of its fair value.
As of September 30, 2018 and December 31, 2017, we had $14.9 million and $12.3 million, respectively, of cost and equity method investments.
The following table summarizes the fair value information at September 30, 2018 and December 31, 2017 for contingent consideration liabilities measured at fair value on a recurring basis in the respective balance sheet line items:
 
 
 
Fair Value Measurements Using
 
 
Financial statement line item
Carrying
Amount
 
Quoted Prices in Active Markets for Identical Assets
(Level 1)
 
Significant
Other Observable Inputs
(Level 2)
 
Significant
Unobservable
Inputs
(Level 3)
 
Fair
Value
September 30, 2018
 
 
 
 
 
 
 
 
 
Other current liabilities- contingent consideration
$
17.4

 
$
—

 
$
—

 
$
17.4

 
$
17.4

Other noncurrent liabilities- contingent consideration
41.4

 
—

 
—

 
41.4

 
41.4

December 31, 2017
 
 
 
 
 
 
 
 
 
Other current liabilities- contingent consideration
1.3

 
—

 
—

 
1.3

 
1.3

Other noncurrent liabilities- contingent consideration
45.2

 
—

 
—

 
45.2

 
45.2


Contingent consideration liabilities relate to Galliprant for which the fair value was estimated using a discounted cash flow analysis and Level 3 inputs, including projections representative of a market participant view for the probability of achieving potential future payments to Aratana Therapeutics, Inc. and an estimated discount rate. The amount to be paid is dependent upon certain development, success-based regulatory, and sales-based milestones. In addition, the amount of royalties to be paid is calculated as a percentage of net sales dependent upon the timing and geography and will, therefore, vary directly with increases and decreases in net sales of Galliprant. There is no cap on the amount that may be paid pursuant to this arrangement. During the second quarter of 2018, as a result of an increase in the projected cash flows related to Galliprant, we increased the fair value of the contingent consideration liabilities by $8.5 million. The additional expense was recognized in other-net (income) expense.
We have long term debt of $2.5 billion that is recorded at amortized cost in our condensed consolidated balance sheet as of September 30, 2018. We consider the carrying value of the long term debt to be representative of its fair value as of September 30, 2018. The fair value of this long term debt is estimated based on quoted market prices of similar liabilities and is classified as Level 2. As of December 31, 2017, long term debt was not material.
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.10.0.1
Income Taxes
 9 Months Ended
Sep. 30, 2018
Income Tax Disclosure [Abstract]  
Income Taxes
Note 10. Income Taxes
Prior to Separation
During the periods presented in the unaudited condensed consolidated and combined financial statements, our operations were generally included in the tax grouping of other Lilly entities within the respective entity's tax jurisdiction; however, in certain jurisdictions, we filed separate tax returns. Prior to the Separation, the income tax expense included in these financial statements has been calculated using the separate return basis as if Elanco filed separate tax returns.
For the three and nine months ended September 30, 2018, we incurred $18.6 million and $46.2 million, respectively, of income tax expense. For the three and nine months ended September 30, 2018, the effective tax rate of 23.6% and 39.7%, respectively, was primarily attributable to a net operating loss in the U.S. for which no tax benefit was recognized and a valuation allowance was recorded.
For the three and nine months ended September 30, 2017, despite reporting a loss before taxes of $9.1 million and $77.2 million, respectively, we incurred $11.6 million and $72.0 million of income tax expense. The tax expense recorded related primarily to income generated in certain foreign jurisdictions as no tax benefit was recorded for U.S. net operating losses.
In December 2017, the President of the U.S. signed into law the Tax Cuts and Jobs Act (2017 Tax Act), which includes significant changes to the U.S. corporate income tax system, including a reduction in the corporate income tax rate, transition to a territorial tax system, and modifications to the international tax provisions. At September 30, 2018, our accounting for the 2017 Tax Act is incomplete; however, we expect to complete our accounting by December 2018. As discussed in our combined financial statements and accompanying notes as of and for the year ended December 31, 2017 included in our IPO Prospectus, we recorded provisional adjustments for effects that we were able to reasonably estimate. Those effects included the one-time repatriation transition tax (also known as the Toll Tax), re-measurement of deferred tax assets and liabilities, unremitted earnings, executive compensation, and uncertain tax positions. At December 31, 2017, we were not able to make reasonable estimates for Global Intangible Low-Taxed Income (GILTI) deferred taxes or changes to the valuation allowances; therefore, we did not record provisional amounts. We are still evaluating the effects of the GILTI provisions and assessing our valuation allowances, and we have not yet concluded upon our accounting policy election with respect to GILTI deferred taxes or the application of intra entity transfers of inventory; therefore, the estimated annual effective tax rate reflects GILTI as a period expense. For the three and nine months ended September 30, 2018, we have not made any additional measurement-period adjustments related to provisional amounts as we are continuing to collect and analyze additional information as well as evaluate the interpretations and assumptions made. Updates to the calculations may result in material changes to the provisional adjustments recorded at December 31, 2017 and the estimated annual effective tax rate.
As part of Lilly, we are included in Lilly's U.S. tax examinations by the Internal Revenue Service (IRS). The IRS examination of tax years 2013-2015 began in 2016. While we believe it is reasonably possible that this audit could reach a resolution within the next twelve months, the IRS examination of tax years 2013-2015 remains ongoing. For periods prior to the Separation, Lilly will retain the liabilities related to such IRS audit resolutions.
Impact of Separation
In connection with the Separation, we entered into a tax matters agreement (TMA) with Lilly that, among other things, formalized our agreement related to the responsibility for historical tax positions for the periods prior to the Separation for jurisdictions where our business was included in the consolidated or combined tax returns of Lilly. The TMA also established a tax sharing agreement for jurisdictions where our business will continue to be included in Lilly's consolidated or combined tax returns for a period of time.
Based on the TMA, Lilly retained the tax benefits and liabilities associated with all periods prior to the Separation date for any jurisdiction where we were included in a consolidated or combined tax return. The financial statements for periods prior to Separation included certain deferred tax assets related to tax credit and net operating loss carryovers that resulted from our tax expense being calculated on a separate return basis that will not transfer to us either because they were used by Lilly or are retained by Lilly and reflected certain tax liabilities that will be retained by Lilly. We recorded an adjustment to our consolidated balance sheet at the date of Separation to reflect our tax positions based on the TMA. This resulted in a decrease in tax liabilities by $31.2 million as these tax liabilities will be retained by Lilly.
At September 30, 2018, we have net operating losses for international tax purposes of approximately $190 million which will expire between 2022 and 2028. These net operating losses are partially reserved. Deferred tax assets related to state net operating losses are $6.2 million. The state net operating losses will generally expire between 2035 and 2037.
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.10.0.1
Contingencies
 9 Months Ended
Sep. 30, 2018
Commitments and Contingencies Disclosure [Abstract]  
Contingencies
Note 11. Contingencies
We are party to various legal actions in the normal course of business. We record a liability if there is a claim for which it is probable a payment will be made and the amount is estimable. At September 30, 2018 and December 31, 2017, we had no liabilities established related to litigation as there are no claims which were probable and estimable. We have not historically had any significant litigation expense and are not currently subject to any claim.
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.10.0.1
Geographic Information
 9 Months Ended
Sep. 30, 2018
Segment Reporting [Abstract]  
Geographic Information
We operate as a single operating segment engaged in the development, manufacturing, marketing and sales of animal health products worldwide for both food animals and companion animals. Consistent with our operational structure, our President and Chief Executive Officer (CEO), as the chief operating decision maker, makes resource allocation and business process decisions globally across our consolidated business. Strategic decisions are managed globally with global functional leaders responsible for determining significant cost/investments and with regional leaders responsible for overseeing the execution of the global strategy. Our global research and development organization is responsible for development of new products. Our manufacturing organization is responsible for the manufacturing and supply of products and for the optimization of our supply chain. Regional leaders are responsible for the distribution and sale of our products and for local direct costs. The business is also supported by global corporate staff functions. Managing and allocating resources at the global corporate level enables our CEO to assess the overall level of resources available and how to best deploy these resources across functions, product types, regional commercial organizations and research and development projects in line with our overarching long-term corporate-wide strategic goals, rather than on a product or geographic basis. Consistent with this decision-making process, our CEO uses consolidated, single-segment financial information for purposes of evaluating performance, allocating resources, setting incentive compensation targets, as well as forecasting future period financial results.
Our products include Rumensin®, Optaflexx®, Denagard®, Tylan®, Maxiban® and other products for livestock and poultry, as well as Trifexis®, Interceptor®, Comfortis® and other products for companion animals.
We have a single customer who accounted for 11.1% and 9.4% of revenue for the three months ended September 30, 2018 and 2017, respectively, and for 11.5% and 11.9% of revenue for the nine months ended September 30, 2018 and 2017, respectively. The product sales resulted in accounts receivable with this customer of $79.5 million and $88.0 million as of September 30, 2018 and December 31, 2017, respectively.
We are exposed to the risk of changes in social, political and economic conditions inherent in foreign operations and our results of operations and the value of its foreign assets are affected by fluctuations in foreign currency exchange rates.
Selected geographic area information was as follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Revenue—to unaffiliated customers (1)
 
 
 
 
 
 
 
United States
$
382.2

 
$
321.4

 
$
1,108.6

 
$
1,054.6

International
378.9

 
375.7

 
1,158.9

 
1,080.1

Revenue
$
761.1

 
$
697.1

 
$
2,267.5

 
$
2,134.7


 
September 30, 2018
 
December 31, 2017
Long-lived assets (2)
 
 
 
United States
$
589.5

 
$
604.7

United Kingdom
195.9

 
204.4

Other foreign countries
190.5

 
190.2

Long-lived assets
$
975.9

 
$
999.3


 
(1)    Revenue is attributed to the countries based on the location of the customer.
(2)    Long-lived assets consist of property and equipment, net, and certain noncurrent assets.
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.10.0.1
Earnings Per Share
 9 Months Ended
Sep. 30, 2018
Earnings Per Share [Abstract]  
Earnings Per Share
Note 13. Earnings Per Share
We have calculated earnings per share assuming 365,625,000 shares were outstanding for all periods presented. This represents an aggregate of 293,290,000 shares of our common stock held by Lilly (which represents the 100 shares held by Lilly prior to giving effect to the 2,932,900-for-1 stock split that occurred on September 19, 2018), the issuance of 62,900,000 shares of our common stock in the IPO, and the issuance of 9,435,000 shares of our common stock sold pursuant to the underwriters’ option to purchase additional shares.
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.10.0.1
Related Party Agreements and Transactions
 9 Months Ended
Sep. 30, 2018
Related Party Transactions [Abstract]  
Related Party Agreements and Transactions
Note 14. Related Party Agreements and Transactions
Separation-Related Agreements with Lilly
As described in Note 1, in connection with the Separation Lilly transferred to us substantially all of its animal health businesses in exchange for approximately $4.2 billion. This is reflected as consideration to Lilly in our statement of equity. In addition, we entered into a master separation agreement and a transitional services agreement with Lilly.
Master Separation Agreement (MSA)
As stated in Note 1, Lilly transferred to us at the time of Separation, through a series of transactions, the businesses that will continue as part of Elanco. For a certain portion of our operations, the legal transfer of our net assets did not occur prior to the Separation due to certain regulatory requirements in each of these countries. Under the MSA entered into with Lilly, we are responsible for the business activities conducted by Lilly on our behalf and are subject to the risks and entitled to the benefits generated by these operations and assets. As a result, the related assets and liabilities and results of operations have been reported in our unaudited condensed consolidated and combined financial statements. The total net assets associated with these jurisdictions are $84.5 million and the annual profits are insignificant. Upon Separation, we retained $275.0 million, which is reflected as restricted cash, that will be used to fund the purchase of these operations from Lilly at the time of the local country closing and have an offsetting payable to Lilly. If the amount of local purchases is less than $275.0 million, we are required to repay the remaining amount to Lilly.
In addition, based on the MSA, we are required to distribute to Lilly any amount of cash in excess of $300.0 million held at September 30, 2018. As a result, we have reflected an additional $359.9 million of restricted cash on our balance sheet with an offsetting payable to Lilly at September 30, 2018.
Transitional Services Agreement (TSA)
Historically, Lilly has provided us significant shared services and resources related to corporate functions such as executive oversight, treasury, legal, finance, human resources, tax, internal audit, financial reporting, information technology and investor relations, which we refer to collectively as the "Lilly Services." Under the terms of the TSA, we will be able to use Lilly Services for a fixed term established on a service-by-service basis. We will pay Lilly mutually agreed-upon fees for the Lilly Services provided under the TSA, which will be based on Lilly's cost (including third-party costs) of providing the Lilly Services through March 31, 2021, and subject to a mark-up of 7% thereafter, with additional inflation-based escalation beginning January 1, 2020. The fees under the TSA become payable for all periods beginning after October 1, 2018.
We also entered into a TMA, an employee matters agreement, a toll manufacturing and supply agreement and a registration rights agreement with Lilly in connection with the Separation.


Transactions with Lilly Prior to Separation
We did not historically operate as a standalone business and had various relationships with Lilly whereby Lilly provided services to us.
Transfers to/from Lilly, net
As discussed in the basis of presentation, net parent company investment is primarily impacted by contributions from Lilly which are the result of treasury activity and net funding provided by or distributed to Lilly. For the three months ended September 30, 2018 and 2017, respectively, the net transfers (to)/from Lilly were $(116.8) million and $38.1 million. For the nine months ended September 30, 2018 and 2017, respectively, the net transfers (to)/from Lilly were $(226.3) million and $862.7 million, respectively. The most significant activity impacting the 2017 transfer was the financing by Lilly of our acquisition in the amount of $882.1 million for Boehringer Ingelheim Vetmedica, Inc.'s United States feline, canine, and rabies vaccine portfolio and other related assets in 2017. Other activities that impacted the net transfers (to)/from Lilly include corporate overhead and other allocations, income taxes, retirement benefits, and centralized cash management.
Corporate Overhead and Other Allocations
Lilly provides us certain services, including executive oversight, treasury, legal, finance, human resources, tax, internal audit, financial reporting, information technology and investor relations. We provide Lilly certain services related to manufacturing support. Our financial statements reflect an allocation of these costs. When specific identification is not practicable, the remainder have been allocated primarily on a proportional cost method on a basis of revenue or headcount.
The allocations of services from Lilly to us were reflected as follows in the unaudited condensed consolidated and combined statements of operations:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Cost of sales
$
7.0

 
$
7.7

 
$
21.8

 
$
23.0

Research and development
0.7

 
0.7

 
2.2

 
2.1

Marketing, selling and administrative
26.4

 
27.7

 
81.2

 
82.7

Total
$
34.1

 
$
36.1

 
$
105.2

 
$
107.8


We provide Lilly certain services related to manufacturing support. Allocations of manufacturing support from us to Lilly of $1.3 million and $1.5 million for the three months ended September 30, 2018 and 2017, respectively, as well as $3.7 million and $4.5 million for the nine months ended September 30, 2018 and 2017, respectively, reduced the cost of sales in the unaudited condensed consolidated and combined statements of operations.
The financial information herein may not necessarily reflect our consolidated financial position, results of operations and cash flows in the future or what they would have been if we had been a separate, standalone entity during the periods presented. Management believes that the methods used to allocate expenses are reasonable.
Stock-based Compensation
Our employees participate in Lilly stock-based compensation plans, the costs of which have been allocated to us and recorded in cost of sales, research and development, and marketing, selling and administrative expenses in the unaudited condensed consolidated and combined statements of operations. The costs of such plans related to our employees were $6.9 million and $6.2 million for the three months ended September 30, 2018 and 2017, respectively, as well as $20.2 million and $18.7 million for the nine months ended September 30, 2018 and 2017, respectively.
Retirement Benefits
Our employees participate in defined benefit pension and other post retirement plans sponsored by Lilly, the costs and benefits of which have been recorded in the unaudited condensed consolidated and combined statement of operations in cost of sales, research and development, and marketing, selling and administrative expenses. For the three and nine months ended September 30, 2018, the benefit of such plans related to our employees was $1.6 million and $0.3 million, respectively, and for the three and nine months ended September 30, 2017 the costs of such plans related to our employees were $1.7 million and $5.1 million, respectively.
Centralized Cash Management
Lilly uses a centralized approach to cash management and financing of operations. Until Separation, the majority of our business was party to Lilly’s cash pooling arrangements to maximize Lilly's availability of cash for general operating and investing purposes. Under these cash pooling arrangements, cash balances were swept regularly from our accounts. Cash transfers to and from Lilly’s cash concentration accounts and the resulting balances at the end of each reporting period were reflected in net parent company investment in the condensed consolidated and combined balance sheets.
Debt
Lilly’s third-party debt and the related interest expense have not been allocated to us for any of the periods presented as we were not the legal obligor of the debt and Lilly borrowings were not directly attributable to our business.
Commercial Operations
We sell certain products to and receives certain goods and services from a customer/vendor, whose chairman and Chief Executive Officer is a member of Lilly's Board of Directors. These product sales resulted in revenue of $4.2 million and $6.6 million for the three months ended September 30, 2018 and 2017, respectively, and of $16.4 million and $17.8 million for the nine months ended September 30, 2018 and 2017, respectively. The product sales resulted in accounts receivable of $1.9 million and $2.0 million at September 30, 2018 and December 31, 2017, respectively. The purchase of goods and services resulted in cost of sales and operating expenses of $1.4 million and $1.1 million for the three months ended September 30, 2018 and 2017, respectively, as well as $3.3 million and $5.3 million September 30, 2018 and 2017, respectively. The purchase of goods and services resulted in accounts payable of $0.4 million and $0.3 million at September 30, 2018 and December 31, 2017, respectively.
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.10.0.1
Basis of Presentation (Policies)
 9 Months Ended
Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation
We have prepared the accompanying unaudited condensed consolidated and combined financial statements in accordance with the requirements of Form 10-Q and, therefore, they do not include all information and footnotes necessary for a fair presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States (GAAP). In our opinion, the financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for a fair presentation of the results of operations for the periods shown. In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates.
Reclassifications
Certain reclassifications have been made to prior periods in the unaudited condensed consolidated and combined financial statements and accompanying notes to conform with current presentation.
Consolidation
For the periods after Separation, the financial statements are prepared on a consolidated basis. For periods prior to the Separation, our financial statements are combined, have been prepared on a standalone basis, and are derived from Lilly's consolidated financial statements and accounting records. The unaudited condensed combined financial statements reflect the financial position, results of operations and cash flows related to the animal health businesses that were transferred to Elanco Parent and are prepared in conformity with GAAP.
The unaudited condensed combined financial statements include the attribution of certain assets and liabilities that historically have been held at the Lilly corporate level but which are specifically identifiable or attributable to the businesses that have been transferred to Elanco Parent. All intercompany transactions and accounts within Elanco have been eliminated. All transactions between us and Lilly are considered to be effectively settled in the unaudited condensed combined financial statements at the time the intercompany transaction is recorded. The total net effect of the settlement of these intercompany transactions is reflected in the unaudited condensed combined statements of cash flows as a financing activity and in the condensed combined balance sheets as net parent company investment.
Expenses Related to Certain Corporate Functions
These unaudited condensed combined financial statements include an allocation of expenses related to certain Lilly corporate functions, including executive oversight, treasury, legal, finance, human resources, tax, internal audit, financial reporting, information technology and investor relations. These expenses have been allocated to us based on direct usage or benefit where specifically identifiable, with the remainder allocated primarily on a pro rata basis of revenue, headcount and other measures. We consider the expenses methodology and results to be reasonable for all periods presented. However, the allocations may not be indicative of the actual expense that would have been incurred had we operated as an independent, publicly traded company for the periods presented. It is impractical to estimate what the standalone costs of Elanco would have been in the historical periods.
Income Tax
The income tax amounts in the unaudited condensed combined financial statements have been calculated based on a separate return methodology and presented as if our operations were separate taxpayers in the respective jurisdictions. We file income tax returns in the United States (U.S.) federal jurisdiction and various state, local and non-U.S. jurisdictions. Certain of these income tax returns are filed on a consolidated or combined basis with Eli Lilly and Company and/or its subsidiaries.
Benefit and Combined Stock-Based Compensation Plans
Lilly maintains various benefit and combined stock-based compensation plans at a corporate level and other benefit plans at a country level. Our employees participate in such programs and the portion of the cost of those plans related to our employees is included in our financial statements. However, the condensed combined balance sheets do not include any equity issued related to stock-based compensation plans or any net benefit plan obligations unless the benefit plan covers only our dedicated employees or where the legal obligation associated with the benefit plan will transfer to Elanco.
Equity Balance
Prior to Separation, the equity balance in the unaudited condensed combined financial statements represents the excess of total assets over liabilities, including intercompany balances between us and Lilly (net parent company investment) and accumulated other comprehensive loss. Net parent company investment is primarily impacted by contributions from Lilly which are the result of treasury activities and net funding provided by or distributed to Lilly.
New Financial Accounting Pronouncements
The following table provides a brief description of accounting standards that were effective January 1, 2018 and were adopted on that date:
Standard
 
Description
 
Effect on the financial statements or other significant matters
Accounting Standards Update 2014-09 and various other related updates, Revenue from Contracts with Customers
 
This standard replaced existing revenue recognition standards and requires entities to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. An entity can apply the new revenue standard retrospectively to each prior reporting period presented or with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. We applied the latter approach.
 
Application of the new standard to applicable contracts had no impact to net parent company investment as of January 1, 2018. Disclosures required by the new standard are included in Note 5.
Accounting Standards Update 2016-16, Income Taxes: Intra-Entity Transfers of Assets Other Than Inventory
 
This standard requires entities to recognize the income tax consequences of intra-entity transfers of assets other than inventory at the time of transfer. This standard requires a modified retrospective approach to adoption.
 
Upon adoption, the cumulative effect of applying the standard resulted in a decrease to net parent company investment of approximately $0.3 million. Adoption of this standard did not result in a material change in net income for the three and nine months ended September 30, 2018.
Accounting Standards Update 2017-07, Compensation-Retirement Benefits: Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost
 
This standard was issued to improve the transparency and comparability among organizations by requiring entities to separate their net periodic pension cost and net periodic postretirement benefit cost into a service cost component and other components. Previously, the costs of the other components along with the service cost component were classified based upon the function of the employee. This standard requires entities to classify the service cost component in the same financial statement line item or items as other compensation costs arising from services rendered by pertinent employees. The other components of net benefit cost are now presented separately from the line items that include the service cost component. When applicable, the service cost component is now the only component eligible for capitalization. An entity should apply the new standard retrospectively for the classification of the service cost and other components and prospectively for the capitalization of the service cost component.
 
Upon adoption of this standard, pension and postretirement benefit cost components other than service costs are presented in other–net, (income) expense. Retrospective application was not material to the combined statement of operations for the three and nine months ended September 30, 2017. We do not expect application of the new standard to have a material impact on an ongoing basis.
The following table provides a brief description of the accounting standard that has not yet been adopted and could have a material effect on the consolidated financial statements:
Standard
 
Description
 
Effective Date
 
Effect on the financial statements or other significant matters
Accounting Standards Update 2016-02, Leases
 
This standard was issued to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities, including leases classified as operating leases under current GAAP, on the balance sheet and requiring additional disclosures about leasing arrangements. An entity can apply the new leases standard retrospectively to each prior reporting period presented or with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. We plan to use the latter approach.
 
This standard is effective January 1, 2019, with early adoption permitted. We intend to adopt this standard on that date.
 
We are in the process of determining the impact on our consolidated financial statements. We have selected a software solution to be compatible with our enterprise software system. Development of our selected solution is ongoing, as it is not yet fully compliant with the requirements of the standard. The timely readiness of the lease software system is critical to ensure an efficient and effective adoption of the standard.
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.10.0.1
Implementation of New Financial Accounting Pronouncements (Tables)
 9 Months Ended
Sep. 30, 2018
Accounting Changes and Error Corrections [Abstract]  
Description of Accounting Standards Adopted and Not Yet Adopted
The following table provides a brief description of accounting standards that were effective January 1, 2018 and were adopted on that date:
Standard
 
Description
 
Effect on the financial statements or other significant matters
Accounting Standards Update 2014-09 and various other related updates, Revenue from Contracts with Customers
 
This standard replaced existing revenue recognition standards and requires entities to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. An entity can apply the new revenue standard retrospectively to each prior reporting period presented or with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. We applied the latter approach.
 
Application of the new standard to applicable contracts had no impact to net parent company investment as of January 1, 2018. Disclosures required by the new standard are included in Note 5.
Accounting Standards Update 2016-16, Income Taxes: Intra-Entity Transfers of Assets Other Than Inventory
 
This standard requires entities to recognize the income tax consequences of intra-entity transfers of assets other than inventory at the time of transfer. This standard requires a modified retrospective approach to adoption.
 
Upon adoption, the cumulative effect of applying the standard resulted in a decrease to net parent company investment of approximately $0.3 million. Adoption of this standard did not result in a material change in net income for the three and nine months ended September 30, 2018.
Accounting Standards Update 2017-07, Compensation-Retirement Benefits: Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost
 
This standard was issued to improve the transparency and comparability among organizations by requiring entities to separate their net periodic pension cost and net periodic postretirement benefit cost into a service cost component and other components. Previously, the costs of the other components along with the service cost component were classified based upon the function of the employee. This standard requires entities to classify the service cost component in the same financial statement line item or items as other compensation costs arising from services rendered by pertinent employees. The other components of net benefit cost are now presented separately from the line items that include the service cost component. When applicable, the service cost component is now the only component eligible for capitalization. An entity should apply the new standard retrospectively for the classification of the service cost and other components and prospectively for the capitalization of the service cost component.
 
Upon adoption of this standard, pension and postretirement benefit cost components other than service costs are presented in other–net, (income) expense. Retrospective application was not material to the combined statement of operations for the three and nine months ended September 30, 2017. We do not expect application of the new standard to have a material impact on an ongoing basis.
The following table provides a brief description of the accounting standard that has not yet been adopted and could have a material effect on the consolidated financial statements:
Standard
 
Description
 
Effective Date
 
Effect on the financial statements or other significant matters
Accounting Standards Update 2016-02, Leases
 
This standard was issued to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities, including leases classified as operating leases under current GAAP, on the balance sheet and requiring additional disclosures about leasing arrangements. An entity can apply the new leases standard retrospectively to each prior reporting period presented or with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. We plan to use the latter approach.
 
This standard is effective January 1, 2019, with early adoption permitted. We intend to adopt this standard on that date.
 
We are in the process of determining the impact on our consolidated financial statements. We have selected a software solution to be compatible with our enterprise software system. Development of our selected solution is ongoing, as it is not yet fully compliant with the requirements of the standard. The timely readiness of the lease software system is critical to ensure an efficient and effective adoption of the standard.
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.10.0.1
Revenue (Tables)
 9 Months Ended
Sep. 30, 2018
Revenue from Contract with Customer [Abstract]  
Summary of Activity in Sales Rebates and Discounts Liability
The following table summarizes the activity in the sales rebates and discounts liability in the U.S.:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,

2018
 
2017
 
2018
 
2017
Beginning balance
$
99.1

 
$
118.7

 
$
114.8

 
$
116.1

Reduction of revenue
53.5

 
48.6

 
154.2

 
184.9

Payments
(49.1
)
 
(49.6
)
 
(165.5
)
 
(183.3
)
Ending balance
$
103.5

 
$
117.7

 
$
103.5

 
$
117.7
Disaggregation of Revenue
The following table summarizes our revenue disaggregated by product category:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Companion Animal Disease Prevention
$
188.6

 
$
140.4

 
$
603.9

 
$
519.7

Companion Animal Therapeutics
80.5

 
63.5

 
211.1

 
181.8

Companion Animal Other
27.7

 
48.3

 
69.3

 
119.9

Food Animal Future Protein & Health
162.8

 
164.5

 
502.1

 
456.0

Food Animal Ruminants & Swine
301.5

 
280.4

 
881.1

 
857.3

Revenue
$
761.1

 
$
697.1

 
$
2,267.5

 
$
2,134.7
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.10.0.1
Asset Impairment, Restructuring and Other Special Charges (Tables)
 9 Months Ended
Sep. 30, 2018
Restructuring and Related Activities [Abstract]  
Total Charges Related to Asset Impairment, Restructuring and Other Special Charges
Our total charges related to asset impairment, restructuring and other special charges, including integration of acquired businesses, in the unaudited condensed consolidated and combined statements of operations consisted of the following:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Cash expense:
 
 
 
 
 
 
 
Severance
$
(0.2
)
 
$
5.8

 
$
(2.8
)
 
$
62.1

Integration and other
4.9

 
6.4

 
10.5

 
75.1

Exit costs
1.5

 
11.5

 
11.2

 
24.3

Total cash expense
6.2

 
23.7

 
18.9

 
161.5

Non-cash expense
 
 
 
 
 
 
 
Asset impairment
6.2

 
—

 
63.9

 
43.8

Total non-cash expense
6.2

 
—

 
63.9

 
43.8

Gain on sale of fixed assets
—

 
—

 
—

 
(16.0
)
Total
$
12.4

 
$
23.7

 
$
82.8

 
$
189.3
Summary of Activity in Reserves
The following table summarizes the activity in our reserves established in connection with these restructuring activities:
 
Exit costs
 
Severance
 
Total
Balance at December 31, 2016
$
11.5

 
$
26.6

 
$
38.1

Charges
24.3

 
62.1

 
86.4

Cash paid
(7.6
)
 
(61.8
)
 
(69.4
)
Balance at September 30, 2017
$
28.2

 
$
26.9

 
$
55.1

 
 
 
 
 
 
Balance at December 31, 2017
$
34.9

 
$
43.1

 
$
78.0

Charges
11.2

 
(2.8
)
 
8.4

Separation adjustment
(5.9
)

—


(5.9
)
Cash paid
(10.9
)
 
(22.6
)
 
(33.5
)
Balance at September 30, 2018
$
29.3

 
$
17.7

 
$
47.0
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.10.0.1
Inventories (Tables)
 9 Months Ended
Sep. 30, 2018
Inventory Disclosure [Abstract]  
Schedule of Inventories
Inventories consisted of the following:
 
September 30, 2018
 
December 31, 2017
Finished products
$
408.1

 
$
452.0

Work in process
572.3

 
580.0

Raw materials and supplies
71.4

 
70.4

Total (approximates replacement cost)
1,051.8

 
1,102.4

Decrease to LIFO cost
(43.1
)
 
(40.1
)
Inventories
$
1,008.7

 
$
1,062.3
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.10.0.1
Debt (Tables)
 9 Months Ended
Sep. 30, 2018
Debt Disclosure [Abstract]  
Schedule of Long-term Debt
Long-term debt as of September 30, 2018 consisted of the following:
 
September 30, 2018

Term credit facility
$
500.0

3.912% Senior Notes due 2021
500.0

4.272% Senior Notes due 2023
750.0

4.900% Senior Notes due 2028
750.0

Other obligations
0.2

Unamortized debt issuance costs
(21.7
)
Total long-term debt
2,478.5

Less current portion of long-term debt
—

 
$
2,478.5
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.10.0.1
Financial Instruments and Fair Value (Tables)
 9 Months Ended
Sep. 30, 2018
Fair Value Disclosures [Abstract]  
Summary of Fair Value Information
The following table summarizes the fair value information at September 30, 2018 and December 31, 2017 for contingent consideration liabilities measured at fair value on a recurring basis in the respective balance sheet line items:
 
 
 
Fair Value Measurements Using
 
 
Financial statement line item
Carrying
Amount
 
Quoted Prices in Active Markets for Identical Assets
(Level 1)
 
Significant
Other Observable Inputs
(Level 2)
 
Significant
Unobservable
Inputs
(Level 3)
 
Fair
Value
September 30, 2018
 
 
 
 
 
 
 
 
 
Other current liabilities- contingent consideration
$
17.4

 
$
—

 
$
—

 
$
17.4

 
$
17.4

Other noncurrent liabilities- contingent consideration
41.4

 
—

 
—

 
41.4

 
41.4

December 31, 2017
 
 
 
 
 
 
 
 
 
Other current liabilities- contingent consideration
1.3

 
—

 
—

 
1.3

 
1.3

Other noncurrent liabilities- contingent consideration
45.2

 
—

 
—

 
45.2

 
45.2
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.10.0.1
Geographic Information (Tables)
 9 Months Ended
Sep. 30, 2018
Segment Reporting [Abstract]  
Revenue by Selected Geographic Area Information
Revenue is attributed to the countries based on the location of the customer.
Selected geographic area information was as follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Revenue—to unaffiliated customers (1)
 
 
 
 
 
 
 
United States
$
382.2

 
$
321.4

 
$
1,108.6

 
$
1,054.6

International
378.9

 
375.7

 
1,158.9

 
1,080.1

Revenue
$
761.1

 
$
697.1

 
$
2,267.5

 
$
2,134.7
Long-lived Assets by Selected Geographic Area Information
 
September 30, 2018
 
December 31, 2017
Long-lived assets (2)
 
 
 
United States
$
589.5

 
$
604.7

United Kingdom
195.9

 
204.4

Other foreign countries
190.5

 
190.2

Long-lived assets
$
975.9

 
$
999.3

Long-lived assets consist of property and equipment, net, and certain noncurrent assets.
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.10.0.1
Related Party Agreements and Transactions (Tables)
 9 Months Ended
Sep. 30, 2018
Related Party Transactions [Abstract]  
Allocations of Services
The allocations of services from Lilly to us were reflected as follows in the unaudited condensed consolidated and combined statements of operations:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Cost of sales
$
7.0

 
$
7.7

 
$
21.8

 
$
23.0

Research and development
0.7

 
0.7

 
2.2

 
2.1

Marketing, selling and administrative
26.4

 
27.7

 
81.2

 
82.7

Total
$
34.1

 
$
36.1

 
$
105.2

 
$
107.8
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.10.0.1
Nature of Business and Organization (Details)
$ / shares in Units, shares in Millions, $ in Millions
 2 Months Ended 9 Months Ended
Sep. 24, 2018
USD ($)
$ / shares
shares
Sep. 30, 2018
USD ($)
brand
country
Sep. 30, 2018
USD ($)
brand
country
Sep. 30, 2017
USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]        
Number of brands in diverse portfolio (more than) | brand   125 125  
Number of countries in which entity operates (more than) | country   90 90  
Subsidiary, Sale of Stock [Line Items]        
Amount transferred to parent     $ 3,559.1 $ 0.0
IPO        
Subsidiary, Sale of Stock [Line Items]        
Number of shares issued | shares 72.3      
Percentage of total outstanding shares 19.80%      
Price per share (usd per share) | $ / shares $ 24      
Total net proceeds, after underwriting discounts and commissions $ 1,700.0      
Payments made to date   $ 4,200.0 $ 4,200.0  
Amount transferred to parent   $ 3,600.0    
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.10.0.1
Basis of Presentation (Details) - USD ($)
$ in Millions
Sep. 30, 2018
Jun. 30, 2018
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Dec. 31, 2016
Error Corrections and Prior Period Adjustments Restatement [Line Items]            
Sales rebates and discounts liability $ 103.5 $ 99.1 $ 114.8 $ 117.7 $ 118.7 $ 116.1
Total current liabilities 1,245.4   643.1      
Total liabilities 4,074.4   1,160.0      
Net parent company investment 0.0   8,036.9      
Total equity $ 5,137.1   7,780.3 $ 7,962.7   7,017.4
Rebates Related to Product Held in Wholesalers Pipeline | Adjustment            
Error Corrections and Prior Period Adjustments Restatement [Line Items]            
Sales rebates and discounts liability     10.5      
Total current liabilities     10.5      
Total liabilities     10.5      
Net parent company investment     (10.5)     (10.5)
Total equity     (10.5)     (10.5)
Rebates Related to Product Held in Wholesalers Pipeline | Previously Reported            
Error Corrections and Prior Period Adjustments Restatement [Line Items]            
Sales rebates and discounts liability     155.0      
Total current liabilities     632.6      
Total liabilities     1,149.5      
Net parent company investment     8,047.4     7,484.8
Total equity     $ 7,790.8     $ 7,027.9
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.10.0.1
Impact of Separation (Details) - USD ($)
 9 Months Ended
Sep. 24, 2018
Sep. 30, 2018
Sep. 05, 2018
Aug. 28, 2018
Debt Instrument [Line Items]        
Increase in net assets $ 58,300,000 $ 58,300,000    
Elanco | Lilly        
Debt Instrument [Line Items]        
Ownership percentage of outstanding Common stock   80.20%    
Senior Notes        
Debt Instrument [Line Items]        
Aggregate principal amount       $ 2,000,000,000
Credit Facility | Senior Unsecured Revolving Credit Facility        
Debt Instrument [Line Items]        
Credit facility, maximum borrowing capacity 750,000,000   $ 750,000,000  
Credit Facility | Senior Unsecured Term Credit Facility        
Debt Instrument [Line Items]        
Credit facility, maximum borrowing capacity $ 500,000,000   $ 500,000,000  
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.10.0.1
Implementation of New Financial Accounting Pronouncements (Details) - USD ($)
$ in Millions
Sep. 30, 2018
Dec. 31, 2017
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
Net parent company investment $ 0.0 $ (8,036.9)
Accounting Standards Update 2016-16    
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
Net parent company investment $ 0.3  
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.10.0.1
Revenue - Narrative (Details)
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Concentration Risk [Line Items]        
Payment terms     Payment terms differ by jurisdiction and customer, but payment terms in most of our major jurisdictions typically range from 30 to 100 days from date of shipment.  
Rebate period     6 months  
Geographic Concentration Risk | Contract With Customer Liability | United States        
Concentration Risk [Line Items]        
Concentration risk     70.00% 71.00%
Geographic Concentration Risk | Contract With Customer Liability | Next Largest Country        
Concentration Risk [Line Items]        
Concentration risk     8.00% 6.00%
Product Return Concentration Risk | Net Revenue        
Concentration Risk [Line Items]        
Concentration risk 1.00% 1.00% 1.00% 1.00%
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.10.0.1
Revenue - Summary of Activity in Sales Rebates and Discounts Liability (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Change In Contract With Customer, Liability [Roll Forward]        
Beginning balance $ 99.1 $ 118.7 $ 114.8 $ 116.1
Reduction of revenue 53.5 48.6 154.2 184.9
Payments (49.1) (49.6) (165.5) (183.3)
Ending balance $ 103.5 $ 117.7 $ 103.5 $ 117.7
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.10.0.1
Revenue - Disaggregation of Revenue (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Disaggregation of Revenue [Line Items]        
Revenue $ 761.1 $ 697.1 $ 2,267.5 $ 2,134.7
Companion Animal Disease Prevention        
Disaggregation of Revenue [Line Items]        
Revenue 188.6 140.4 603.9 519.7
Companion Animal Therapeutics        
Disaggregation of Revenue [Line Items]        
Revenue 80.5 63.5 211.1 181.8
Companion Animal Other        
Disaggregation of Revenue [Line Items]        
Revenue 27.7 48.3 69.3 119.9
Food Animal Future Protein & Health        
Disaggregation of Revenue [Line Items]        
Revenue 162.8 164.5 502.1 456.0
Food Animal Ruminants & Swine        
Disaggregation of Revenue [Line Items]        
Revenue $ 301.5 $ 280.4 $ 881.1 $ 857.3
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.10.0.1
Asset Impairment, Restructuring and Other Special Charges - Total Charges Related to Asset Impairment, Restructuring and Other Special Charges (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Cash expense:        
Severance $ (0.2) $ 5.8 $ (2.8) $ 62.1
Integration and other 4.9 6.4 10.5 75.1
Exit costs 1.5 11.5 11.2 24.3
Total cash expense 6.2 23.7 18.9 161.5
Non-cash expense        
Asset impairment 6.2 0.0 63.9 43.8
Total non-cash expense 6.2 0.0 63.9 43.8
Gain on sale of fixed assets 0.0 0.0 0.0 (16.0)
Total cash expense $ 12.4 $ 23.7 $ 82.8 $ 189.3
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.10.0.1
Asset Impairment, Restructuring and Other Special Charges - Narrative (Details)
$ in Millions
 9 Months Ended
Sep. 30, 2018
USD ($)
Restructuring and Related Activities [Abstract]  
Intangible asset impairments $ 19.9
Fixed asset impairments $ 44.0
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.10.0.1
Asset Impairment, Restructuring and Other Special Charges - Summary of Activity in Reserves (Details) - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Restructuring Reserve [Roll Forward]    
Balance at beginning of period $ 78.0 $ 38.1
Charges 8.4 86.4
Separation adjustment (5.9)  
Cash paid (33.5) (69.4)
Balance at end of period 47.0 55.1
Exit costs    
Restructuring Reserve [Roll Forward]    
Balance at beginning of period 34.9 11.5
Charges 11.2 24.3
Separation adjustment (5.9)  
Cash paid (10.9) (7.6)
Balance at end of period 29.3 28.2
Severance    
Restructuring Reserve [Roll Forward]    
Balance at beginning of period 43.1 26.6
Charges (2.8) 62.1
Separation adjustment 0.0  
Cash paid (22.6) (61.8)
Balance at end of period $ 17.7 $ 26.9
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.10.0.1
Inventories - Schedule of Inventories (Details) - USD ($)
$ in Millions
Sep. 30, 2018
Dec. 31, 2017
Inventory Disclosure [Abstract]    
Finished products $ 408.1 $ 452.0
Work in process 572.3 580.0
Raw materials and supplies 71.4 70.4
Total (approximates replacement cost) 1,051.8 1,102.4
Decrease to LIFO cost (43.1) (40.1)
Inventories $ 1,008.7 $ 1,062.3
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.10.0.1
Inventories - Narrative (Details)
$ in Millions
 9 Months Ended
Sep. 30, 2018
USD ($)
Inventory Disclosure [Abstract]  
Inventory write-offs $ 38.6
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.10.0.1
Debt - Schedule of Long-term Debt (Details) - USD ($)
$ in Millions
Sep. 30, 2018
Aug. 28, 2018
Dec. 31, 2017
Debt Instrument [Line Items]      
Unamortized debt issuance costs $ (21.7)    
Total long-term debt 2,478.5    
Less current portion of long-term debt 0.0    
Total long-term debt, excluding current portion 2,478.5   $ 0.0
Credit Facility | Term credit facility      
Debt Instrument [Line Items]      
Long-term debt, gross $ 500.0    
Senior Notes | 3.912% Senior Notes due 2021      
Debt Instrument [Line Items]      
Interest rate 3.912% 3.912%  
Long-term debt, gross $ 500.0    
Senior Notes | 4.272% Senior Notes due 2023      
Debt Instrument [Line Items]      
Interest rate 4.272% 4.272%  
Long-term debt, gross $ 750.0    
Senior Notes | 4.900% Senior Notes due 2028      
Debt Instrument [Line Items]      
Interest rate 4.90% 4.90%  
Long-term debt, gross $ 750.0    
Other obligations      
Debt Instrument [Line Items]      
Long-term debt, gross $ 0.2    
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.10.0.1
Debt - Narrative (Details) - USD ($)
Sep. 05, 2018
Sep. 30, 2018
Sep. 24, 2018
Aug. 28, 2018
Dec. 31, 2017
Senior Notes          
Debt Instrument [Line Items]          
Aggregate principal amount       $ 2,000,000,000  
Senior Notes | 3.912% Senior Notes due 2021          
Debt Instrument [Line Items]          
Borrowings outstanding   $ 500,000,000      
Aggregate principal amount       $ 500,000,000  
Interest rate   3.912%   3.912%  
Senior Notes | 4.272% Senior Notes due 2023          
Debt Instrument [Line Items]          
Borrowings outstanding   $ 750,000,000      
Aggregate principal amount       $ 750,000,000  
Interest rate   4.272%   4.272%  
Senior Notes | 4.900% Senior Notes due 2028          
Debt Instrument [Line Items]          
Borrowings outstanding   $ 750,000,000      
Aggregate principal amount       $ 750,000,000  
Interest rate   4.90%   4.90%  
Revolving credit facility | Credit Facility          
Debt Instrument [Line Items]          
Credit facility term 5 years        
Credit facility, maximum borrowing capacity $ 750,000,000   $ 750,000,000    
Borrowings outstanding         $ 0
Term credit facility | Credit Facility          
Debt Instrument [Line Items]          
Credit facility term 3 years        
Credit facility, maximum borrowing capacity $ 500,000,000   $ 500,000,000    
Borrowings outstanding   $ 500,000,000      
Interest rate at period end   3.50%      
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.10.0.1
Financial Instruments and Fair Value - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended
Jun. 30, 2018
Sep. 30, 2018
Dec. 31, 2017
Fair Value Disclosures [Abstract]      
Cost and equity method investments   $ 14.9 $ 12.3
Amortized Cost      
Business Acquisition, Contingent Consideration [Line Items]      
Long term debt   $ 2,500.0  
Aratana Therapeutics, Inc.      
Business Acquisition, Contingent Consideration [Line Items]      
Increase in fair value of contingent consideration liabilities $ 8.5    
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.10.0.1
Financial Instruments and Fair Value - Summary of Fair Value Information (Details) - Recurring - USD ($)
$ in Millions
Sep. 30, 2018
Dec. 31, 2017
Other current liabilities- contingent consideration | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration liabilities $ 0.0 $ 0.0
Other current liabilities- contingent consideration | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration liabilities 0.0 0.0
Other current liabilities- contingent consideration | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration liabilities 1.3 17.4
Other current liabilities- contingent consideration | Carrying Amount    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration liabilities 1.3 17.4
Other current liabilities- contingent consideration | Fair Value    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration liabilities 1.3 17.4
Other noncurrent liabilities- contingent consideration | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration liabilities 0.0 0.0
Other noncurrent liabilities- contingent consideration | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration liabilities 0.0 0.0
Other noncurrent liabilities- contingent consideration | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration liabilities 45.2 41.4
Other noncurrent liabilities- contingent consideration | Carrying Amount    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration liabilities 45.2 41.4
Other noncurrent liabilities- contingent consideration | Fair Value    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration liabilities $ 45.2 $ 41.4
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.10.0.1
Income Taxes (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 24, 2018
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Income Tax Disclosure [Abstract]          
Income tax expense (benefit)   $ 18.6 $ 11.6 $ 46.2 $ 72.0
Income (loss) before income taxes   $ 78.8 $ (9.1) $ 116.3 $ (77.2)
Effective tax rate   23.60%   39.70%  
Decrease in tax liabilities $ 31.2        
International          
Operating Loss Carryforwards [Line Items]          
Net operating loss carryforwards that expire   $ 190.0   $ 190.0  
State          
Operating Loss Carryforwards [Line Items]          
Net operating loss carryforwards that expire   $ 6.2   $ 6.2  
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.10.0.1
Contingencies (Details) - USD ($)
Sep. 30, 2018
Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]    
Liabilities related to litigation $ 0 $ 0
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.10.0.1
Geographic Information - Narrative (Details)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2018
USD ($)
Sep. 30, 2017
Sep. 30, 2018
USD ($)
segment
Sep. 30, 2017
Dec. 31, 2017
USD ($)
Segment Reporting [Abstract]          
Number of operating segments | segment     1    
Concentration Risk [Line Items]          
Accounts receivable $ 606.1   $ 606.1   $ 567.4
Product Sales          
Concentration Risk [Line Items]          
Accounts receivable $ 79.5   $ 79.5   $ 88.0
Customer Concentration Risk | Revenue | Single Customer          
Concentration Risk [Line Items]          
Concentration risk 11.10% 9.40% 11.50% 11.90%  
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.10.0.1
Geographic Information - Revenue by Selected Geographic Area Information (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Revenues from External Customers and Long-Lived Assets [Line Items]        
Revenue—to unaffiliated customers $ 761.1 $ 697.1 $ 2,267.5 $ 2,134.7
United States        
Revenues from External Customers and Long-Lived Assets [Line Items]        
Revenue—to unaffiliated customers 382.2 321.4 1,108.6 1,054.6
International        
Revenues from External Customers and Long-Lived Assets [Line Items]        
Revenue—to unaffiliated customers $ 378.9 $ 375.7 $ 1,158.9 $ 1,080.1
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.10.0.1
Geographic Information - Long-lived Assets by Selected Geographic Area Information (Details) - USD ($)
$ in Millions
Sep. 30, 2018
Dec. 31, 2017
Revenues from External Customers and Long-Lived Assets [Line Items]    
Long-lived assets $ 975.9 $ 999.3
United States    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Long-lived assets 589.5 604.7
United Kingdom    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Long-lived assets 195.9 204.4
Other foreign countries    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Long-lived assets $ 190.5 $ 190.2
XML 62 R52.htm IDEA: XBRL DOCUMENT v3.10.0.1
Earnings Per Share (Details)
 3 Months Ended 9 Months Ended
Sep. 24, 2018
shares
Sep. 19, 2018
Sep. 30, 2018
shares
Sep. 30, 2017
shares
Sep. 30, 2018
shares
Sep. 30, 2017
shares
Sep. 18, 2018
shares
Subsidiary, Sale of Stock [Line Items]              
Number of shares outstanding     365,625,000 365,265,000 365,265,000 365,265,000  
Stock split ratio   2,932,900          
IPO, excluding Underwriters' Option              
Subsidiary, Sale of Stock [Line Items]              
Number of shares issued 62,900,000            
Underwriters' Option              
Subsidiary, Sale of Stock [Line Items]              
Number of shares issued 9,435,000            
Elanco | Lilly              
Subsidiary, Sale of Stock [Line Items]              
Common shares outstanding     293,290,000   293,290,000   100
XML 63 R53.htm IDEA: XBRL DOCUMENT v3.10.0.1
Related Party Agreements and Transactions - Narrative (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Dec. 31, 2017
Related Party Transaction [Line Items]          
Net transfers (to)/from Lilly $ (116,800,000) $ 38,100,000 $ (226,300,000) $ 862,700,000  
Acquisition amount     0 882,100,000  
Boehringer Ingelheim Vetmedica, Inc.          
Related Party Transaction [Line Items]          
Acquisition amount       882,100,000  
Lilly          
Related Party Transaction [Line Items]          
Stock-based compensation 6,900,000 6,200,000 20,200,000 18,700,000  
Benefit of defined benefit pension plan 1,600,000   300,000    
Costs of defined benefit pension plan   1,700,000   5,100,000  
Lilly | MSA          
Related Party Transaction [Line Items]          
Total net assets 84,500,000   84,500,000    
Restricted cash retained 275,000,000   275,000,000    
Local purchases minimum 275,000,000   275,000,000    
Cash to be distributed in excess of 300,000,000.0   300,000,000.0    
Additional restricted cash 359,900,000   $ 359,900,000    
Lilly | TSA          
Related Party Transaction [Line Items]          
Mark-up rate     7.00%    
Lilly | Manufacturing Support          
Related Party Transaction [Line Items]          
Revenue from related parties 1,300,000 1,500,000 $ 3,700,000 4,500,000  
Director | Commercial Operations          
Related Party Transaction [Line Items]          
Revenue from related parties 4,200,000 6,600,000 16,400,000 17,800,000  
Accounts receivable 1,900,000   1,900,000   $ 2,000,000
Purchases of goods and services 1,400,000 $ 1,100,000 3,300,000 $ 5,300,000  
Accounts payable 400,000   400,000   $ 300,000
IPO          
Related Party Transaction [Line Items]          
Amount transferred to parent $ 4,200,000,000   $ 4,200,000,000    
XML 64 R54.htm IDEA: XBRL DOCUMENT v3.10.0.1
Related Party Agreements and Transactions - Allocations of Services (Details) - Lilly - Transitional Services Agreement - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Related Party Transaction [Line Items]        
Allocation of services $ 34.1 $ 36.1 $ 105.2 $ 107.8
Cost of sales        
Related Party Transaction [Line Items]        
Allocation of services 7.0 7.7 21.8 23.0
Research and development        
Related Party Transaction [Line Items]        
Allocation of services 0.7 0.7 2.2 2.1
Marketing, selling and administrative        
Related Party Transaction [Line Items]        
Allocation of services $ 26.4 $ 27.7 $ 81.2 $ 82.7
EXCEL 65 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 67 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 69 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 192 194 1 false 63 0 false 7 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://www.elanco.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - Unaudited Condensed Consolidated and Combined Statements of Operations Sheet http://www.elanco.com/role/UnauditedCondensedConsolidatedAndCombinedStatementsOfOperations Unaudited Condensed Consolidated and Combined Statements of Operations Statements 2 false false R3.htm 1002000 - Statement - Unaudited Condensed Consolidated and Combined Statements of Comprehensive Income (Loss) Sheet http://www.elanco.com/role/UnauditedCondensedConsolidatedAndCombinedStatementsOfComprehensiveIncomeLoss Unaudited Condensed Consolidated and Combined Statements of Comprehensive Income (Loss) Statements 3 false false R4.htm 1003000 - Statement - Condensed Consolidated and Combined Balance Sheets Sheet http://www.elanco.com/role/CondensedConsolidatedAndCombinedBalanceSheets Condensed Consolidated and Combined Balance Sheets Statements 4 false false R5.htm 1003501 - Statement - Condensed Consolidated and Combined Balance Sheets (Parenthetical) Sheet http://www.elanco.com/role/CondensedConsolidatedAndCombinedBalanceSheetsParenthetical Condensed Consolidated and Combined Balance Sheets (Parenthetical) Statements 5 false false R6.htm 1004000 - Statement - Unaudited Condensed Consolidated and Combined Statements of Equity Sheet http://www.elanco.com/role/UnauditedCondensedConsolidatedAndCombinedStatementsOfEquity Unaudited Condensed Consolidated and Combined Statements of Equity Statements 6 false false R7.htm 1004000 - Statement - Unaudited Condensed Consolidated and Combined of Cash Flows Sheet http://www.elanco.com/role/UnauditedCondensedConsolidatedAndCombinedOfCashFlows Unaudited Condensed Consolidated and Combined of Cash Flows Statements 7 false false R8.htm 2101100 - Disclosure - Nature of Business and Organization Sheet http://www.elanco.com/role/NatureOfBusinessAndOrganization Nature of Business and Organization Notes 8 false false R9.htm 2102100 - Disclosure - Basis of Presentation Sheet http://www.elanco.com/role/BasisOfPresentation Basis of Presentation Notes 9 false false R10.htm 2103100 - Disclosure - Impact of Separation Sheet http://www.elanco.com/role/ImpactOfSeparation Impact of Separation Notes 10 false false R11.htm 2104100 - Disclosure - Implementation of New Financial Accounting Pronouncements Sheet http://www.elanco.com/role/ImplementationOfNewFinancialAccountingPronouncements Implementation of New Financial Accounting Pronouncements Notes 11 false false R12.htm 2105100 - Disclosure - Revenue Sheet http://www.elanco.com/role/Revenue Revenue Notes 12 false false R13.htm 2106100 - Disclosure - Asset Impairment, Restructuring and Other Special Charges Sheet http://www.elanco.com/role/AssetImpairmentRestructuringAndOtherSpecialCharges Asset Impairment, Restructuring and Other Special Charges Notes 13 false false R14.htm 2107100 - Disclosure - Inventories Sheet http://www.elanco.com/role/Inventories Inventories Notes 14 false false R15.htm 2108100 - Disclosure - Debt Sheet http://www.elanco.com/role/Debt Debt Notes 15 false false R16.htm 2109100 - Disclosure - Financial Instruments and Fair Value Sheet http://www.elanco.com/role/FinancialInstrumentsAndFairValue Financial Instruments and Fair Value Notes 16 false false R17.htm 2110100 - Disclosure - Income Taxes Sheet http://www.elanco.com/role/IncomeTaxes Income Taxes Notes 17 false false R18.htm 2111100 - Disclosure - Contingencies Sheet http://www.elanco.com/role/Contingencies Contingencies Notes 18 false false R19.htm 2131100 - Disclosure - Geographic Information Sheet http://www.elanco.com/role/GeographicInformation Geographic Information Notes 19 false false R20.htm 2137100 - Disclosure - Earnings Per Share Sheet http://www.elanco.com/role/EarningsPerShare Earnings Per Share Notes 20 false false R21.htm 2140100 - Disclosure - Related Party Agreements and Transactions Sheet http://www.elanco.com/role/RelatedPartyAgreementsAndTransactions Related Party Agreements and Transactions Notes 21 false false R22.htm 2202201 - Disclosure - Basis of Presentation (Policies) Sheet http://www.elanco.com/role/BasisOfPresentationPolicies Basis of Presentation (Policies) Policies http://www.elanco.com/role/ImplementationOfNewFinancialAccountingPronouncements 22 false false R23.htm 2304301 - Disclosure - Implementation of New Financial Accounting Pronouncements (Tables) Sheet http://www.elanco.com/role/ImplementationOfNewFinancialAccountingPronouncementsTables Implementation of New Financial Accounting Pronouncements (Tables) Tables http://www.elanco.com/role/ImplementationOfNewFinancialAccountingPronouncements 23 false false R24.htm 2305301 - Disclosure - Revenue (Tables) Sheet http://www.elanco.com/role/RevenueTables Revenue (Tables) Tables http://www.elanco.com/role/Revenue 24 false false R25.htm 2306301 - Disclosure - Asset Impairment, Restructuring and Other Special Charges (Tables) Sheet http://www.elanco.com/role/AssetImpairmentRestructuringAndOtherSpecialChargesTables Asset Impairment, Restructuring and Other Special Charges (Tables) Tables http://www.elanco.com/role/AssetImpairmentRestructuringAndOtherSpecialCharges 25 false false R26.htm 2307301 - Disclosure - Inventories (Tables) Sheet http://www.elanco.com/role/InventoriesTables Inventories (Tables) Tables http://www.elanco.com/role/Inventories 26 false false R27.htm 2308301 - Disclosure - Debt (Tables) Sheet http://www.elanco.com/role/DebtTables Debt (Tables) Tables http://www.elanco.com/role/Debt 27 false false R28.htm 2309301 - Disclosure - Financial Instruments and Fair Value (Tables) Sheet http://www.elanco.com/role/FinancialInstrumentsAndFairValueTables Financial Instruments and Fair Value (Tables) Tables http://www.elanco.com/role/FinancialInstrumentsAndFairValue 28 false false R29.htm 2331301 - Disclosure - Geographic Information (Tables) Sheet http://www.elanco.com/role/GeographicInformationTables Geographic Information (Tables) Tables http://www.elanco.com/role/GeographicInformation 29 false false R30.htm 2340301 - Disclosure - Related Party Agreements and Transactions (Tables) Sheet http://www.elanco.com/role/RelatedPartyAgreementsAndTransactionsTables Related Party Agreements and Transactions (Tables) Tables http://www.elanco.com/role/RelatedPartyAgreementsAndTransactions 30 false false R31.htm 2401401 - Disclosure - Nature of Business and Organization (Details) Sheet http://www.elanco.com/role/NatureOfBusinessAndOrganizationDetails Nature of Business and Organization (Details) Details http://www.elanco.com/role/NatureOfBusinessAndOrganization 31 false false R32.htm 2402402 - Disclosure - Basis of Presentation (Details) Sheet http://www.elanco.com/role/BasisOfPresentationDetails Basis of Presentation (Details) Details http://www.elanco.com/role/BasisOfPresentationPolicies 32 false false R33.htm 2403401 - Disclosure - Impact of Separation (Details) Sheet http://www.elanco.com/role/ImpactOfSeparationDetails Impact of Separation (Details) Details http://www.elanco.com/role/ImpactOfSeparation 33 false false R34.htm 2404402 - Disclosure - Implementation of New Financial Accounting Pronouncements (Details) Sheet http://www.elanco.com/role/ImplementationOfNewFinancialAccountingPronouncementsDetails Implementation of New Financial Accounting Pronouncements (Details) Details http://www.elanco.com/role/ImplementationOfNewFinancialAccountingPronouncementsTables 34 false false R35.htm 2405402 - Disclosure - Revenue - Narrative (Details) Sheet http://www.elanco.com/role/RevenueNarrativeDetails Revenue - Narrative (Details) Details 35 false false R36.htm 2405403 - Disclosure - Revenue - Summary of Activity in Sales Rebates and Discounts Liability (Details) Sheet http://www.elanco.com/role/RevenueSummaryOfActivityInSalesRebatesAndDiscountsLiabilityDetails Revenue - Summary of Activity in Sales Rebates and Discounts Liability (Details) Details 36 false false R37.htm 2405404 - Disclosure - Revenue - Disaggregation of Revenue (Details) Sheet http://www.elanco.com/role/RevenueDisaggregationOfRevenueDetails Revenue - Disaggregation of Revenue (Details) Details 37 false false R38.htm 2406402 - Disclosure - Asset Impairment, Restructuring and Other Special Charges - Total Charges Related to Asset Impairment, Restructuring and Other Special Charges (Details) Sheet http://www.elanco.com/role/AssetImpairmentRestructuringAndOtherSpecialChargesTotalChargesRelatedToAssetImpairmentRestructuringAndOtherSpecialChargesDetails Asset Impairment, Restructuring and Other Special Charges - Total Charges Related to Asset Impairment, Restructuring and Other Special Charges (Details) Details 38 false false R39.htm 2406403 - Disclosure - Asset Impairment, Restructuring and Other Special Charges - Narrative (Details) Sheet http://www.elanco.com/role/AssetImpairmentRestructuringAndOtherSpecialChargesNarrativeDetails Asset Impairment, Restructuring and Other Special Charges - Narrative (Details) Details http://www.elanco.com/role/AssetImpairmentRestructuringAndOtherSpecialChargesTables 39 false false R40.htm 2406404 - Disclosure - Asset Impairment, Restructuring and Other Special Charges - Summary of Activity in Reserves (Details) Sheet http://www.elanco.com/role/AssetImpairmentRestructuringAndOtherSpecialChargesSummaryOfActivityInReservesDetails Asset Impairment, Restructuring and Other Special Charges - Summary of Activity in Reserves (Details) Details 40 false false R41.htm 2407402 - Disclosure - Inventories - Schedule of Inventories (Details) Sheet http://www.elanco.com/role/InventoriesScheduleOfInventoriesDetails Inventories - Schedule of Inventories (Details) Details 41 false false R42.htm 2407403 - Disclosure - Inventories - Narrative (Details) Sheet http://www.elanco.com/role/InventoriesNarrativeDetails Inventories - Narrative (Details) Details 42 false false R43.htm 2408402 - Disclosure - Debt - Schedule of Long-term Debt (Details) Sheet http://www.elanco.com/role/DebtScheduleOfLongTermDebtDetails Debt - Schedule of Long-term Debt (Details) Details 43 false false R44.htm 2408403 - Disclosure - Debt - Narrative (Details) Sheet http://www.elanco.com/role/DebtNarrativeDetails Debt - Narrative (Details) Details 44 false false R45.htm 2409402 - Disclosure - Financial Instruments and Fair Value - Narrative (Details) Sheet http://www.elanco.com/role/FinancialInstrumentsAndFairValueNarrativeDetails Financial Instruments and Fair Value - Narrative (Details) Details 45 false false R46.htm 2409403 - Disclosure - Financial Instruments and Fair Value - Summary of Fair Value Information (Details) Sheet http://www.elanco.com/role/FinancialInstrumentsAndFairValueSummaryOfFairValueInformationDetails Financial Instruments and Fair Value - Summary of Fair Value Information (Details) Details 46 false false R47.htm 2410401 - Disclosure - Income Taxes (Details) Sheet http://www.elanco.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.elanco.com/role/IncomeTaxes 47 false false R48.htm 2411401 - Disclosure - Contingencies (Details) Sheet http://www.elanco.com/role/ContingenciesDetails Contingencies (Details) Details http://www.elanco.com/role/Contingencies 48 false false R49.htm 2431402 - Disclosure - Geographic Information - Narrative (Details) Sheet http://www.elanco.com/role/GeographicInformationNarrativeDetails Geographic Information - Narrative (Details) Details 49 false false R50.htm 2431403 - Disclosure - Geographic Information - Revenue by Selected Geographic Area Information (Details) Sheet http://www.elanco.com/role/GeographicInformationRevenueBySelectedGeographicAreaInformationDetails Geographic Information - Revenue by Selected Geographic Area Information (Details) Details 50 false false R51.htm 2431404 - Disclosure - Geographic Information - Long-lived Assets by Selected Geographic Area Information (Details) Sheet http://www.elanco.com/role/GeographicInformationLongLivedAssetsBySelectedGeographicAreaInformationDetails Geographic Information - Long-lived Assets by Selected Geographic Area Information (Details) Details 51 false false R52.htm 2437401 - Disclosure - Earnings Per Share (Details) Sheet http://www.elanco.com/role/EarningsPerShareDetails Earnings Per Share (Details) Details http://www.elanco.com/role/EarningsPerShare 52 false false R53.htm 2440402 - Disclosure - Related Party Agreements and Transactions - Narrative (Details) Sheet http://www.elanco.com/role/RelatedPartyAgreementsAndTransactionsNarrativeDetails Related Party Agreements and Transactions - Narrative (Details) Details 53 false false R54.htm 2440403 - Disclosure - Related Party Agreements and Transactions - Allocations of Services (Details) Sheet http://www.elanco.com/role/RelatedPartyAgreementsAndTransactionsAllocationsOfServicesDetails Related Party Agreements and Transactions - Allocations of Services (Details) Details 54 false false All Reports Book All Reports elan-20180930.xml elan-20180930.xsd elan-20180930_cal.xml elan-20180930_def.xml elan-20180930_lab.xml elan-20180930_pre.xml http://xbrl.sec.gov/country/2017-01-31 http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/us-gaap/2018-01-31 http://fasb.org/srt/2018-01-31 true true ZIP 71 0001739104-18-000005-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001739104-18-000005-xbrl.zip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�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

  •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end